| 1 |
Carman N, Picoraro JA. Advances in Endoscopy for Pediatric Inflammatory Bowel Disease. Gastrointest Endosc Clin N Am 2023;33:447-61. [PMID: 36948755 DOI: 10.1016/j.giec.2022.10.002] [Reference Citation Analysis]
|
| 2 |
Hayashi Y, Takabayashi K, Kato M, Tojo A, Aoki Y, Hagihara Y, Yoshida K, Yoshimatsu Y, Kiyohara H, Sugimoto S, Nanki K, Mikami Y, Sujino T, Mutaguchi M, Kawaguchi T, Hosoe N, Yahagi N, Ogata H, Kanai T. Usefulness of texture and color enhancement imaging in assessing mucosal healing in patients with ulcerative colitis. Gastrointest Endosc 2023;97:759-766.e1. [PMID: 36460084 DOI: 10.1016/j.gie.2022.11.019] [Reference Citation Analysis]
|
| 3 |
Feagan BG, Sands BE, Sandborn WJ, Germinaro M, Vetter M, Shao J, Sheng S, Johanns J, Panés J; VEGA Study Group. Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. Lancet Gastroenterol Hepatol 2023;8:307-20. [PMID: 36738762 DOI: 10.1016/S2468-1253(22)00427-7] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 4 |
Rodríguez-hernández O, Carrillo-palau M, Hernández-camba A, Alonso-abreu I, Ramos L, de Armas-rillo L, Martín-gonzález C, López-mejías R, González-gay MÁ, Ferraz-amaro I. Serum Levels of Lipoprotein Lipase Are Increased in Patients with Inflammatory Bowel Disease. IJMS 2023;24:5194. [DOI: 10.3390/ijms24065194] [Reference Citation Analysis]
|
| 5 |
Pavia G, Spagnuolo R, Quirino A, Marascio N, Giancotti A, Simeone S, Cosco C, Tino E, Carrabetta F, Di Gennaro G, Nobile C, Bianco A, Matera G, Doldo P. COVID-19 Vaccine Booster Shot Preserves T Cells Immune Response Based on Interferon-Gamma Release Assay in Inflammatory Bowel Disease (IBD) Patients on Anti-TNFα Treatment. Vaccines 2023;11:591. [DOI: 10.3390/vaccines11030591] [Reference Citation Analysis]
|
| 6 |
Shelygin YA, Ivashkin VT, Belousova EA, Reshetov IV, Maev IV, Achkasov SI, Abdulganieva DI, Alekseeva OA, Bakulin IG, Barysheva OY, Bolikhov KV, Vardanyan AV, Veselov AV, Veselov VV, Golovenko OV, Gubonina IV, Denisenko VL, Dolgushina AI, Kashnikov VN, Knyazev OV, Kostenko NV, Lakhin AV, Makarchuk PA, Moskalev AI, Nanaeva BA, Nikitin IG, Nikitina NV, Odintsova AK, Omelyanovskiy VV, Оshchepkov AV, Pavlenko VV, Poluektova EA, Sitkin SI, Sushkov OI, Tarasova LV, Tkachev AV, Тimerbulatov VM, Uspenskaya YB, Frolov SA, Khlynova OV, Chashkova EY, Chesnokova OV, Shapina MV, Sheptulin AA, Shifrin OS, Shkurko TV, Shchukina OB. Ulcerative colitis (K51), adults. Koloproktologiâ 2023;22:10-44. [DOI: 10.33878/2073-7556-2023-22-1-10-44] [Reference Citation Analysis]
|
| 7 |
Lim KY, Raja Ali RA, Wong Z, Zaki FM, Maktar JF, Muhammad Nawawi KN. Evaluation of intestinal ultrasound for disease activity assessment in patients with inflammatory bowel disease: A cross-sectional study at a tertiary centre in Malaysia. Saudi J Gastroenterol 2023. [PMID: 36876618 DOI: 10.4103/sjg.sjg_531_22] [Reference Citation Analysis]
|
| 8 |
Kamitani Y, Kurumi H, Kanda T, Ikebuchi Y, Yoshida A, Kawaguchi K, Yashima K, Umekita Y, Isomoto H. Comparative study between histochemical mucus volume, histopathological findings, and endocytoscopic scores in patients with ulcerative colitis. Medicine (Baltimore) 2023;102:e33033. [PMID: 36862904 DOI: 10.1097/MD.0000000000033033] [Reference Citation Analysis]
|
| 9 |
Sandborn WJ, Vermeire S, Peyrin-Biroulet L, Dubinsky MC, Panes J, Yarur A, Ritter T, Baert F, Schreiber S, Sloan S, Cataldi F, Shan K, Rabbat CJ, Chiorean M, Wolf DC, Sands BE, D'Haens G, Danese S, Goetsch M, Feagan BG. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet 2023:S0140-6736(23)00061-2. [PMID: 36871574 DOI: 10.1016/S0140-6736(23)00061-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 10 |
Burisch J, Zhao M, Odes S, De Cruz P, Vermeire S, Bernstein CN, Kaplan GG, Duricova D, Greenberg D, Melberg HO, Watanabe M, Ahn HS, Targownik L, Pittet VEH, Annese V, Park KT, Katsanos KH, Høivik ML, Krznaric Z, Chaparro M, Loftus EV Jr, Lakatos PL, Gisbert JP, Bemelman W, Moum B, Gearry RB, Kappelman MD, Hart A, Pierik MJ, Andrews JM, Ng SC, D'Inca R, Munkholm P. The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol 2023:S2468-1253(23)00003-1. [PMID: 36871566 DOI: 10.1016/S2468-1253(23)00003-1] [Reference Citation Analysis]
|
| 11 |
Mangia M, Giuffrida E, Figini V, Colombo A, Carli E, Lavagna A, Mendolaro M, Morello E, Cosimato M, Rocca R, Pagana G, Daperno M. Agreement between patients and physicians on scores of inflammatory bowel disease activity and burden assessed on a telemonitoring platform. Scand J Gastroenterol 2023;58:240-7. [PMID: 36148538 DOI: 10.1080/00365521.2022.2124538] [Reference Citation Analysis]
|
| 12 |
Tursi A, Mocci G, Allegretta L, Aragona G, Bianco MA, Colucci R, Cuomo A, Della Valle N, Ferronato A, Forti G, Gaiani F, Giorgetti G, Graziani MG, Lofano K, Lorenzetti R, Larussa T, Penna A, Pica R, Pranzo G, Rodino' S, Scarcelli A, Zampaletta C, Bassotti G, Cazzato AI, Chiri S, Clemente V, Cocco A, De' Angelis G, Donnarumma L, Faggiani R, Graziosi C, Le Grazie M, Luzza F, Meucci C, Monterubbianesi R, Pagnini C, Perazzo P, Picchio M, Sacco R, Sebkova L, Serio M, Napolitano D, Pugliese D, Scaldaferri F, Schiavoni E, Turchini L, Armuzzi A, Elisei W, Maconi G, Papa A. Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study. Inflamm Bowel Dis 2023;29:376-83. [PMID: 35579320 DOI: 10.1093/ibd/izac092] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 13 |
Mocci G, Tursi A, Maconi G, Cataletti G, Mantia B, Serio M, Scarcelli A, Pagnini C, Graziani MG, Di Paolo MC, Pranzo G, Luppino I, Paese P, Elisei W, Monterubbianesi R, Faggiani R, Ferronato A, Perini B, Savarino E, Onidi FM, Binaghi L, Usai Satta P, Schiavoni E, Napolitano D, Scaldaferri F, Pugliese D, Pica R, Cocco A, Zippi M, Rodino S, Sebkova L, Rocco G, Sacchi C, Zampaletta C, Gaiani F, De Angelis G, Kayali S, Fanigliulo L, Lorenzetti R, Allegretta L, Scorza S, Cuomo A, Donnarumma L, Della Valle N, Sacco R, Forti G, Antonelli E, Bassotti G, Iannelli C, Luzza F, Aragona G, Perazzo P, Lauria A, Piergallini S, Colucci R, Bianco MA, Meucci C, Giorgetti G, Clemente V, Fiorella S, Penna A, De Medici A, Picchio M, Papa A. Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study. Expert Opin Biol Ther 2023;23:293-304. [PMID: 36843568 DOI: 10.1080/14712598.2023.2185510] [Reference Citation Analysis]
|
| 14 |
Kawashima K, Oshima N, Kishimoto K, Kataoka M, Fukunaga M, Kotani S, Sonoyama H, Oka A, Mishima Y, Kazumori H, Ishikawa N, Araki A, Ishihara S. Low Fecal Calprotectin Predicts Histological Healing in Patients with Ulcerative Colitis with Endoscopic Remission and Leads to Prolonged Clinical Remission. Inflamm Bowel Dis 2023;29:359-66. [PMID: 35583193 DOI: 10.1093/ibd/izac095] [Reference Citation Analysis]
|
| 15 |
Shahnazari M, Afshar S, Emami MH, Amini R, Jalali A. Novel biomarkers for neoplastic progression from ulcerative colitis to colorectal cancer: a systems biology approach. Sci Rep 2023;13:3413. [PMID: 36854781 DOI: 10.1038/s41598-023-29344-y] [Reference Citation Analysis]
|
| 16 |
Xu W, Liu F, Hua Z, Gu Y, Lian L, Cui L, Ding Z, Du P. Comparison of The Toronto IBD Global Endoscopic Reporting (TIGER) score, Mayo endoscopic score (MES), and ulcerative colitis endoscopic index of severity (UCEIS) in predicting the need for ileal pouch-anal anastomosis in patients with ulcerative colitis. Int J Colorectal Dis 2023;38:53. [PMID: 36840832 DOI: 10.1007/s00384-023-04347-3] [Reference Citation Analysis]
|
| 17 |
van de Meeberg MM, Verheij ER, Fidder HH, Bouma G, Huitema ADR, Oldenburg B. Potential of Mesalazine Therapeutic Drug Monitoring by Measuring Fecal Excretion in Patients With Ulcerative Colitis. Ther Drug Monit 2023. [PMID: 36823707 DOI: 10.1097/FTD.0000000000001084] [Reference Citation Analysis]
|
| 18 |
Hagiwara S, Abe N, Hosoi K, Hara T, Ishige T, Shimizu H, Mizuochi T, Kakiuchi T, Kunisaki R, Matsuoka R, Kondou H, Kakuta F, Nakayama Y, Kimura T, Honma H, Hirano D, Saruta M, Yoshida T, Okayasu I, Etani Y, Maeyama T. Utility of a rapid assay for Prostaglandin E-major urinary metabolite as a biomarker in pediatric ulcerative colitis.. [DOI: 10.21203/rs.3.rs-2552506/v1] [Reference Citation Analysis]
|
| 19 |
Darie AM, Sinopoulou V, Ajay V, Bel Kok K, Patel KV, Limdi J, Arebi N, Smith P, Din S, Din S, Shale M, Subramanian S, Pavlidis P, Cooney R, McGonagle D, A C S Wong N, Moran GW, Gordon M. BSG 2024 IBD guidelines protocol (standard operating procedures). BMJ Open Gastroenterol 2023;10. [PMID: 36764690 DOI: 10.1136/bmjgast-2022-001067] [Reference Citation Analysis]
|
| 20 |
Loveikyte R, Bourgonje AR, van der Reijden JJ, Bulthuis MLC, Hawinkels LJAC, Visschedijk MC, Festen EAM, van Dullemen HM, Weersma RK, van Goor H, van der Meulen-de Jong AE, Dijkstra G. Hepcidin and Iron Status in Patients With Inflammatory Bowel Disease Undergoing Induction Therapy With Vedolizumab or Infliximab. Inflamm Bowel Dis 2023:izad010. [PMID: 36748574 DOI: 10.1093/ibd/izad010] [Reference Citation Analysis]
|
| 21 |
Seong G, Song JH, Kim JE, Kim TJ, Kim ER, Hong SN, Chang DK, Kim SH, Ha SY, Kim YH. Histologic Activity and Steroid Use History Are Risk Factors of Clinical Relapse in Ulcerative Colitis With Mayo Endoscopic Subscore of 0 or 1. Inflamm Bowel Dis 2023;29:238-44. [PMID: 35396998 DOI: 10.1093/ibd/izac075] [Reference Citation Analysis]
|
| 22 |
Singh A, Midha V, Mahajan R, Verma S, Kakkar C, Grover J, Singh D, Kaur R, Masih A, Bansal N, Wall C, Sood A. Evaluation of Nutritional Characteristics Reveals Similar Prevalence of Malnutrition in Patients with Ulcerative Colitis and Crohn's Disease. Dig Dis Sci 2023;68:580-95. [PMID: 36064826 DOI: 10.1007/s10620-022-07652-z] [Reference Citation Analysis]
|
| 23 |
Pham K, Mtalitinya GS, Aristide C, Airewele EA, Nyakaru DK, McMahon P, Mulaki GM, Corstjens PLAM, J de Dood C, van Dam GJ, Changalucha JM, Mazigo HD, Lee MH, Jaka H, Downs JA. Effects of Schistosoma mansoni and praziquantel treatment on the lower gastrointestinal mucosa: A cohort study in Tanzania. Acta Trop 2023;238:106752. [PMID: 36410422 DOI: 10.1016/j.actatropica.2022.106752] [Reference Citation Analysis]
|
| 24 |
Fan Y, Mu R, Xu H, Xie C, Zhang Y, Liu L, Wang L, Shi H, Hu Y, Ren J, Qin J, Wang L, Cai S. Novel deep learning-based computer-aided diagnosis system for predicting inflammatory activity in ulcerative colitis. Gastrointest Endosc 2023;97:335-46. [PMID: 35985375 DOI: 10.1016/j.gie.2022.08.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 25 |
Sturm A, Schmidt C. Klassifikation der chronisch entzündlichen Darmerkrankungen. Endo-Praxis 2023;39:25-34. [DOI: 10.1055/a-1776-3452] [Reference Citation Analysis]
|
| 26 |
Song C, Kakuta Y, Negoro K, Moroi R, Masamune A, Sasaki E, Nakamura N, Nakayama M. Collection of patient-generated health data with a mobile application and transfer to hospital information system via QR codes. Computer Methods and Programs in Biomedicine Update 2023. [DOI: 10.1016/j.cmpbup.2023.100099] [Reference Citation Analysis]
|
| 27 |
Xue JC, Yuan S, Meng H, Hou XT, Li J, Zhang HM, Chen LL, Zhang CH, Zhang QG. The role and mechanism of flavonoid herbal natural products in ulcerative colitis. Biomed Pharmacother 2023;158:114086. [PMID: 36502751 DOI: 10.1016/j.biopha.2022.114086] [Reference Citation Analysis]
|
| 28 |
Sempere L, Bernabeu P, Cameo J, Gutiérrez A, García MG, García MF, Aguas M, Belén O, Zapater P, Jover R, van-der Hofstadt C, Ruiz-Cantero MT. Gender Biases and Diagnostic Delay in Inflammatory Bowel Disease: Multicenter Observational Study. Inflamm Bowel Dis 2023:izad001. [PMID: 36719111 DOI: 10.1093/ibd/izad001] [Reference Citation Analysis]
|
| 29 |
Fuxman C, Sicilia B, Linares ME, García-López S, González Sueyro R, González-Lamac Y, Zabana Y, Hinojosa J, Barreiro de Acosta M, Balderramo D, Balfour D, Bellicoso M, Daffra P, Morelli D, Orsi M, Rausch A, Ruffinengo O, Toro M, Sambuelli A, Novillo A, Gomollón F, De Paula JA. GADECCU 2022 Guideline for the treatment of Ulcerative Colitis. Adaptation and updating of the GETECCU 2020 Guideline. Gastroenterol Hepatol 2023:S0210-5705(23)00014-6. [PMID: 36731724 DOI: 10.1016/j.gastrohep.2023.01.009] [Reference Citation Analysis]
|
| 30 |
Da Rio L, Spadaccini M, Parigi TL, Gabbiadini R, Dal Buono A, Busacca A, Maselli R, Fugazza A, Colombo M, Carrara S, Franchellucci G, Alfarone L, Facciorusso A, Hassan C, Repici A, Armuzzi A. Artificial intelligence and inflammatory bowel disease: Where are we going? World J Gastroenterol 2023; 29(3): 508-520 [PMID: 36688019 DOI: 10.3748/wjg.v29.i3.508] [Reference Citation Analysis]
|
| 31 |
Armuzzi A, Hart A, Cappelleri JC, Mammar N, Hur P, Hoskin B, Hennessy F, Milligan G, Dignass A. Characteristics, clinical outcomes and patient-reported outcomes of patients with ulcerative colitis receiving tofacitinib: a real-world survey in the United States and five European countries. BMC Gastroenterol 2023;23:17. [PMID: 36658481 DOI: 10.1186/s12876-023-02640-7] [Reference Citation Analysis]
|
| 32 |
Caron B, Jairath V, D'Amico F, Al Awadhi S, Dignass A, Hart AL, Kobayashi T, Kotze PG, Magro F, Siegmund B, Paridaens K, Danese S, Peyrin-Biroulet L. International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients. Medicina (Kaunas) 2023;59:183. [PMID: 36676807 DOI: 10.3390/medicina59010183] [Reference Citation Analysis]
|
| 33 |
Ueno N, Sugiyama Y, Kobayashi Y, Murakami Y, Iwama T, Sasaki T, Kunogi T, Sakatani A, Takahashi K, Tanaka K, Serikawa S, Ando K, Kashima S, Muto M, Inaba Y, Moriichi K, Tanabe H, Okumura T, Fujiya M. Concomitant pharmacologic medications influence the clinical outcomes of granulocyte and monocyte adsorptive apheresis in patients with ulcerative colitis: A multicenter retrospective cohort study. J Clin Apher 2023. [PMID: 36636880 DOI: 10.1002/jca.22040] [Reference Citation Analysis]
|
| 34 |
Reiss Z, Rob F, Kolar M, Schierova D, Kreisinger J, Jackova Z, Roubalova R, Coufal S, Mihula M, Thon T, Bajer L, Novakova M, Vasatko M, Kostovcikova K, Galanova N, Lukas M, Kverka M, Tresnak Hercogova J, Tlaskalova-Hogenova H, Jiraskova Zakostelska Z. Skin microbiota signature distinguishes IBD patients and reflects skin adverse events during anti-TNF therapy. Front Cell Infect Microbiol 2022;12:1064537. [PMID: 36704107 DOI: 10.3389/fcimb.2022.1064537] [Reference Citation Analysis]
|
| 35 |
Ramos L, Teo-Loy J, Barreiro-de Acosta M. Disease clearance in ulcerative colitis: Setting the therapeutic goals for future in the treatment of ulcerative colitis. Front Med (Lausanne) 2022;9:1102420. [PMID: 36698823 DOI: 10.3389/fmed.2022.1102420] [Reference Citation Analysis]
|
| 36 |
Rosa I, Conti C, Zito L, Efthymakis K, Neri M, Porcelli P. Has the COVID-19 Pandemic Worsened Health-Related Quality of Life of Patients with Inflammatory Bowel Disease? A Longitudinal Disease Activity-Controlled Study. Int J Environ Res Public Health 2023;20. [PMID: 36673856 DOI: 10.3390/ijerph20021103] [Reference Citation Analysis]
|
| 37 |
Fuentes-Valenzuela E, García-Alonso FJ, Maroto-Martín C, Juan Casamayor L, Garrote JA, Almendros Muñoz R, De Prado Á, Vara Castrodeza A, Marinero MÁ, Calleja Carbajosa R, Barrio J. Influence of HLADQA1*05 Genotype in Adults With Inflammatory Bowel Disease and Anti-TNF Treatment With Proactive Therapeutic Drug Monitoring: A Retrospective Cohort Study. Inflamm Bowel Dis 2023:izac259. [PMID: 36617284 DOI: 10.1093/ibd/izac259] [Reference Citation Analysis]
|
| 38 |
Sandborn WJ, Danese S, Leszczyszyn J, Romatowski J, Altintas E, Peeva E, Hassan-Zahraee M, Vincent MS, Reddy PS, Banfield C, Salganik M, Banerjee A, Gale JD, Hung KE. Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study. Clin Gastroenterol Hepatol 2023:S1542-3565(23)00007-1. [PMID: 36623678 DOI: 10.1016/j.cgh.2022.12.029] [Reference Citation Analysis]
|
| 39 |
Agrawal M, Petralia F, Tepler A, Durbin L, Reinisch W, Colombel JF, Shah SC. Gender-Based Differences in Response to Tumor Necrosis Factor Inhibitor Therapies for Ulcerative Colitis: Individual Participant Data Meta-Analyses of Clinical Trials. Inflamm Bowel Dis 2023;29:1-8. [PMID: 35366313 DOI: 10.1093/ibd/izac067] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 40 |
Ledder O, Turner D. Clinical Indices for Pediatric Inflammatory Bowel Disease Research. Pediatric Inflammatory Bowel Disease 2023. [DOI: 10.1007/978-3-031-14744-9_46] [Reference Citation Analysis]
|
| 41 |
Kurimoto N, Nishida Y, Hosomi S, Itani S, Kobayashi Y, Nakata R, Ominami M, Nadatani Y, Fukunaga S, Otani K, Tanaka F, Nagami Y, Taira K, Kamata N, Fujiwara Y. Neutrophil-to-lymphocyte ratio may predict clinical relapse in ulcerative colitis patients with mucosal healing. PLoS One 2023;18:e0280252. [PMID: 36634124 DOI: 10.1371/journal.pone.0280252] [Reference Citation Analysis]
|
| 42 |
El-Atrebi KA, Taher E, El Aguizy FH, Ali RM, Hegazy A, El-Sayed MM, Eysa B, El-Atreby AA, Mohammed AA, El-Bassyouni HT. A descriptive study of inflammatory bowel disease at an Egyptian tertiary care center. Rev Gastroenterol Mex (Engl Ed) 2023;88:12-8. [PMID: 34887218 DOI: 10.1016/j.rgmxen.2021.11.015] [Reference Citation Analysis]
|
| 43 |
Na SY, Choi CH, Song EM, Bang KB, Park SH, Kim ES, Park JJ, Keum B, Lee CK, Lee BI, Ryoo SB, Koh SJ, Choi M, Kim JS; IBD Research Group of the Korean Association for the Study of Intestinal Diseases. Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis. Intest Res 2023;21:61-87. [PMID: 35645321 DOI: 10.5217/ir.2022.00007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 44 |
Takatsu N, Hisabe T, Kishi M, Takeda T, Yasukawa S, Koga A, Kinjo K, Hirai F, Ueki T, Yao K. Thiopurine naivety at tacrolimus induction is a predictor of long-term remission in patients with intractable ulcerative colitis who responded to tacrolimus. J Gastroenterol Hepatol 2023;38:52-60. [PMID: 36128954 DOI: 10.1111/jgh.16006] [Reference Citation Analysis]
|
| 45 |
Shin SY, Kim Y, Kim WS, Moon JM, Lee KM, Jung SA, Park H, Huh EY, Kim BC, Lee SC, Choi CH; IBD Research Group of the Korean Association for the Study of Intestinal Diseases. Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease. Intest Res 2023;21:148-60. [PMID: 35692191 DOI: 10.5217/ir.2021.00168] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 46 |
Regueiro M, Hunter T, Lukanova R, Shan M, Wild R, Knight H, Bannikoppa P, Naegeli AN. Burden of Fatigue Among Patients with Ulcerative Colitis and Crohn's Disease: Results from a Global Survey of Patients and Gastroenterologists. Adv Ther 2023;40:474-88. [PMID: 36370288 DOI: 10.1007/s12325-022-02364-2] [Reference Citation Analysis]
|
| 47 |
Böcker U. Therapie des Morbus Crohn und der Colitis ulcerosa. Pflege bei chronisch-entzündlichen Darmerkrankungen 2023. [DOI: 10.1007/978-3-662-64938-1_11] [Reference Citation Analysis]
|
| 48 |
Schmidt C. Endoskopie. Pflege bei chronisch-entzündlichen Darmerkrankungen 2023. [DOI: 10.1007/978-3-662-64938-1_8] [Reference Citation Analysis]
|
| 49 |
Vitali F, Morgenstern N, Eckstein M, Atreya R, Waldner M, Hartmann A, Neurath MF, Rath T. Endocytoscopy for assessing histologic inflammation in ulcerative colitis: development and prospective validation of the ELECT (ErLangen Endocytoscopy in ColiTis) score (with videos). Gastrointest Endosc 2023;97:100-111.e1. [PMID: 36058265 DOI: 10.1016/j.gie.2022.08.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 50 |
Li X, Tang Z, Liu Y, Zhu X, Liu F. Risk prediction model based on blood biomarkers for predicting moderate to severe endoscopic activity in patients with ulcerative colitis. Front Med (Lausanne) 2023;10:1101237. [PMID: 36895716 DOI: 10.3389/fmed.2023.1101237] [Reference Citation Analysis]
|
| 51 |
Yan A, Butcher J, Schramm L, Mack DR, Stintzi A. Multiomic spatial analysis reveals a distinct mucosa-associated virome. Gut Microbes 2023;15:2177488. [PMID: 36823020 DOI: 10.1080/19490976.2023.2177488] [Reference Citation Analysis]
|
| 52 |
Liwinski T, Hübener S, Henze L, Hübener P, Heinemann M, Tetzlaff M, Hiller MI, Jagemann B, Surabattula R, Leeming D, Karsdal M, Monguzzi E, Schachschal G, Rösch T, Bang C, Franke A, Lohse AW, Schuppan D, Schramm C. A prospective pilot study of a gluten-free diet for primary sclerosing cholangitis and associated colitis. Aliment Pharmacol Ther 2023;57:224-36. [PMID: 36266939 DOI: 10.1111/apt.17256] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 53 |
Saha A, Dreyfuss I, Sarfraz H, Friedman M, Markowitz J. Dietary Considerations for Inflammatory Bowel Disease Are Useful for Treatment of Checkpoint Inhibitor-Induced Colitis. Cancers (Basel) 2022;15. [PMID: 36612082 DOI: 10.3390/cancers15010084] [Reference Citation Analysis]
|
| 54 |
Kuk KW, Gwon JY, Soh JS, Lim H, Kang HS, Moon SH, Muraga A, Yoo JW. Clinical significance and long-term prognosis of ulcerative colitis patients with appendiceal orifice inflammation. BMC Gastroenterol 2022;22:532. [PMID: 36544086 DOI: 10.1186/s12876-022-02627-w] [Reference Citation Analysis]
|
| 55 |
Perin RL, Magro DO, Andrade AR, Argollo M, Carvalho NS, Damião AOMC, Dotti AZ, Ferreira SDC, Flores C, Ludvig JC, Nones RB, Queiroz NSF, Parra RS, Steinwurz F, Teixeira FV, Kotze PG. Effectiveness and Safety of Tofacitinib in the Management of Ulcerative Colitis: A Brazilian Observational Multicentric Study. Crohns Colitis 360 2023;5:otac050. [PMID: 36777366 DOI: 10.1093/crocol/otac050] [Reference Citation Analysis]
|
| 56 |
Axelrad J, Long M, Horst S, Afzali A, Sapir T, Fajardo K, De Felice K, Sandler R, Cross R. A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and Persistence With Inflammatory Bowel Disease Therapy (ASSIST Study): Protocol for a Randomized Controlled Trial. JMIR Res Protoc 2022;11:e40382. [PMID: 36520519 DOI: 10.2196/40382] [Reference Citation Analysis]
|
| 57 |
Uchiyama K, Takagi T, Mizushima K, Hirai Y, Asaeda K, Sugaya T, Kajiwara M, Kashiwagi S, Toyokawa Y, Hotta Y, Tanaka M, Inoue K, Katada K, Kamada K, Ishikawa T, Yasuda H, Konishi H, Kishimoto M, Naito Y, Itoh Y. Mucosal addressin cell adhesion molecule 1 expression reflects mucosal inflammation and subsequent relapse in patients with ulcerative colitis. J Crohns Colitis 2022:jjac182. [PMID: 36511086 DOI: 10.1093/ecco-jcc/jjac182] [Reference Citation Analysis]
|
| 58 |
Codina-Jiménez C, Bosch Peligero M, Rodríguez-Bernuz C, Montraveta M, Marin S, Quiñones C. Successful long-term treatment of paediatric ulcerative colitis with vedolizumab: a case report. Eur J Hosp Pharm 2022:ejhpharm-2022-003434. [PMID: 36600475 DOI: 10.1136/ejhpharm-2022-003434] [Reference Citation Analysis]
|
| 59 |
Iacucci M, Cannatelli R, Parigi TL, Nardone OM, Tontini GE, Labarile N, Buda A, Rimondi A, Bazarova A, Bisschops R, Del Amor R, Meseguer P, Naranjo V, Ghosh S, Grisan E; PICaSSO group. A virtual chromoendoscopy artificial intelligence system to detect endoscopic and histologic activity/remission and predict clinical outcomes in ulcerative colitis. Endoscopy 2022. [PMID: 36228649 DOI: 10.1055/a-1960-3645] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 60 |
Steinsbø Ø, Carlsen A, Aasprong OG, Aabakken L, Tvedt-Gundersen E, Bjørkhaug S, Gjerde R, Normann Karlsen L, Grimstad T. Histologic healing and factors associated with complete remission following conventional treatment in ulcerative colitis. Therap Adv Gastroenterol 2022;15:17562848221140659. [PMID: 36506747 DOI: 10.1177/17562848221140659] [Reference Citation Analysis]
|
| 61 |
Kitakata S, Furukawa S, Miyake T, Shiraishi K, Tange K, Hashimoto Y, Yagi S, Ninomiya T, Suzuki S, Shibata N, Murakami H, Ohashi K, Tomida H, Yamamoto Y, Takeshita E, Ikeda Y, Hiasa Y. Association between clinical outcomes and restless legs syndrome in Japanese patients with ulcerative colitis. J Sleep Res 2022;31:e13691. [PMID: 35852410 DOI: 10.1111/jsr.13691] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 62 |
Hans A, Battat R, Lukin DJ. Article Topic: Positioning Ulcerative Colitis Therapies in 2022 and Beyond. Curr Gastroenterol Rep 2022;24:157-70. [PMID: 36327029 DOI: 10.1007/s11894-022-00853-6] [Reference Citation Analysis]
|
| 63 |
Constant BD, Baldassano R, Kirsch J, Mitchel EB, Stein R, Albenberg L. Tofacitinib Salvage Therapy for Children Hospitalized for Corticosteroid- and Biologic-Refractory Ulcerative Colitis. J Pediatr Gastroenterol Nutr 2022;75:724-30. [PMID: 36122389 DOI: 10.1097/MPG.0000000000003616] [Reference Citation Analysis]
|
| 64 |
Mounsif S, Setouani H, Nadi A, Ghalim F, Delsa H. Management of Ulcerative Colitis Flare-Ups in the Era of COVID-19. Cureus 2022;14:e32153. [PMID: 36601162 DOI: 10.7759/cureus.32153] [Reference Citation Analysis]
|
| 65 |
Reliability. A Practical Approach to Quantitative Validation of Patient‐Reported Outcomes 2022. [DOI: 10.1002/9781119376354.ch4] [Reference Citation Analysis]
|
| 66 |
Kim KO, Kim EY, Lee YJ, Lee HS, Kim ES, Chung YJ, Jang BI, Kim SK, Yang CH. Efficacy, safety and tolerability of oral sulphate tablet for bowel preparation in patients with inflammatory bowel disease: A multicentre randomized controlled study. J Crohns Colitis 2022;16:1706-13. [PMID: 35689818 DOI: 10.1093/ecco-jcc/jjac080] [Reference Citation Analysis]
|
| 67 |
Iacucci M, Jeffery L, Acharjee A, Grisan E, Buda A, Nardone OM, Smith SCL, Labarile N, Zardo D, Ungar B, Hunter S, Mao R, Cannatelli R, Shivaji UN, Parigi TL, Reynolds GM, Gkoutos GV, Ghosh S. Computer-Aided Imaging Analysis of Probe-Based Confocal Laser Endomicroscopy With Molecular Labeling and Gene Expression Identifies Markers of Response to Biological Therapy in IBD Patients: The Endo-Omics Study. Inflamm Bowel Dis 2022:izac233. [PMID: 36378498 DOI: 10.1093/ibd/izac233] [Reference Citation Analysis]
|
| 68 |
Dubinsky MC, Shan M, Delbecque L, Lissoos T, Hunter T, Harding G, Stassek L, Andrae D, Lewis JD. Psychometric evaluation of the Urgency NRS as a new patient-reported outcome measure for patients with ulcerative colitis. J Patient Rep Outcomes 2022;6:114. [DOI: 10.1186/s41687-022-00522-2] [Reference Citation Analysis]
|
| 69 |
Shimoyama T, Yamamoto T, Yoshiyama S, Nishikawa R, Umegae S. Leucine-Rich Alpha-2 Glycoprotein Is a Reliable Serum Biomarker for Evaluating Clinical and Endoscopic Disease Activity in Inflammatory Bowel Disease. Inflamm Bowel Dis 2022:izac230. [PMID: 36334015 DOI: 10.1093/ibd/izac230] [Reference Citation Analysis]
|
| 70 |
Rosso AD, Aguilera P, Quesada S, Mascardi F, Mascuka SN, Cimolai MC, Cerezo J, Spiazzi R, Conlon C, Milano C, Iraola GM, Penas-steinhardt A, Belforte FS. Comprehensive Phenotyping in Inflammatory Bowel Disease: Search for Biomarker Algorithms in the Transkingdom Interactions Context. Microorganisms 2022;10:2190. [DOI: 10.3390/microorganisms10112190] [Reference Citation Analysis]
|
| 71 |
Matsumoto S, Mashima H. Usefulness of the Optimal Cutoff Value and Delta Value of Leucine-Rich Alpha 2 Glycoprotein in Ulcerative Colitis. Crohns Colitis 360 2022;4:otac039. [PMID: 36778513 DOI: 10.1093/crocol/otac039] [Reference Citation Analysis]
|
| 72 |
Dahl EK, Abed OK, Kjeldsen J, Donia M, Svane IM, Dige A, Agnholt JS, Bjerrum JT, Seidelin JB. Safety and efficacy of infliximab and corticosteroid therapy in checkpoint inhibitor-induced colitis. Aliment Pharmacol Ther 2022;56:1370-82. [PMID: 36123319 DOI: 10.1111/apt.17201] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 73 |
de Waal T, Handin N, Brouwers J, Ferrante M, Vermeire S, Vanuytsel T, Artursson P, Augustijns P. The impact of inflammation on the expression of drug transporters and metabolic enzymes in colonic tissue from ulcerative colitis patients. International Journal of Pharmaceutics 2022;628:122282. [DOI: 10.1016/j.ijpharm.2022.122282] [Reference Citation Analysis]
|
| 74 |
Tokita K, Shimizu H, Takeuchi I, Shimizu T, Arai K. Long-Term Efficacy and Safety of Golimumab for Ulcerative Colitis in a Pediatric Inflammatory Bowel Disease Center in Japan. Pediatr Gastroenterol Hepatol Nutr 2022;25:461-72. [PMID: 36451693 DOI: 10.5223/pghn.2022.25.6.461] [Reference Citation Analysis]
|
| 75 |
Horiuchi I, Horiuchi A, Umemura T. Serum Leucine-Rich α2 Glycoprotein: A Biomarker for Predicting the Presence of Ulcerative Colitis but Not Ulcerative Proctitis. J Clin Med 2022;11. [PMID: 36362594 DOI: 10.3390/jcm11216366] [Reference Citation Analysis]
|
| 76 |
Murphy ME, Bhattacharya S, Axelrad JE. Diagnosis and Monitoring of Ulcerative Colitis. Clin Colon Rectal Surg 2022;35:421-7. [PMID: 36591402 DOI: 10.1055/s-0042-1758047] [Reference Citation Analysis]
|
| 77 |
Dotti I, Mayorgas A, Salas A. Generation of human colon organoids from healthy and inflammatory bowel disease mucosa. PLoS One 2022;17:e0276195. [PMID: 36301950 DOI: 10.1371/journal.pone.0276195] [Reference Citation Analysis]
|
| 78 |
Hawa K, Maltz R, Donegan A, Prasad V, Dotson JL, Boyle B, Michel HK. Postcolectomy Enteritis in a Pediatric Patient With Ulcerative Colitis. JPGN Reports 2022;3:e255. [DOI: 10.1097/pg9.0000000000000255] [Reference Citation Analysis]
|
| 79 |
Kitahata S, Furukawa S, Miyake T, Shiraishi K, Tange K, Hashimoto Y, Yagi S, Ninomiya T, Suzuki S, Shibata N, Murakami H, Ohashi K, Tomida H, Yamamoto Y, Takeshita E, Ikeda Y, Hiasa Y. Association between socioeconomic status and mucosal healing in Japanese patients with ulcerative colitis: a cross-sectional study. BMJ Open Gastroenterol 2022;9:e001000. [PMID: 36261231 DOI: 10.1136/bmjgast-2022-001000] [Reference Citation Analysis]
|
| 80 |
Bahnam P, Hanzel J, Ma C, Zou L, Narula N, Singh S, Kahan B, Jairath V. Most placebo-controlled trials in inflammatory bowel disease were underpowered because of overestimated drug efficacy rates: Results from a systematic review of induction studies. J Crohns Colitis 2022:jjac150. [PMID: 36219564 DOI: 10.1093/ecco-jcc/jjac150] [Reference Citation Analysis]
|
| 81 |
Haga K, Shibuya T, Osada T, Sato S, Fukuo Y, Kobayashi O, Yamada T, Asaoka D, Ito K, Nomura K, Haraikawa M, Nomura O, Fukushima H, Murakami T, Ishikawa D, Hojo M, Nagahara A. Early Clinical Remission Is a Predictor of Long-Term Remission with the Use of Vedolizumab for Ulcerative Colitis. Biomedicines 2022;10:2526. [PMID: 36289788 DOI: 10.3390/biomedicines10102526] [Reference Citation Analysis]
|
| 82 |
Miyazu T, Ishida N, Asai Y, Tamura S, Tani S, Yamade M, Hamaya Y, Iwaizumi M, Osawa S, Furuta T, Baba S, Sugimoto K. Importance of eosinophilic infiltration of the colonic mucosa in ulcerative colitis patients who are refractory to maintenance therapy: A prospective, single-center study. Medicine (Baltimore) 2022;101:e31017. [PMID: 36221337 DOI: 10.1097/MD.0000000000031017] [Reference Citation Analysis]
|
| 83 |
Elamir A, Shaker O, Kamal M, Khalefa A, Abdelwahed M, Abd El Reheem F, Ahmed T, Hassan E, Ayoub S. Expression profile of serum LncRNA THRIL and MiR-125b in inflammatory bowel disease. PLoS One 2022;17:e0275267. [PMID: 36206229 DOI: 10.1371/journal.pone.0275267] [Reference Citation Analysis]
|
| 84 |
Fang N, Deng H, Fu T, Zhang Z, Long X, Wang X, Tian L. Association between caregiver ability and quality of life for people with inflammatory bowel disease: The mediation effect of positive feelings of caregivers. Front Psychol 2022;13:988150. [DOI: 10.3389/fpsyg.2022.988150] [Reference Citation Analysis]
|
| 85 |
Hanzel J, Bossuyt P, Pittet V, Samaan M, Tripathi M, Czuber-Dochan W, Burisch J, Leone S, Saldaña R, Baert F, Kopylov U, Jäghult S, Adamina M, Arebi N, Gecse K. Development of a Core Outcome Set for Real-World Data in Inflammatory Bowel Disease: A European Crohn's and Colitis Organisation (ECCO) Position Paper. J Crohns Colitis 2022:jjac136. [PMID: 36190188 DOI: 10.1093/ecco-jcc/jjac136] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 86 |
Bessissow T, Kron CM, Marcus V, Lemieux C, Laneuville J, Afif W, Wild G, Lakatos PL, Brassard P, Bitton A. Impact of Endoscopic and Histologic Activity on Disease Relapse in Ulcerative Colitis. Am J Gastroenterol 2022;117:1632-8. [PMID: 35862833 DOI: 10.14309/ajg.0000000000001912] [Reference Citation Analysis]
|
| 87 |
Marinelli C, Zingone F, Lupo MG, Marin R, D'Incà R, Gubbiotti A, Massimi D, Casadei C, Barberio B, Ferri N, Savarino E. Serum Levels of PCSK9 Are Increased in Patients With Active Ulcerative Colitis Representing a Potential Biomarker of Disease Activity: A Cross-sectional Study. J Clin Gastroenterol 2022;56:787-93. [PMID: 34560758 DOI: 10.1097/MCG.0000000000001607] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 88 |
Schairer J, Fahad H. Endoscopy in the Surgically Altered Bowel. Gastrointest Endosc Clin N Am 2022;32:777-99. [PMID: 36202516 DOI: 10.1016/j.giec.2022.05.009] [Reference Citation Analysis]
|
| 89 |
Visseren T, Erler NS, Heimbach JK, Eaton JE, Selzner N, Gulamhusein A, van der Heide F, Porte RJ, van Hoek B, Alwayn IP, Metselaar HJ, Ijzermans JN, Darwish Murad S. Inflammatory conditions play a role in recurrence of PSC after liver transplantation – an international multicentre study. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100599] [Reference Citation Analysis]
|
| 90 |
Kamp KJ, Hawes SE, Tse CS, Singh S, Dang N, Oberai R, Weaver SA, Melmed GY, Siegel CA, van Deen WK; IBD Qorus. Concordance and Discordance Between Patient-reported Remission, Patient-reported Outcomes, and Physician Global Assessment. Inflamm Bowel Dis 2022:izac206. [PMID: 36179129 DOI: 10.1093/ibd/izac206] [Reference Citation Analysis]
|
| 91 |
Démaris A, Widigson ESK, Ilvemark JFKF, Steenholdt C, Seidelin JB, Huisinga W, Michelet R, Aulin LBS, Kloft C. Ulcerative Colitis and Acute Severe Ulcerative Colitis Patients Are Overlooked in Infliximab Population Pharmacokinetic Models: Results from a Comprehensive Review. Pharmaceutics 2022;14:2095. [PMID: 36297530 DOI: 10.3390/pharmaceutics14102095] [Reference Citation Analysis]
|
| 92 |
Niu W, Chen Y, Wang L, Li J, Cui Z, Lv J, Yang F, Huo J, Zhang Z, Ju J. The combination of sodium alginate and chlorogenic acid enhances the therapeutic effect on ulcerative colitis by the regulation of inflammation and the intestinal flora. Food Funct 2022. [PMID: 36173280 DOI: 10.1039/d2fo01619b] [Reference Citation Analysis]
|
| 93 |
Peerani F, Watt M, Ismond KP, Whitlock R, Ambrosio L, Hotte N, Mitchell N, Bailey RJ, Kroeker K, Dieleman LA, Siffledeen J, Lim A, Wong K, Halloran BP, Baumgart DC, Taylor L, Raman M, Madsen KL, Tandon P. A randomized controlled trial of a multicomponent online stress reduction intervention in inflammatory bowel disease. Therap Adv Gastroenterol 2022;15:17562848221127238. [PMID: 36187365 DOI: 10.1177/17562848221127238] [Reference Citation Analysis]
|
| 94 |
Inciuraite R, Ramonaite R, Kupcinskas J, Dalgediene I, Kulokiene U, Kiudelis V, Varkalaite G, Zvirbliene A, Jonaitis LV, Kiudelis G, Franke A, Juzenas S, Skieceviciene J. Crypt-top and crypt-bottom colonic epithelial cell microRNA profiling reveals cell type-specific response in active and quiescent ulcerative colitis.. [DOI: 10.1101/2022.09.25.22280336] [Reference Citation Analysis]
|
| 95 |
Ishida N, Kaneko M, Asai Y, Miyazu T, Tamura S, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. Effect of disease duration on fecal biomarkers in ulcerative colitis: a prospective cohort study. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02502-8] [Reference Citation Analysis]
|
| 96 |
Lolli E, De Cristofaro E, Marafini I, Troncone E, Neri B, Zorzi F, Biancone L, Calabrese E, Monteleone G. Endoscopic Predictors of Neoplastic Lesions in Inflammatory Bowel Diseases Patients Undergoing Chromoendoscopy. Cancers (Basel) 2022;14. [PMID: 36139586 DOI: 10.3390/cancers14184426] [Reference Citation Analysis]
|
| 97 |
Gordon BL, Galati JS, Yang S, Longman RS, Lukin D, Scherl EJ, Battat R. Prevalence and factors associated with vitamin C deficiency in inflammatory bowel disease. World J Gastroenterol 2022; 28(33): 4834-4845 [DOI: 10.3748/wjg.v28.i33.4834] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 98 |
Uraoka T, Igarashi M. Development and clinical usefulness of a unique red dichromatic imaging technology in gastrointestinal endoscopy: A narrative review. Therap Adv Gastroenterol 2022;15:17562848221118302. [PMID: 36082177 DOI: 10.1177/17562848221118302] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 99 |
Nielsen DL, Juhl CB, Chen IM, Kellermann L, Nielsen OH. Immune checkpoint Inhibitor–Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis. Cancer Treatment Reviews 2022;109:102440. [DOI: 10.1016/j.ctrv.2022.102440] [Reference Citation Analysis]
|
| 100 |
Jena A, Dutta U, Shah J, Sharma V, Prasad KK, Shivaprakash RM, Mandavdhare HS, Samanta J, Sharma P, Popli P, Sharma AK, Sinha SK, Chakrabarti A, Kochhar R. Oral Fluconazole Therapy in Patients With Active Ulcerative Colitis Who Have Detectable Candida in the Stool : A Double-Blind Randomized Placebo-controlled Trial. J Clin Gastroenterol 2022;56:705-11. [PMID: 34516459 DOI: 10.1097/MCG.0000000000001609] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 101 |
Mc Gettigan N, Hanley M, Skelly F, Dowling J, Dunne R, Morrin MM, Mccaffrey N, O'toole A, Boland K. Impact of a physician-led exercise programme on quality of life, muscle mass and clinical response in inflammatory bowel disease patients during induction with disease-modifying therapy: a study protocol. BMJ Open Gastroenterol 2022;9:e000959. [DOI: 10.1136/bmjgast-2022-000959] [Reference Citation Analysis]
|
| 102 |
Inaba K, Higashiyama M, Watanabe C, Tomioka A, Ito S, Tanemoto R, Mizoguchi A, Nishii S, Wada A, Sugihara N, Hanawa Y, Horiuchi K, Akita Y, Okada Y, Kurihara C, Narimatsu K, Komoto S, Tomita K, Karasuyama H, Satoh T, Hokari R. Proinflammatory role of basophils in oxazolone-induced chronic intestinal inflammation. J Gastroenterol Hepatol 2022;37:1768-75. [PMID: 35877196 DOI: 10.1111/jgh.15964] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 103 |
Fujii R, Awaga Y, Nozawa K, Matsushita M, Hama A, Natsume T, Takamatsu H. Regional brain activation during rectal distention and attenuation with alosetron in a nonhuman primate model of irritable bowel syndrome. FASEB BioAdvances 2022. [DOI: 10.1096/fba.2022-00048] [Reference Citation Analysis]
|
| 104 |
Zhu S, Han M, Liu S, Fan L, Shi H, Li P. Composition and diverse differences of intestinal microbiota in ulcerative colitis patients. Front Cell Infect Microbiol 2022;12:953962. [DOI: 10.3389/fcimb.2022.953962] [Reference Citation Analysis]
|
| 105 |
Nagasaka M, Nakagawa Y, Kamano T, Omori T, Nakaoka K, Funasaka K, Miyahara R, Hashimoto S, Shibata T, Hirooka Y. Endoscopic imaging in inflammatory bowel disease. J Med Ultrason (2001) 2022. [PMID: 36036332 DOI: 10.1007/s10396-022-01250-2] [Reference Citation Analysis]
|
| 106 |
Caron B, Jairath V, D'Amico F, Paridaens K, Magro F, Danese S, Peyrin-Biroulet L. Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review. United European Gastroenterol J 2022. [PMID: 36029157 DOI: 10.1002/ueg2.12283] [Reference Citation Analysis]
|
| 107 |
Knyazev OV, Kagramanova AV, Lishchinskaya AA, Babaian AF, Shkurko TV, Nanaeva BA, Li IA. Comparative evaluation of the effectiveness of monotherapy of ulcerative colitis with mesalazine MMX and combination therapy with non-prolonged mesalazines with rectal forms. Medicinskij sovet 2022. [DOI: 10.21518/2079-701x-2022-16-14-96-106] [Reference Citation Analysis]
|
| 108 |
Ishida N, Tani S, Asai Y, Miyazu T, Tamura S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. Lymphocyte to monocyte ratio and serum albumin changes predict tacrolimus therapy outcomes in patients with ulcerative colitis. Sci Rep 2022;12:13572. [PMID: 35945329 DOI: 10.1038/s41598-022-17763-2] [Reference Citation Analysis]
|
| 109 |
Aloi M, D'Arcangelo G, Rossetti D, Bucherini S, Felici E, Romano C, Martinelli M, Dipasquale V, Lionetti P, Oliva S. Occurrence and Clinical Impact of Eosinophilic Esophagitis in a Large Cohort of Children With Inflammatory Bowel Disease. Inflamm Bowel Dis 2022:izac172. [PMID: 35942651 DOI: 10.1093/ibd/izac172] [Reference Citation Analysis]
|
| 110 |
Carreras J. Artificial Intelligence Analysis of Ulcerative Colitis Using an Autoimmune Discovery Transcriptomic Panel. Healthcare 2022;10:1476. [DOI: 10.3390/healthcare10081476] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 111 |
Dziegielewski C, Gupta S, McCurdy JD, Sy R, Saloojee N, Murthy SK. Pancolonic Dye Spray Chromoendoscopy to Detect and Resect Ill-Defined Neoplastic Lesions in Colonic Inflammatory Bowel Disease. J Can Assoc Gastroenterol 2023;6:37-41. [PMID: 36789142 DOI: 10.1093/jcag/gwac024] [Reference Citation Analysis]
|
| 112 |
Sood A, Singh A, Mahajan R, Midha V, Bernstein CN, Rubin DT. (Re)Appraising Remission in Ulcerative Colitis. Inflamm Bowel Dis 2022:izac170. [PMID: 35917172 DOI: 10.1093/ibd/izac170] [Reference Citation Analysis]
|
| 113 |
Ruan GC, Jin X, Zhou WX, You Y, Iacucci M, Ghosh S, Gui XY, Li J, Qian JM. External validation of the Paddington International Virtual Electronic ChromoendoScopy ScOre as a good endoscopic score to define mucosal healing and predict long-term clinical outcomes in ulcerative colitis. J Dig Dis 2022;23:446-54. [PMID: 36121308 DOI: 10.1111/1751-2980.13126] [Reference Citation Analysis]
|
| 114 |
Ghiassian SD, Voitalov I, Withers JB, Santolini M, Saleh A, Akmaev VR. Network-based response module comprised of gene expression biomarkers predicts response to infliximab at treatment initiation in ulcerative colitis. Transl Res 2022;246:78-86. [PMID: 35306220 DOI: 10.1016/j.trsl.2022.03.006] [Reference Citation Analysis]
|
| 115 |
Vaziri H, Turshudzhyan A, Vecchio E. Immunotherapy-induced Colitis: A Comprehensive Review of Epidemiology, Clinical Presentation, Diagnostic Workup, and Management Plan. J Clin Gastroenterol 2022;56:555-64. [PMID: 35470301 DOI: 10.1097/MCG.0000000000001705] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 116 |
Agraib LM, Yamani MI, Tayyem R, Abu-sneineh AT, Rayyan YM. Probiotic supplementation induces remission and changes in the immunoglobulins and inflammatory response in active ulcerative colitis patients: A pilot, randomized, double-blind, placebo-controlled study. Clinical Nutrition ESPEN 2022. [DOI: 10.1016/j.clnesp.2022.08.020] [Reference Citation Analysis]
|
| 117 |
Mocci G, Bodini G, Allegretta L, Cazzato AI, Chiri S, Aragona G, Perazzo P, Ferronato A, Graziani MG, Pagnini C, Zampaletta C, Graziosi C, Picchio M, Elisei W, Maconi G, Tursi A. Adalimumab Biosimilar GP2017 versus Adalimumab Originator in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study. Biomedicines 2022;10:1799. [DOI: 10.3390/biomedicines10081799] [Reference Citation Analysis]
|
| 118 |
Song Z, Zhang M, Ren Y, Iang B. [Improved Mayo Endoscopic Score has a higher value for evaluating clinical severity of ulcerative colitis]. Nan Fang Yi Ke Da Xue Xue Bao 2022;42:997-1005. [PMID: 35869761 DOI: 10.12122/j.issn.1673-4254.2022.07.05] [Reference Citation Analysis]
|
| 119 |
Tavakoli P, Vollmer-conna U, Hadzi-pavlovic D, Vázquez-campos X, Grimm MC. The Interplay Between Use of Biological Therapies, Psychological State, and the Microbiome in IBD. Front Med 2022;9. [DOI: 10.3389/fmed.2022.788992] [Reference Citation Analysis]
|
| 120 |
Bar-Yoseph H, Blatt A, Gerassy S, Pressman S, Mousa A, Sabo E, Waterman M, Ungar B, Ben-Horin S, Chowers Y. Differential Serum-intestinal Dynamics of Infliximab and Adalimumab in Inflammatory Bowel Disease Patients. J Crohns Colitis 2022;16:884-92. [PMID: 34849649 DOI: 10.1093/ecco-jcc/jjab208] [Reference Citation Analysis]
|
| 121 |
Gundersen MD, Larsen KB, Johnsen KM, Goll R, Florholmen J, Haraldsen G. Hypo-osmotic stress induces the epithelial alarmin IL-33 in the colonic barrier of ulcerative colitis. Sci Rep 2022;12:11550. [PMID: 35798804 DOI: 10.1038/s41598-022-15573-0] [Reference Citation Analysis]
|
| 122 |
Schwab E, Cula GO, Standish K, Yip SSF, Stojmirovic A, Ghanem L, Chehoud C. Automatic estimation of ulcerative colitis severity from endoscopy videos using ordinal multi-instance learning. Computer Methods in Biomechanics and Biomedical Engineering: Imaging & Visualization 2022;10:425-433. [DOI: 10.1080/21681163.2021.1997644] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 123 |
Matsuoka K, Watanabe M, Ohmori T, Nakajima K, Ishida T, Ishiguro Y, Kanke K, Kobayashi K, Hirai F, Watanabe K, Mizusawa H, Kishida S, Miura Y, Ohta A, Kajioka T, Hibi T, Motoya S, Maemoto A, Fujiya M, Ashida T, Goto M, Matsumoto T, Suzuki Y, Hamahata Y, Nakagawa T, Kato N, Kato J, Endo Y, Suzuki R, Matsuda K, Ohmiya N, Katsushima S, Hosomi S, Tarumi K, Watanabe C, Saito M, Yokoyama Y, Inaba T, Sakata Y, Hongo H, Shibuya T, Kawakami K, Kakuta Y, Irisawa A, Yoshimura N, Fukuda K, Shirai T, Ichikawa H, Nagata J, Suzuki T, Yokoyama K, Tomidokoro T, Kojima Y, Yamada M, Yamamoto H, Yamamoto T, Horiki N, Obata H, Inoue S, Tanaka S, Toyokawa T, Kunihiro M, Hisabe T, Ogata S, Takeshima F, Matsushima K, Matsuhashi N, Sakuraba H, Iwabuchi M, Tsuchiya A, Uchiyama K, Kanai T, Nakamura M, Yokoyama T, Hida N, Mitsuyama K, Osada T, Hiraoka S, Tsuzuki T, Masuo T, Hokari R, Kobayashi T, Saruta M, Araki M, Araki H, Shimizu M, Kikuchi M, Nishikawa T, Takedatsu H, Aoyagi K, Ochiai T, Toda N, Mizokami Y, Nagahori M, Matsueda K, Kino H, Kanamori A, Suzuki T, Sakurai T, Kudo M, Kitano A, Hisamatsu T, Kumagai S, Ninomiya T, Mori K, Yoshida S, Goto M. AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. The Lancet Gastroenterology & Hepatology 2022;7:648-57. [DOI: 10.1016/s2468-1253(22)00022-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 124 |
Golovics PA, Gonczi L, Reinglas J, Verdon C, Pundir S, Afif W, Wild G, Bitton A, Bessissow T, Lakatos PL. Patient-Reported Outcome and Clinical Scores Are Equally Accurate in Predicting Mucosal Healing in Ulcerative Colitis: A Prospective Study. Dig Dis Sci 2022;67:3089-95. [PMID: 34286411 DOI: 10.1007/s10620-021-07178-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 125 |
Header D, Aboelwafa R, Elkeleny M, Bedewy E, Ellakany A. C-reactive protein/albumin ratio (CAR) as a marker for detecting acute severe ulcerative colitis in Egyptian patients. Revista de Gastroenterología de México (English Edition) 2022. [DOI: 10.1016/j.rgmxen.2022.06.007] [Reference Citation Analysis]
|
| 126 |
Sathiaseelan M, Bolia R, Barallon R, Alex G, Hardikar W, Rajanayagam J. Impact of ulcerative colitis on liver-related outcomes of children with primary sclerosing cholangitis. J Paediatr Child Health 2022;58:1221-7. [PMID: 35373867 DOI: 10.1111/jpc.15954] [Reference Citation Analysis]
|
| 127 |
Cannatelli R, Bazarova A, Furfaro F, Parigi TL, Zardo D, Nardone OM, Spaggiari P, Villanacci V, Cadei M, Labarile N, Smith SCL, Danese S, Ghosh S, Iacucci M. Reproducibility of the electronic chromoendoscopy PICaSSO score (Paddington International Virtual ChromoendoScopy ScOre) in ulcerative colitis using multiple endoscopic platforms: a prospective multicenter international study (with video). Gastrointest Endosc 2022;96:73-83. [PMID: 35182574 DOI: 10.1016/j.gie.2022.02.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 128 |
Takishima K, Maeda Y, Ogata N, Misawa M, Mori Y, Homma M, Nemoto T, Miyata Y, Akimoto Y, Mochida K, Takashina Y, Tanaka K, Ichimasa K, Nakamura H, Sasanuma S, Kudo T, Hayashi T, Wakamura K, Miyachi H, Baba T, Ishida F, Ohtsuka K, Kudo SE. Beyond complete endoscopic healing: Goblet appearance using an endocytoscope to predict future sustained clinical remission in ulcerative colitis. Dig Endosc 2022;34:1030-9. [PMID: 34816494 DOI: 10.1111/den.14202] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 129 |
Mukherjee A, Tsuchiwata S, Nicholas T, Cook JA, Modesto I, Su C, D'Haens GR, Sandborn WJ. Exposure-Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies. Clin Pharmacol Ther 2022;112:90-100. [PMID: 35380740 DOI: 10.1002/cpt.2601] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 130 |
Kim KO. Endoscopic activity in inflammatory bowel disease: clinical significance and application in practice. Clin Endosc 2022;55:480-8. [PMID: 35898147 DOI: 10.5946/ce.2022.108] [Reference Citation Analysis]
|
| 131 |
Emeasoba EU, Ibeson CE, Kundal S, Biondi S, Nwosu I, Golfeyz S, Kantrowitz M, Khodorskiy D. A Rare Case of New-Onset Ulcerative Colitis in a Nonagenarian. Cureus 2022. [DOI: 10.7759/cureus.26203] [Reference Citation Analysis]
|
| 132 |
Axelrad J, Long M, Horst S, Afzali A, Sapir T, Fajardo K, De Felice K, Sandler R, Cross R. A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence with Inflammatory Bowel DiSease Therapy—ASSIST Study: A Randomized Controlled Trial (Preprint).. [DOI: 10.2196/preprints.40382] [Reference Citation Analysis]
|
| 133 |
Higuchi N, Hiraga H, Sasaki Y, Hiraga N, Igarashi S, Hasui K, Ogasawara K, Maeda T, Murai Y, Tatsuta T, Kikuchi H, Chinda D, Mikami T, Matsuzaka M, Sakuraba H, Fukuda S. Automated evaluation of colon capsule endoscopic severity of ulcerative colitis using ResNet50. PLoS One 2022;17:e0269728. [PMID: 35687553 DOI: 10.1371/journal.pone.0269728] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 134 |
Ishida N, Asai Y, Miyazu T, Tamura S, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. Lymphocyte-to-monocyte ratio is a short-term predictive marker of ulcerative colitis after induction of advanced therapy. Gastroenterol Rep (Oxf) 2022;10:goac025. [PMID: 35692303 DOI: 10.1093/gastro/goac025] [Reference Citation Analysis]
|
| 135 |
Pednekar DD, Liguori MA, Marques CNH, Zhang T, Zhang N, Zhou Z, Amoako K, Gu H. From Static to Dynamic: A Review on the Role of Mucus Heterogeneity in Particle and Microbial Transport. ACS Biomater Sci Eng 2022. [PMID: 35696291 DOI: 10.1021/acsbiomaterials.2c00182] [Reference Citation Analysis]
|
| 136 |
Jedel S, Beck T, Swanson G, Hood MM, Voigt RM, Gorenz A, Jakate S, Raeisi S, Hobfoll S, Keshavarzian A. Mindfulness Intervention Decreases Frequency and Severity of Flares in Inactive Ulcerative Colitis Patients: Results of a Phase II, Randomized, Placebo-Controlled Trial. Inflamm Bowel Dis 2022;28:1872-92. [PMID: 35661212 DOI: 10.1093/ibd/izac036] [Reference Citation Analysis]
|
| 137 |
Caputo A, Parente P, Cadei M, Fassan M, Rispo A, Leoncini G, Bassotti G, Del Sordo R, Metelli C, Daperno M, Armuzzi A, Villanacci V; SHMHS Study Group. Simplified Histologic Mucosal Healing Scheme (SHMHS) for inflammatory bowel disease: a nationwide multicenter study of performance and applicability. Tech Coloproctol 2022. [PMID: 35648263 DOI: 10.1007/s10151-022-02628-7] [Reference Citation Analysis]
|
| 138 |
Ferrante M, Schirbel A, Pierik MJ, Haas T, Flamant M, Khalifa A, Philip G, Cornillie F, Meehan AG, Govoni M. Patient-reported continuous clinical response to golimumab in adults with moderately to severely active ulcerative colitis: results from GO OBSERVE, a real-world European observational study. Eur J Gastroenterol Hepatol 2022;34:646-54. [PMID: 35412484 DOI: 10.1097/MEG.0000000000002374] [Reference Citation Analysis]
|
| 139 |
Yoshida A, Kimura K, Morizane T, Ueno F. Predictor of primary response to antitumor necrosis factor-α therapy for inflammatory bowel disease: a single-center observational study. Eur J Gastroenterol Hepatol 2022;34:640-5. [PMID: 35352693 DOI: 10.1097/MEG.0000000000002372] [Reference Citation Analysis]
|
| 140 |
Sassaki LY, Magro DO, Saad-hossne R, Baima JP, Flores C, Correia LM, Celani LMS, De Abreu Ferrari MDL, Zacharias P, Feitosa MR, Dos Santos CHM, De Freitas Lins Neto MA, Quaresma AB, De Lima Junior SF, De Vasconcelos GBS, Cassol OS, Dos Santos Pinto A, Kurachi G, Goncalves Filho FDA, Gasparini RG, Furlan TK, Catapani WR, Coy CSR, De Souza Menegassi V, Colombo MM, Fróes RDSB, Teixeira FV, Moraes AC, Santana GO, Parente JML, Vilela EG, Queiroz NSF, Kotze PG; GEDIIB (Brazilian Study Group of IBD). Anti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB). BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02341-7] [Reference Citation Analysis]
|
| 141 |
Janker L, Schuster D, Bortel P, Hagn G, Brunmair J, Meier-menches SM, Mader JC, Slany A, Bileck A, Madl C, Unger L, Hennlich B, Weitmayr B, Del Favero G, Pils D, Pukrop T, Pfisterer N, Feichtenschlager T, Gerner C. Multi-omics empowered deep phenotyping of ulcerative colitis.. [DOI: 10.1101/2022.05.25.22275502] [Reference Citation Analysis]
|
| 142 |
Hanzel J, Jairath V. A TIGER Among Endoscopic Indices in Inflammatory Bowel Disease. J Crohns Colitis 2022;16:519-20. [PMID: 35060602 DOI: 10.1093/ecco-jcc/jjab235] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 143 |
Zittan E, Steinhart AH, Aran H, Milgrom R, Gralnek IM, Zelber-Sagi S, Silverberg MS. The Toronto IBD Global Endoscopic Reporting [TIGER] Score: A Single, Easy to Use Endoscopic Score for Both Crohn's Disease and Ulcerative Colitis Patients. J Crohns Colitis 2022;16:544-53. [PMID: 34272937 DOI: 10.1093/ecco-jcc/jjab122] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 144 |
Weiß F, Czichos C, Knobe L, Voges L, Bojarski C, Michel G, Fromm M, Krug SM. MarvelD3 Is Upregulated in Ulcerative Colitis and Has Attenuating Effects during Colitis Indirectly Stabilizing the Intestinal Barrier. Cells 2022;11:1541. [DOI: 10.3390/cells11091541] [Reference Citation Analysis]
|
| 145 |
Bullard EA, Mundo AI, Bess SN, Priest KM, Muldoon TJ. Minimally Invasive In Vivo Endoscopic Monitoring of Dextran Sulfate Sodium-induced Murine Colitis. MethodsX 2022. [DOI: 10.1016/j.mex.2022.101744] [Reference Citation Analysis]
|
| 146 |
Gui X, Bazarova A, Del Amor R, Vieth M, de Hertogh G, Villanacci V, Zardo D, Parigi TL, Røyset ES, Shivaji UN, Monica MAT, Mandelli G, Bhandari P, Danese S, Ferraz JG, Hayee B, Lazarev M, Parra-Blanco A, Pastorelli L, Panaccione R, Rath T, Tontini GE, Kiesslich R, Bisschops R, Grisan E, Naranjo V, Ghosh S, Iacucci M. PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system. Gut 2022;71:889-98. [PMID: 35173041 DOI: 10.1136/gutjnl-2021-326376] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 147 |
Ge C, Lu Y, Shen H, Zhu L. Monitoring of intestinal inflammation and prediction of recurrence in ulcerative colitis. Scandinavian Journal of Gastroenterology 2022;57:513-524. [DOI: 10.1080/00365521.2021.2022193] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 148 |
Header D, Aboelwafa R, Elkeleny M, Bedewy E, Ellakany A. El índice proteína C reactiva/albúmina como marcador para detectar colitis aguda ulcerosa grave en pacientes egipcios. Revista de Gastroenterología de México 2022. [DOI: 10.1016/j.rgmx.2021.03.010] [Reference Citation Analysis]
|
| 149 |
Gravina AG, Federico A, Facchiano A, Scidà G, Pellegrino R, Palladino G, Loguercio C, Docimo L, Romano M, Tolone S. Anorectal Function with High-Resolution Anorectal Manometry in Active Ulcerative Colitis and after Remission: A Pilot Study. Rev Recent Clin Trials 2022;17:97-102. [PMID: 35570544 DOI: 10.2174/1574887117666220513110705] [Reference Citation Analysis]
|
| 150 |
Sakurai T, Akita Y, Miyashita H, Miyazaki R, Maruyama Y, Saito T, Shimada M, Yamasaki T, Arhihiro S, Kato T, Matsuura T, Ikegami M, Okayasu I, Saruta M. Prostaglandin E-major urinary metabolite diagnoses mucosal healing in patients with ulcerative colitis in remission phase. J Gastroenterol Hepatol 2022;37:847-54. [PMID: 35064604 DOI: 10.1111/jgh.15782] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 151 |
Najdawi F, Sucipto K, Mistry P, Hennek S, Jayson C, Lin M, Fahy D, Kinsey S, Wapinski I, Beck AH, Resnick MB, Khosla A, Drage MG. Artificial Intelligence Enables Quantitative Assessment of Ulcerative Colitis Histology.. [DOI: 10.1101/2022.04.28.22274339] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 152 |
Nardone OM, Snir Y, Hodson J, Cannatelli R, Labarile N, Siau K, Hassan C, Yanai H, Dotan I, Ghosh S, Iacucci M. Advanced technology for assessment of endoscopic and histological activity in ulcerative colitis: a systematic review and meta-analysis. Therap Adv Gastroenterol 2022;15:17562848221092594. [PMID: 35509428 DOI: 10.1177/17562848221092594] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 153 |
Maeda Y, Kudo SE, Ogata N, Misawa M, Iacucci M, Homma M, Nemoto T, Takishima K, Mochida K, Miyachi H, Baba T, Mori K, Ohtsuka K, Mori Y. Evaluation in real-time use of artificial intelligence during colonoscopy to predict relapse of ulcerative colitis: a prospective study. Gastrointest Endosc 2022;95:747-756.e2. [PMID: 34695422 DOI: 10.1016/j.gie.2021.10.019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 154 |
Dubinsky MC, Irving PM, Panaccione R, Naegeli AN, Potts-Bleakman A, Arora V, Shan M, Travis S. Incorporating patient experience into drug development for ulcerative colitis: development of the Urgency Numeric Rating Scale, a patient-reported outcome measure to assess bowel urgency in adults. J Patient Rep Outcomes 2022;6:31. [PMID: 35362902 DOI: 10.1186/s41687-022-00439-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 155 |
Smith BJ, Piceno Y, Zydek M, Zhang B, Syriani LA, Terdiman JP, Kassam Z, Ma A, Lynch SV, Pollard KS, El-Nachef N. Strain-resolved analysis in a randomized trial of antibiotic pretreatment and maintenance dose delivery mode with fecal microbiota transplant for ulcerative colitis. Sci Rep 2022;12:5517. [PMID: 35365713 DOI: 10.1038/s41598-022-09307-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 156 |
Plevris N, Lees CW. Disease Monitoring in Inflammatory Bowel Disease: Evolving Principles and Possibilities. Gastroenterology 2022;162:1456-1475.e1. [PMID: 35101422 DOI: 10.1053/j.gastro.2022.01.024] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 157 |
Khanna R, Ma C, Jairath V, Vande Casteele N, Zou G, Feagan BG. Endoscopic Assessment of Inflammatory Bowel Disease Activity in Clinical Trials. Clin Gastroenterol Hepatol 2022;20:727-736.e2. [PMID: 33338657 DOI: 10.1016/j.cgh.2020.12.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 158 |
Raine T, Pavey H, Qian W, Moran GW, Subramanian S, Swaby L, Travis SP, Din S, Irving PM, Lindsay JO, Parkes M, Kennedy NA. Establishment of a validated central reading system for ileocolonoscopy in an academic setting. Gut 2022;71:661-4. [PMID: 35022265 DOI: 10.1136/gutjnl-2021-325575] [Reference Citation Analysis]
|
| 159 |
Limpias Kamiya KJ, Hosoe N, Hayashi Y, Kawaguchi T, Takabayashi K, Ogata H, Kanai T. Video capsule endoscopy in inflammatory bowel disease. DEN Open 2022;2. [DOI: 10.1002/deo2.26] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 160 |
Le Berre C, Ricciuto A, Peyrin-Biroulet L, Turner D. Evolving Short- and Long-Term Goals of Management of Inflammatory Bowel Diseases: Getting It Right, Making It Last. Gastroenterology 2022;162:1424-38. [PMID: 34995529 DOI: 10.1053/j.gastro.2021.09.076] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 161 |
Lokhmatov MM, Budkina TN, Khavkin AI, Tupylenko AV, Oldakovsky VI. Draft clinical guidelines for endoscopic diagnosis of ulcerative colitis in children. jour 2022. [DOI: 10.31146/1682-8658-ecg-197-1-87-98] [Reference Citation Analysis]
|
| 162 |
Pang L, Liu H, Liu Z, Tan J, Zhou LY, Qiu Y, Lin X, He J, Li X, Lin S, Ghosh S, Mao R, Chen M. Role of Telemedicine in Inflammatory Bowel Disease: Systematic Review and Meta-analysis of Randomized Controlled Trials. J Med Internet Res 2022;24:e28978. [PMID: 35323120 DOI: 10.2196/28978] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 163 |
Hyams JS, Turner D, Cohen SA, Szakos E, Kowalska-Duplaga K, Ruemmele F, Croft NM, Korczowski B, Lawrence P, Bhatia S, Kadali H, Chen C, Sun W, Rosario M, Kabilan S, Treem W, Rossiter G, Lirio RA. Pharmacokinetics, Safety and Efficacy of Intravenous Vedolizumab in Paediatric Patients with Ulcerative Colitis or Crohn's Disease: Results from the Phase 2 HUBBLE Study. J Crohns Colitis 2022;16:1243-54. [PMID: 35301512 DOI: 10.1093/ecco-jcc/jjac036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 164 |
Xu W, Liu F, Tang W, Gu Y, Zhong J, Cui L, Du P. The Mayo Endoscopic Score Is a Novel Predictive Indicator for Malignant Transformation in Ulcerative Colitis: A Long-Term Follow-Up Multicenter Study. Front Surg 2022;9:832219. [DOI: 10.3389/fsurg.2022.832219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 165 |
Sinagra E, Busacca A, Guida L, Carrozza L, Brinch D, Crispino F, Maida M, Battaglia S, Celsa C, Cammà C, Cappello M. Telemedicine Is an Effective Tool to Monitor Disease Activity in IBD Patients in the COVID-19 Era: A Single Centre Experience Based on Objective Data. Gastroenterology Insights 2022;13:117-26. [DOI: 10.3390/gastroent13010013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 166 |
Emoto S, Yokoyama Y, Nozawa H, Kawai K, Sasaki K, Murono K, Kishikawa J, Ozawa T, Abe S, Nagai Y, Anzai H, Sonoda H, Ishibashi R, Koike K, Ishihara S. Preoperative diagnosis of obstructive colitis in colorectal cancer patients who underwent self-expandable metallic stent insertion as a bridge to surgery. Asian J Surg 2022:S1015-9584(22)00193-2. [PMID: 35272908 DOI: 10.1016/j.asjsur.2022.02.026] [Reference Citation Analysis]
|
| 167 |
Vitello A, Grova M, Pugliese D, Rizzello F, Lanzarotto F, Lavagna A, Caccaro R, Cappello M, Viola A, Ribaldone DG, Principi M, Stasi E, Scribano ML, Maida M, Soriano A, Bezzio C, Bodini G, Mocciaro F, Privitera AC, Simondi D, Giuffrida E, D'Incà R, Ricci C, Gionchetti P, Armuzzi A, Orlando A, Daperno M; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy. Dig Liver Dis 2022;54:352-7. [PMID: 34538764 DOI: 10.1016/j.dld.2021.08.020] [Reference Citation Analysis]
|
| 168 |
Wang Y, Li C, Wang W, Wang J, Li J, Qian S, Cai C, Liu Y. Serum Albumin to Globulin Ratio is Associated with the Presence and Severity of Inflammatory Bowel Disease. JIR 2022;Volume 15:1907-20. [DOI: 10.2147/jir.s347161] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 169 |
Grimstad T, Skjellerudsveen BM, Kvaløy JT, Skoie IM, Carlsen A, Karlsen LN, Aabakken L, Omdal R. The influence of disease activity on fatigue in patients with ulcerative colitis - a longitudinal study. Scand J Gastroenterol 2022;57:290-7. [PMID: 34846950 DOI: 10.1080/00365521.2021.2007281] [Reference Citation Analysis]
|
| 170 |
Allocca M, Dell'Avalle C, Craviotto V, Furfaro F, Zilli A, D'Amico F, Bonovas S, Peyrin-Biroulet L, Fiorino G, Danese S. Predictive value of Milan ultrasound criteria in ulcerative colitis: A prospective observational cohort study. United European Gastroenterol J 2022. [PMID: 35233934 DOI: 10.1002/ueg2.12206] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 171 |
Nardone OM, Bazarova A, Bhandari P, Cannatelli R, Daperno M, Ferraz J, Goetz M, Gui X, Hayee B, De Hertogh G, Lazarev M, Li J, Parra-Blanco A, Pastorelli L, Panaccione R, Occhipinti V, Rath T, Smith SCL, Shivaji UN, Tontini GE, Vieth M, Villanacci V, Zardo D, Bisschops R, Kiesslich R, Ghosh S, Iacucci M. Endoscopic remission assessed with PICaSSO virtual electronic chromendoscopy accurately predicts clinical outcomes in ulcerative colitis. United European Gastroenterol J 2022. [PMID: 35194978 DOI: 10.1002/ueg2.12185] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 172 |
Sedano R, Hogan M, Nguyen TM, Chang J, Zou GY, Macdonald JK, Vande Casteele N, Hanzel J, Crowley E, Battat R, Dulai PS, Singh S, D'Haens G, Sandborn W, Feagan BG, Ma C, Jairath V. Systematic Review and Meta-Analysis: Clinical, Endoscopic, Histological and Safety Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. J Crohns Colitis 2022;16:224-43. [PMID: 34309658 DOI: 10.1093/ecco-jcc/jjab135] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 173 |
Stallmach A, Grunert P, Stallhofer J, Löffler B, Baier M, Rödel J, Kiehntopf M, Neugebauer S, Pieper DH, Junca H, Tannapfel A, Merkel U, Schumacher U, Breternitz-Gruhne M, Heller T, Schauer A, Hartmann M, Steube A. Transfer of FRozen Encapsulated multi-donor Stool filtrate for active ulcerative Colitis (FRESCO): study protocol for a prospective, multicenter, double-blind, randomized, controlled trial. Trials 2022;23:173. [PMID: 35193638 DOI: 10.1186/s13063-022-06095-1] [Reference Citation Analysis]
|
| 174 |
Sutton RT, Zai Ane OR, Goebel R, Baumgart DC. Artificial intelligence enabled automated diagnosis and grading of ulcerative colitis endoscopy images. Sci Rep 2022;12:2748. [PMID: 35177717 DOI: 10.1038/s41598-022-06726-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 175 |
Mavroudis G, Simrén M, Öhman L, Strid H. Health-related quality of life in patients with long-standing ulcerative colitis in remission. Therap Adv Gastroenterol 2022;15:17562848211062406. [PMID: 35173800 DOI: 10.1177/17562848211062406] [Reference Citation Analysis]
|
| 176 |
Parigi TL, Mastrorocco E, Da Rio L, Allocca M, D'Amico F, Zilli A, Fiorino G, Danese S, Furfaro F. Evolution and New Horizons of Endoscopy in Inflammatory Bowel Diseases. J Clin Med 2022;11:872. [PMID: 35160322 DOI: 10.3390/jcm11030872] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 177 |
Li J, Liu Z, Hu P, Wen Z, Cao Q, Zou X, Chen Y, Wang Y, Zhong J, Shen X, Demuth D, Fadeeva O, Xie L, Chen J, Qian J. Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from China with inflammatory bowel disease: results from the EXPLORE study. BMC Gastroenterol 2022;22:44. [PMID: 35120446 DOI: 10.1186/s12876-021-02074-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 178 |
Ali I, Abdo Q, Al-hihi SM, Shawabkeh A. Association between ulcerative colitis and Helicobacter pylori infection: A case-control study. Heliyon 2022;8:e08930. [DOI: 10.1016/j.heliyon.2022.e08930] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 179 |
Ma C, Jeyarajah J, Guizzetti L, Parker CE, Singh S, Dulai PS, D'Haens GR, Sandborn WJ, Feagan BG, Jairath V. Modeling Endoscopic Improvement after Induction Treatment With Mesalamine in Patients With Mild-to-Moderate Ulcerative Colitis. Clin Gastroenterol Hepatol 2022;20:447-454.e1. [PMID: 33279779 DOI: 10.1016/j.cgh.2020.11.040] [Reference Citation Analysis]
|
| 180 |
Arai N, Kudo T, Tokita K, Kyodo R, Sato M, Miyata E, Hosoi K, Ikuse T, Jimbo K, Ohtsuka Y, Shimizu T. Expression of Oncogenic Molecules in Pediatric Ulcerative Colitis. Digestion 2022;103:150-8. [PMID: 34718239 DOI: 10.1159/000519559] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 181 |
Awad A, Madla CM, McCoubrey LE, Ferraro F, Gavins FKH, Buanz A, Gaisford S, Orlu M, Siepmann F, Siepmann J, Basit AW. Clinical translation of advanced colonic drug delivery technologies. Adv Drug Deliv Rev 2022;181:114076. [PMID: 34890739 DOI: 10.1016/j.addr.2021.114076] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 182 |
Suzuki T, Naitoh I, Katano T, Matsuura K, Nagura Y, Fujiwara K, Nojiri S, Kataoka H. A Case of Primary Sclerosing Cholangitis and Autoimmune Hepatitis Overlapping Syndrome Complicated by Ulcerative Colitis. Intern Med 2022. [PMID: 35110488 DOI: 10.2169/internalmedicine.8866-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 183 |
Verma A, Varma S, Freedberg DE, Axelrad JE. A Simple Emergency Department-Based Score Predicts Complex Hospitalization in Patients with Inflammatory Bowel Disease. Dig Dis Sci 2022;67:629-38. [PMID: 33606139 DOI: 10.1007/s10620-021-06877-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 184 |
Shimodaira Y, Watanabe K, Fukuda S, Watanabe N, Koizumi S, Matsuhashi T, Onochi K, Iijima K. Limited endoscopic mucosal inflammation on equivalent to Mayo endoscopic subscore of 0 unaffect clinical relapse of ulcerative colitis. Scand J Gastroenterol 2022;57:165-8. [PMID: 34663142 DOI: 10.1080/00365521.2021.1991467] [Reference Citation Analysis]
|
| 185 |
Asonuma K, Kobayashi T, Nakano M, Sagami S, Kiyohara H, Matsubayashi M, Morikubo H, Miyatani Y, Okabayashi S, Yamazaki H, Kuroki Y, Hibi T. Residual Short-Segment Distal Inflammation Has No Significant Impact on the Major Relapse of Extensive Ulcerative Colitis. Inflamm Bowel Dis 2022;28:200-7. [PMID: 33847348 DOI: 10.1093/ibd/izab062] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 186 |
Pakoz ZB, Ustaoglu M, Vatansever S, Yuksel ES, Topal F, Adani GL. Serum Immune-Inflammation Index Assessment in the Patients with Ulcerative Colitis. Gastroenterology Research and Practice 2022;2022:1-5. [DOI: 10.1155/2022/9987214] [Reference Citation Analysis]
|
| 187 |
Furukawa S, Yagi S, Shiraishi K, Miyake T, Tange K, Hashimoto Y, Kitahata S, Kawamura T, Ninomiya T, Mori K, Suzuki S, Shibata N, Murakami H, Ohashi K, Hasebe A, Tomida H, Yamamoto Y, Takeshita E, Ikeda Y, Hiasa Y. Effect of disease duration on the association between C-reactive protein-albumin ratio and endoscopic activity in ulcerative colitis. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02113-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 188 |
Parfenov AI, Knyazev OV, Babayan AF, Kagramanova AV. Low adherence to treatment is a weak link in the problems of ulcerative colitis. Terapevticheskii arkhiv 2022;93:1419-27. [DOI: 10.26442/00403660.2021.12.201172] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 189 |
Knyazev OV, Khomeriki SG, Kagramanova АV, Lishchinskaya AA, Smirnova OA, Noskova KK, Parfenov AI. Histological remission of ulcerative colitis with combined anti-cytokine and cell therapy. Terapevticheskii arkhiv 2022;93:1435-42. [DOI: 10.26442/00403660.2021.12.201212] [Reference Citation Analysis]
|
| 190 |
Valcheva R, Armstrong H, Kovic O, Bording-jorgensen M, Veniamin S, Pérez-muñoz ME, Haskey N, Silva M, Peerani F, Wong K, Kao DH, Van Zanten SV, Kroeker KI, Gibson DL, Wine E, Gänzle M, Walter J, Dieleman LA. Double blind placebo-controlled trial for the prevention of ulcerative colitis relapses by β-fructan prebiotics: efficacy and metabolomic analysis.. [DOI: 10.1101/2022.01.16.22269376] [Reference Citation Analysis]
|
| 191 |
Iwamuro M, Takahashi T, Watanabe N, Tanaka T, Inokuchi T, Hiraoka S, Otsuka F, Okada H. Enriched CD45RA-CD62L+ central memory T and decreased CD3+CD56+ natural killer T lymphocyte subsets in the rectum of ulcerative colitis patients. Int J Immunopathol Pharmacol 2022;36:20587384211051982. [PMID: 35021918 DOI: 10.1177/20587384211051982] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 192 |
Peda ES, Alexandrov TL, Baranova TA, Belous SS, Tishaeva IA, Nanaeva BA, Shapina MV, Knyazev OV, Eligulashvili RR, Belinskaya VA, Podolskaya DV. The effectiveness and safety of switching therapy with an original drug to biosimilars in treatment of inflammatory bowel diseases. jour 2022. [DOI: 10.31146/1682-8658-ecg-195-11-35-41] [Reference Citation Analysis]
|
| 193 |
Kudo SE, Maeda Y, Ogata N, Misawa M, Ogawa Y, Takishima K, Ishiyama M, Mochizuki K, Minegishi Y, Ogura Y, Abe M, Okumura T, Matsudaira S, Ishigaki T, Sasanuma S, Mori Y, Kudo T, Hayashi T, Wakamura K, Miyachi H, Baba T, Ishida F, Nemoto T, Hamatani S, Ohtsuka K. Combined endocytoscopy with pit pattern diagnosis in ulcerative colitis-associated neoplasia: Pilot study. Dig Endosc 2022;34:133-43. [PMID: 33641190 DOI: 10.1111/den.13964] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 194 |
Lightner AL, Strong SA. Medical Management of Ulcerative Colitis. The ASCRS Textbook of Colon and Rectal Surgery 2022. [DOI: 10.1007/978-3-030-66049-9_45] [Reference Citation Analysis]
|
| 195 |
Kadota T, Hayashi H, Bise R, Tanaka K, Uchida S. Deep Bayesian Active-Learning-to-Rank for Endoscopic Image Data. Medical Image Understanding and Analysis 2022. [DOI: 10.1007/978-3-031-12053-4_45] [Reference Citation Analysis]
|
| 196 |
Azuma Y, Uchiyama K, Sugaya T, Yasuda T, Hashimoto H, Kajiwara-Kubota M, Sugino S, Kitae H, Torii T, Mizushima K, Doi T, Inoue K, Dohi O, Yoshida N, Kamada K, Ishikawa T, Takagi T, Konishi H, Naito Y, Itoh Y. Deoxycholic acid delays the wound healing of colonic epithelial cells via transmembrane G-protein-coupled receptor 5. J Gastroenterol Hepatol 2022;37:134-43. [PMID: 34477242 DOI: 10.1111/jgh.15676] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 197 |
Ishida N, Miyazu T, Tamura S, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. Real-World Efficacy and Safety Monitoring for Predicting Continuation of Tofacitinib Therapy in Patients with Ulcerative Colitis. Dig Dis Sci 2022;67:3984-92. [PMID: 34460029 DOI: 10.1007/s10620-021-07233-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 198 |
Lin H, Bai Z, Wu Q, Chu G, Zhang Y, Guo X, Qi X. Inflammatory Indexes for Assessing the Severity and Disease Progression of Ulcerative Colitis: A Single-Center Retrospective Study. Front Public Health 2022;10:851295. [PMID: 35359771 DOI: 10.3389/fpubh.2022.851295] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 199 |
Ghahramani S, Tamartash Z, Sayari M, Vahedi H, Karimian F, Heydari S, Bagheri Lankarani K. Risk Factors Affecting 90-day Readmission of Patients with Inflammatory Bowel Disease. Middle East J Dig Dis 2022;14:34-43. [PMID: 36619729 DOI: 10.34172/mejdd.2022.253] [Reference Citation Analysis]
|
| 200 |
Atanasova K, Lotter T, Bekrater-Bodmann R, Kleindienst N, Reindl W, Lis S. Is It a Gut Feeling? Bodily Sensations Associated With the Experience of Valence and Arousal in Patients With Inflammatory Bowel Disease. Front Psychiatry 2022;13:833423. [PMID: 35530019 DOI: 10.3389/fpsyt.2022.833423] [Reference Citation Analysis]
|
| 201 |
Polat G, Ergenc I, Kani HT, Alahdab YO, Atug O, Temizel A. Class Distance Weighted Cross-Entropy Loss for Ulcerative Colitis Severity Estimation. Medical Image Understanding and Analysis 2022. [DOI: 10.1007/978-3-031-12053-4_12] [Reference Citation Analysis]
|
| 202 |
Kamp K, Li N, Lachance D, Saad K, Tolentino E, Yoo L, Heitkemper M, Clark-snustad K, Lee S, Dey N. Interpersonal Variability in Gut Microbial Calprotectin Metabolism. Gastro Hep Advances 2022;1:853-856. [DOI: 10.1016/j.gastha.2022.05.007] [Reference Citation Analysis]
|
| 203 |
Nakase H, Hayashi Y, Hirayama D, Matsumoto T, Matsuura M, Iijima H, Matsuoka K, Ohmiya N, Ishihara S, Hirai F, Abukawa D, Hisamatsu T; J-COSMOS group. Interim analysis of a multicenter registry study of COVID-19 patients with inflammatory bowel disease in Japan (J-COSMOS). J Gastroenterol 2022;57:174-84. [PMID: 35089397 DOI: 10.1007/s00535-022-01851-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 204 |
Kadota T, Abe K, Bise R, Kawamura T, Sakiyama N, Tanaka K, Uchida S. Automatic Estimation of Ulcerative Colitis Severity by Learning to Rank With Calibration. IEEE Access 2022;10:25688-95. [DOI: 10.1109/access.2022.3155769] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 205 |
Vitello D, Mcgee MF. Treatment of severe and fulminant colitis. Seminars in Colon and Rectal Surgery 2022. [DOI: 10.1016/j.scrs.2022.100864] [Reference Citation Analysis]
|
| 206 |
Iacucci M, Cannatelli R. Advanced Colonoscopy Techniques in Inflammatory Bowel Diseases. Gastrointestinal and Pancreatico-Biliary Diseases: Advanced Diagnostic and Therapeutic Endoscopy 2022. [DOI: 10.1007/978-3-030-56993-8_29] [Reference Citation Analysis]
|
| 207 |
Brar MS, Macrae H. IBD Diagnosis and Evaluation. The ASCRS Textbook of Colon and Rectal Surgery 2022. [DOI: 10.1007/978-3-030-66049-9_44] [Reference Citation Analysis]
|
| 208 |
Kishi M, Hirai F, Takatsu N, Hisabe T, Takada Y, Beppu T, Takeuchi K, Naganuma M, Ohtsuka K, Watanabe K, Matsumoto T, Esaki M, Koganei K, Sugita A, Hata K, Futami K, Ajioka Y, Tanabe H, Iwashita A, Shimizu H, Arai K, Suzuki Y, Hisamatsu T. A review on the current status and definitions of activity indices in inflammatory bowel disease: how to use indices for precise evaluation. J Gastroenterol 2022;57:246-66. [PMID: 35235037 DOI: 10.1007/s00535-022-01862-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 209 |
Basil M, Schwartz D, Dalal R, Horst S, Scoville E, Adams D, Beaulieu D, Slaughter JC, Higginbotham T, Vaezi M, Choksi Y. Mucosal Integrity Testing Can Detect Differences in the Rectums of Patients with Inflammatory Bowel Disease Compared to Controls: A Pilot Study. Dig Dis Sci 2022;67:639-45. [PMID: 33638748 DOI: 10.1007/s10620-021-06888-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 210 |
Bakkaloglu OK, Eskazan T, Celik S, Kurt EA, Hatemi I, Erzin Y, Celik AF. Can we predict mucosal remission in ulcerative colitis more precisely with a redefined cutoff level of C-reactive protein? Colorectal Dis 2022;24:77-84. [PMID: 34610199 DOI: 10.1111/codi.15940] [Reference Citation Analysis]
|
| 211 |
Takahara M, Hiraoka S, Ohmori M, Takeuchi K, Takei K, Yasutomi E, Igawa S, Yamamoto S, Yamasaki Y, Inokuchi T, Kinugasa H, Harada K, Ohnishi H, Okada H. The Colon Wall Thickness Measured Using Transabdominal Ultrasonography is Useful for Detecting Mucosal Inflammation in Ulcerative Colitis. Intern Med . [DOI: 10.2169/internalmedicine.8827-21] [Reference Citation Analysis]
|
| 212 |
Cross RK, Sauk JS, Zhuo J, Harrison RW, Kerti SJ, Emeanuru K, O’brien J, Ahmad HA, Sreih AG, Nguyen J, Horst SN, Hudesman D. Poor Patient-Reported Outcomes and Impaired Work Productivity in Patients With Inflammatory Bowel Disease in Remission. Gastro Hep Advances 2022;1:927-935. [DOI: 10.1016/j.gastha.2022.07.003] [Reference Citation Analysis]
|
| 213 |
Tursi A, Mocci G, Allegretta L, Aragona G, Bianco MA, Colucci R, Cuomo A, Della Valle N, Ferronato A, Forti G, Gaiani F, Graziani MG, Lorenzetti R, Luzza F, Paese P, Penna A, Pica R, Pranzo G, Rodinò S, Scarcelli A, Zampaletta C, Brozzi L, Cicerone C, Cocco A, De' Angelis G, Donnarumma L, Fiorella S, Iannelli C, Larussa T, Le Grazie M, Luppino I, Meucci C, FaggianI R, Pagnini C, Perazzo P, Rodriguez-Castro KI, Sacco R, Sebkova L, Serio M, De Monti A, Picchio M, Napolitano D, Schiavoni E, Turchini L, Scaldaferri F, Pugliese D, Guidi L, Laterza L, Privitera G, Pizzoferrato M, Lopetuso LR, Armuzzi A, Elisei W, Maconi G, Papa A. Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy. Expert Opin Biol Ther 2021;:1-8. [PMID: 34904510 DOI: 10.1080/14712598.2022.2007881] [Reference Citation Analysis]
|
| 214 |
Zhang XF, Li P, Ding XL, Chen H, Wang SJ, Jin SB, Guo J, Tian ZB. Comparing the clinical application values of the Degree of Ulcerative Colitis Burden of Luminal Inflammation (DUBLIN) score and Ulcerative Colitis Endoscopic Index of Severity (UCEIS) in patients with ulcerative colitis. Gastroenterol Rep (Oxf) 2021;9:533-42. [PMID: 34925850 DOI: 10.1093/gastro/goab026] [Reference Citation Analysis]
|
| 215 |
Tanida S, Ozeki K, Kanno T, Katano T, Sugimura N, Nishie H, Iwasaki H, Tanaka M, Shimura T, Kubota E, Kataoka H. Combination Therapy With Ustekinumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Refractory Ulcerative Colitis. J Clin Med Res 2021;13:510-4. [PMID: 34925662 DOI: 10.14740/jocmr4625] [Reference Citation Analysis]
|
| 216 |
Zafer M, Zhang H, Dwadasi S, Goens D, Paknikar R, Dalal S, Cohen RD, Pekow J, Rubin DT, Sakuraba A, Micic D. A Clinical Predictive Model for One-year Colectomy in Adults Hospitalized for Severe Ulcerative Colitis. Crohns Colitis 360 2022;4:otab082. [PMID: 36777555 DOI: 10.1093/crocol/otab082] [Reference Citation Analysis]
|
| 217 |
Nijakowski K, Rutkowski R, Eder P, Korybalska K, Witowski J, Surdacka A. Changes in Salivary Parameters of Oral Immunity after Biologic Therapy for Inflammatory Bowel Disease. Life (Basel) 2021;11:1409. [PMID: 34947940 DOI: 10.3390/life11121409] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 218 |
Shinzaki S, Sakagami K, Matsumoto M, Takehara T, Ito H. Nurse-Provided Medication Guidance for Improving Drug Adherence to Thiopurines in Outpatients With Inflammatory Bowel Disease: A Single-Center Prospective Study. Crohns Colitis 360 2022;4:otab081. [PMID: 36777553 DOI: 10.1093/crocol/otab081] [Reference Citation Analysis]
|
| 219 |
Oba J, Sobrado CW, Damião AOMC, Azevedo M, Carlos A, Queiroz N, Len CA, Toma RK, Deboni M, Ozaki MJ, Carrilho FJ, Nahas S, Silva CA. HEALTH-RELATED QUALITY OF LIFE IN ADOLESCENTS AND YOUNG ADULTS WITH INFLAMMATORY BOWEL DISEASE IS ASSOCIATED WITH REDUCTION IN SCHOOL AND WORK PRODUCTIVITY RATHER THAN PHYSICAL IMPAIRMENT: A MULTIDISCIPLINARY STUDY. Arq Gastroenterol 2021;58:541-7. [PMID: 34909863 DOI: 10.1590/S0004-2803.202100000-96] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 220 |
Chen XF, Zhao Y, Guo Y, Huang ZM, Huang XL. Predictive value of fibrinogen in identifying inflammatory bowel disease in active stage. BMC Gastroenterol 2021;21:472. [PMID: 34911464 DOI: 10.1186/s12876-021-02040-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 221 |
Marsh A, Rindfleish S, Bennett K, Croft A, Chachay V. Outcomes of dietary management approaches in active ulcerative colitis: A systematic review. Clin Nutr 2021;41:298-306. [PMID: 34999323 DOI: 10.1016/j.clnu.2021.12.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 222 |
Cao Y, Dai Y, Zhang L, Wang D, Hu W, Yu Q, Wang X, Yu P, Liu W, Ping Y, Sun T, Sang Y, Liu Z, Chen Y, Tao Z. Combined Use of Fecal Biomarkers in Inflammatory Bowel Diseases: Oncostatin M and Calprotectin. J Inflamm Res 2021;14:6409-19. [PMID: 34880643 DOI: 10.2147/JIR.S342846] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 223 |
Hijos-Mallada G, Velamazán R, Marti R, Chueca E, Arechavaleta S, Lué A, Gomollón F, Lanas A, Sostres C. A Patient Self-Made Point-of-Care Fecal Test Improves Diagnostic Accuracy Compared with Fecal Calprotectin Alone in Inflammatory Bowel Disease Patients. Diagnostics (Basel) 2021;11:2323. [PMID: 34943560 DOI: 10.3390/diagnostics11122323] [Reference Citation Analysis]
|
| 224 |
Mokros Ł, Domżał-Magrowska D, Pietras T, Sipowicz K, Talar-Wojnarowska R. The Association between Temperament, Chronotype, Depressive Symptoms, and Disease Activity among Patients with Inflammatory Bowel Disease-A Cross-Sectional Pilot Study. Life (Basel) 2021;11:1347. [PMID: 34947878 DOI: 10.3390/life11121347] [Reference Citation Analysis]
|
| 225 |
Haifer C, Paramsothy S, Kaakoush NO, Saikal A, Ghaly S, Yang T, Luu LDW, Borody TJ, Leong RW. Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol 2021:S2468-1253(21)00400-3. [PMID: 34863330 DOI: 10.1016/S2468-1253(21)00400-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 226 |
Gatopoulou A, Christodoulou DK, Katsanos KH, Bakos D, Mouzas I, Tzouvala M, Theodoropoulou A, Paspatis G, Theocharis G, Thomopoulos K, Giouleme O, Kourikou A, Manolakopoulos S, Zampeli E, Michopoulos S, Karatzas P, Katsaros M, Moschovis D, Orfanoudaki E, Livieratos A, Petrikkou E, Mantzaris GJ. Effect of golimumab on health-related quality of life, other patient-reported outcomes and healthcare resource utilization in patients with moderate-to-severe ulcerative colitis: a real-world multicenter, noninterventional, observational study in Greece. Eur J Gastroenterol Hepatol 2021;33:e615-24. [PMID: 34034278 DOI: 10.1097/MEG.0000000000002182] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 227 |
Razanskaite V, Kallis C, Young B, Williamson PR, Bodger K. Heterogeneity in outcome assessment for inflammatory bowel disease in routine clinical practice: a mixed-methods study in a sample of English hospitals. BMJ Open 2021;11:e056413. [DOI: 10.1136/bmjopen-2021-056413] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 228 |
Magro F, Alves C, Lopes J, Lopes S, Tavares de Sousa H, Cotter J, Macedo da Silva V, Lago P, Vieira A, Brito M, Duarte MAM, Portela F, Silva JP, Ministro P, Arroja B, Carvalho L, Torres J, Santiago M, Estevinho MM, Danese S, Peyrin-Biroulet L, Dias CC, Borralho P, Feakins RM, Carneiro F. Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy. Clin Gastroenterol Hepatol 2021;19:2567-2576.e9. [PMID: 32920215 DOI: 10.1016/j.cgh.2020.09.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 229 |
Tse CS, Jairath V, Feagan BG, Sandborn WJ. Updates in Clinical, Endoscopic, and Histologic Composite and Co-primary Endpoints for Clinical Trials in Inflammatory Bowel Disease. Curr Treat Options Gastro 2021;19:608-627. [DOI: 10.1007/s11938-021-00362-x] [Reference Citation Analysis]
|
| 230 |
Hoy SM. Subcutaneous vedolizumab in moderately to severely active ulcerative colitis or Crohn’s disease: a profile of its use. Drugs Ther Perspect 2021;37:563-572. [DOI: 10.1007/s40267-021-00873-8] [Reference Citation Analysis]
|
| 231 |
Pouw RE, Bisschops R, Gecse KB, de Hertogh G, Iacucci M, Rutter M, Barret M, Biermann K, Czakó L, Hucl T, Jansen M, Savarino E, Spaander MCW, Schmidt PT, Dinis-ribeiro M, Vieth M, van Hooft JE. Endoscopic tissue sampling – Part 2: Lower gastrointestinal tract. European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2021;53:1261-1273. [DOI: 10.1055/a-1671-6336] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 232 |
Takenaka K, Fujii T, Kawamoto A, Suzuki K, Shimizu H, Maeyashiki C, Yamaji O, Motobayashi M, Igarashi A, Hanazawa R, Hibiya S, Nagahori M, Saito E, Okamoto R, Ohtsuka K, Watanabe M. Deep neural network for video colonoscopy of ulcerative colitis: a cross-sectional study. Lancet Gastroenterol Hepatol 2021:S2468-1253(21)00372-1. [PMID: 34856196 DOI: 10.1016/S2468-1253(21)00372-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 233 |
Cao Y, Dai Y, Zhang L, Wang D, Yu Q, Hu W, Wang X, Yu P, Ping Y, Sun T, Sang Y, Liu Z, Chen Y, Tao Z. Serum oncostatin M is a potential biomarker of disease activity and infliximab response in inflammatory bowel disease measured by chemiluminescence immunoassay. Clin Biochem 2021:S0009-9120(21)00310-6. [PMID: 34843732 DOI: 10.1016/j.clinbiochem.2021.11.011] [Reference Citation Analysis]
|
| 234 |
Watanabe J, Furukawa S, Yagi S, Shiraishi K, Hanayama M, Tange K, Hashimoto Y, Kitahata S, Mori K, Ninomiya T, Suzuki S, Shibata N, Murakami H, Ohashi K, Hasebe A, Tomida H, Yamamoto Y, Takeshita E, Ikeda Y, Hiasa Y. Time spent per day in strenuous activity and total physical activity are inversely associated with mucosal healing but not with clinical remission in patients with ulcerative colitis. Ann Gastroenterol 2021;34:796-801. [PMID: 34815645 DOI: 10.20524/aog.2021.0663] [Reference Citation Analysis]
|
| 235 |
De Cristofaro E, Salvatori S, Marafini I, Zorzi F, Alfieri N, Musumeci M, Biancone L, Calabrese E, Monteleone G. Long-Term Outcomes and Predictive Factors of Hospitalized Patients with Severe Ulcerative Colitis Treated with Intravenous Corticosteroids. J Clin Med 2021;10:5413. [PMID: 34830694 DOI: 10.3390/jcm10225413] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 236 |
Furukawa S, Ikeda Y, Yagi S, Miyake T, Shiraishi K, Tange K, Hashimoto Y, Mori K, Ninomiya T, Suzuki S, Shibata N, Murakami H, Ohashi K, Hasebe A, Tomida H, Yamamoto Y, Takeshita E, Hiasa Y. Association Between Peripheral Blood Monocyte Count and Mucosal Healing in Japanese Patients With Ulcerative Colitis. Clin Transl Gastroenterol 2021;12:e00429. [PMID: 34797817 DOI: 10.14309/ctg.0000000000000429] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 237 |
Bhattacharya S, Stoleru G, Patel P, Abutaleb A, Stashek K, Cross RK. Characterization of Mycophenolate Mofetil Gastrointestinal Toxicity and Risk Factors for Severe Disease and Poor Prognosis. Inflamm Bowel Dis 2022;28:811-4. [PMID: 34792581 DOI: 10.1093/ibd/izab254] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 238 |
Schierova D, Roubalova R, Kolar M, Stehlikova Z, Rob F, Jackova Z, Coufal S, Thon T, Mihula M, Modrak M, Kverka M, Bajer L, Kostovcikova K, Drastich P, Hercogova J, Novakova M, Vasatko M, Lukas M, Tlaskalova-Hogenova H, Jiraskova Zakostelska Z. Fecal Microbiome Changes and Specific Anti-Bacterial Response in Patients with IBD during Anti-TNF Therapy. Cells 2021;10:3188. [PMID: 34831411 DOI: 10.3390/cells10113188] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 239 |
Sun D, Chi L, Liu J, Liang J, Guo S, Li S. Psychometric validation of the Chinese version of the Short Inflammatory Bowel Disease Questionnaire and evaluation of its measurement invariance across sex. Health Qual Life Outcomes 2021;19:253. [PMID: 34743727 DOI: 10.1186/s12955-021-01890-x] [Reference Citation Analysis]
|
| 240 |
Danese S, Klopocka M, Scherl EJ, Romatowski J, Allegretti JR, Peeva E, Vincent MS, Schoenbeck U, Ye Z, Hassan-Zahraee M, Rath N, Li G, Neelakantan S, Banfield C, Lepsy C, Chandra DE, Hung KE. Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study. Clin Gastroenterol Hepatol 2021;19:2324-2332.e6. [PMID: 34126262 DOI: 10.1016/j.cgh.2021.06.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 241 |
Eriksson C, Visuri I, Vigren L, Nilsson L, Kärnell A, Hjortswang H, Bergemalm D, Almer S, Hertervig E, Karlén P, Strid H, Halfvarson J; GO SWIBREG study group. Clinical effectiveness of golimumab in ulcerative colitis: a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREG. Scand J Gastroenterol 2021;56:1304-11. [PMID: 34415803 DOI: 10.1080/00365521.2021.1963466] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 242 |
Moriichi K, Fujiya M, Okumura T. The endoscopic diagnosis of mucosal healing and deep remission in inflammatory bowel disease. Digestive Endoscopy 2021;33:1008-1023. [DOI: 10.1111/den.13863] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 243 |
Mateen BA, Patel M, Akobeng AK, Gordon M, Hayee B. 6-thioguanine nucleotide monitoring in azathioprine and mercaptopurine monotherapy for the treatment of inflammatory bowel disease. Cochrane Database of Systematic Reviews 2021;2022. [DOI: 10.1002/14651858.cd014795] [Reference Citation Analysis]
|
| 244 |
Kanazawa M, Tominaga K, Yamamiya A, Tanaka T, Watanabe S, Sugaya T, Abe K, Kanamori A, Arisaka T, Hoshi K, Iijima M, Goda K, Haruyama Y, Irisawa A. Analysis of Endoscopic Evaluation Reliability for Ulcerative Colitis in Histological Remission. Healthcare (Basel) 2021;9:1405. [PMID: 34828451 DOI: 10.3390/healthcare9111405] [Reference Citation Analysis]
|
| 245 |
Knyazev OV, Kagramanova AV, Lishchinskaya AA, Li IA, Podolskaya DV, Shkurko TV, Nanaeva BA, Aleksandrov TL, Baranova TA, Tishaeva IA, Zvyaglova MY, Parfenov AI. Efficacy and safety of tofacitinib in moderate and severe ulcerative colitis in real clinical practice: three years of observation. Medicinskij sovet 2021. [DOI: 10.21518/2079-701x-2021-15-20-29] [Reference Citation Analysis]
|
| 246 |
Burke M, Rashdan S. Management of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer. Front Oncol 2021;11:720759. [PMID: 34660286 DOI: 10.3389/fonc.2021.720759] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 247 |
Knyazev OV, Kagramanova AV, Lishchinskaya AA. Effectiveness of treatment of moderate ulcerative colitis with prolonged mesalazine in real clinical practice. Medicinskij sovet 2021. [DOI: 10.21518/2079-701x-2021-15-144-151] [Reference Citation Analysis]
|
| 248 |
Miranda-Bautista J, Rodríguez-Feo JA, Puerto M, López-Cauce B, Lara JM, González-Novo R, Martín-Hernández D, Ferreiro-Iglesias R, Bañares R, Menchén L. Liver X Receptor Exerts Anti-Inflammatory Effects in Colonic Epithelial Cells via ABCA1 and Its Expression Is Decreased in Human and Experimental Inflammatory Bowel Disease. Inflamm Bowel Dis 2021;27:1661-73. [PMID: 33609028 DOI: 10.1093/ibd/izab034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 249 |
Crawford E, Gestrich C, Malay S, Young D, Perry S, Splawski J, Sferra TJ, Saab S, Moses J. Association of Fecal Calprotectin With Endoscopic and Histologic Activity in Pediatric Inflammatory Bowel Disease. JPGN Reports 2021;2:e129. [DOI: 10.1097/pg9.0000000000000129] [Reference Citation Analysis]
|
| 250 |
Ng AC. Clinical Efficacy of Tofacitinib in Moderate to Severe Ulcerative Colitis. J Crohns Colitis 2021;15:1774. [PMID: 33822914 DOI: 10.1093/ecco-jcc/jjab062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 251 |
Zhang T, Li G, Duan M, Lv T, Feng D, Lu N, Zhou Y, Gu L, Zhu W, Gong J. Perioperative parenteral fish oil supplementation improves postoperative coagulation function and outcomes in patients undergoing colectomy for ulcerative colitis. JPEN J Parenter Enteral Nutr 2021. [PMID: 34609004 DOI: 10.1002/jpen.2269] [Reference Citation Analysis]
|
| 252 |
Ishida N, Takahashi S, Asai Y, Miyazu T, Tamura S, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. Lymphocyte-to-Monocyte Ratio as a Marker for Endoscopic Activity in Ulcerative Colitis. Immuno 2021;1:360-8. [DOI: 10.3390/immuno1040024] [Reference Citation Analysis]
|
| 253 |
Ricciuto A, Carman N, Benchimol EI, Siddiqui I, Putra J, Khanna R, Griffiths AM, Walters TD, Church PC. Prospective Evaluation of Endoscopic and Histologic Indices in Pediatric Ulcerative Colitis Using Centralized Review. Am J Gastroenterol 2021;116:2052-9. [PMID: 34388139 DOI: 10.14309/ajg.0000000000001400] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 254 |
Doeve BH, van de Meeberg MM, van Schaik FDM, Fidder HH. A Systematic Review With Meta-Analysis of the Efficacy of Cannabis and Cannabinoids for Inflammatory Bowel Disease: What Can We Learn From Randomized and Nonrandomized Studies? J Clin Gastroenterol 2021;55:798-809. [PMID: 32675631 DOI: 10.1097/MCG.0000000000001393] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 255 |
El-atrebi K, Taher E, El Aguizy F, Ali R, Hegazy A, El-sayed M, Eysa B, El-atreby A, Mohammed A, El-bassyouni H. Estudio descriptivo de la enfermedad inflamatoria intestinal en un centro de atención terciario egipcio. Revista de Gastroenterología de México 2021. [DOI: 10.1016/j.rgmx.2021.03.004] [Reference Citation Analysis]
|
| 256 |
Rawal KK, Shukla VP, Chikani S, Thakkar M, Ruparelia M, Chudasama RK. Prevalence of extraintestinal manifestations in ulcerative colitis and associated risk factors. Indian J Gastroenterol 2021;40:477-82. [PMID: 34569013 DOI: 10.1007/s12664-021-01181-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 257 |
Wu J, Niu J, Li M, Miao Y. Keratin 1 maintains the intestinal barrier in ulcerative colitis. Genes Genomics 2021;43:1389-402. [PMID: 34562265 DOI: 10.1007/s13258-021-01166-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 258 |
Fiocchi C, Dragoni G, Iliopoulos D, Katsanos K, Ramirez VH, Suzuki K; Scientific Workshop Steering Committee. Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-What, Why, and How. J Crohns Colitis 2021;15:1410-30. [PMID: 33733656 DOI: 10.1093/ecco-jcc/jjab051] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 259 |
Chen D, Fulmer C, Gordon IO, Syed S, Stidham RW, Vande Casteele N, Qin Y, Falloon K, Cohen BL, Wyllie R, Rieder F. Application of Artificial Intelligence to Clinical Practice in Inflammatory Bowel Disease - What the Clinician Needs to Know. J Crohns Colitis 2022;16:460-71. [PMID: 34558619 DOI: 10.1093/ecco-jcc/jjab169] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 260 |
Tripathi K, Dong J, Mishkin BF, Feuerstein JD. Patient Preference and Adherence to Aminosalicylates for the Treatment of Ulcerative Colitis. Clin Exp Gastroenterol 2021;14:343-51. [PMID: 34511961 DOI: 10.2147/CEG.S237653] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 261 |
Villeda-Ramírez MA, Meza-Guillen D, Barreto-Zúñiga R, Yamamoto-Furusho JK. ABCC7/CFTR Expression Is Associated with the Clinical Course of Ulcerative Colitis Patients. Gastroenterol Res Pract 2021;2021:5536563. [PMID: 34512749 DOI: 10.1155/2021/5536563] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 262 |
Moon JR, Lee CK, Hong SN, Im JP, Ye BD, Cha JM, Jung SA, Lee KM, Park DI, Jeen YT, Park YS, Cheon JH, Kim H, Seo B, Kim Y, Kim HJ; MOSAIK study group of the Korean Association for Study of Intestinal Diseases. Unmet Psychosocial Needs of Patients with Newly Diagnosed Ulcerative Colitis: Results from the Nationwide Prospective Cohort Study in Korea. Gut Liver 2020;14:459-67. [PMID: 31533398 DOI: 10.5009/gnl19107] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 263 |
Carrillo-Palau M, Hernández-Camba A, Ramos L, Vela M, Arranz L, Hernández Alvarez-Buylla N, Alonso-Abreu I, Hernández-Pérez A, Hernández-Guerra M, Palazuelos C, Llorca J, González-Gay MÁ, Ferraz-Amaro I. QRISK3 Performance in the Assessment of Cardiovascular Risk in Patients with Inflammatory Bowel Disease. J Clin Med 2021;10:4102. [PMID: 34575213 DOI: 10.3390/jcm10184102] [Reference Citation Analysis]
|
| 264 |
Mo A, Nagpal S, Gettler K, Haritunians T, Giri M, Haberman Y, Karns R, Prince J, Arafat D, Hsu NY, Chuang LS, Argmann C, Kasarskis A, Suarez-Farinas M, Gotman N, Mengesha E, Venkateswaran S, Rufo PA, Baker SS, Sauer CG, Markowitz J, Pfefferkorn MD, Rosh JR, Boyle BM, Mack DR, Baldassano RN, Shah S, LeLeiko NS, Heyman MB, Griffiths AM, Patel AS, Noe JD, Davis Thomas S, Aronow BJ, Walters TD, McGovern DPB, Hyams JS, Kugathasan S, Cho JH, Denson LA, Gibson G. Stratification of risk of progression to colectomy in ulcerative colitis via measured and predicted gene expression. Am J Hum Genet 2021;108:1765-79. [PMID: 34450030 DOI: 10.1016/j.ajhg.2021.07.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 265 |
Takagi T, Uchiyama K, Kajiwara-Kubota M, Kashiwagi S, Toyokawa Y, Hotta Y, Tanaka M, Inoue K, Dohi O, Yoshida N, Kamada K, Ishikawa T, Konishi H, Kishimoto M, Yagi N, Naito Y, Itoh Y. The efficacy of linked color imaging for the endoscopic diagnosis of mucosal healing in quiescent ulcerative colitis. J Gastroenterol Hepatol 2021;36:2448-54. [PMID: 33710655 DOI: 10.1111/jgh.15489] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 266 |
Nomura E, Sujino T, Hosoe N, Yoshimatsu Y, Tanemoto S, Takabayashi K, Mutaguchi M, Shimoda M, Naganuma M, Ogata H, Kanai T. Characteristics of the Mucosal Surface on Scanning Electron Microscopy in Patients with Remitting Ulcerative Colitis. Dig Dis Sci 2021;66:3141-8. [PMID: 32955688 DOI: 10.1007/s10620-020-06609-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 267 |
Kruchinina MV, Svetlova IO, Azgaldyan AV, Osipenko MF, Valuiskikh EY, Gromov AA, Generalov VM, Kruchinin VN, Yakovina IN, Osipenko IV. The method for diagnosing the activity of inflammatory bowel diseases based on a combination of electrical and viscoelastic parameters of erythrocytes and the level of fecal calprotectin. jour 2021;1:40-49. [DOI: 10.31146/1682-8658-ecg-190-6-40-49] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 268 |
Yong HM, Park SJ, Jeon SR, Park H, Kim HG, Lee TH, Park J, Kim JO, Lee JS, Ko BM, Goong HJ, Park S. Endoscopy within 7 days after detecting high calprotectin levels can be useful for therapeutic decision-making in ulcerative colitis. Medicine (Baltimore) 2021;100:e27065. [PMID: 34449501 DOI: 10.1097/MD.0000000000027065] [Reference Citation Analysis]
|
| 269 |
Aoyama Y, Inaba T, Takahashi S, Yasuhara H, Hiraoka S, Morimoto T, Colvin HS, Wato M, Ando M, Nakamura S, Mizobuchi K, Okada H. Anti-proteinase 3 antineutrophil cytoplasmic antibody reflects disease activity and predicts the response to steroid therapy in ulcerative colitis. BMC Gastroenterol 2021;21:325. [PMID: 34425765 DOI: 10.1186/s12876-021-01903-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 270 |
Di Ruscio M, Variola A, Vernia F, Lunardi G, Castelli P, Bocus P, Geccherle A. Role of Ulcerative Colitis Endoscopic Index of Severity (UCEIS) versus Mayo Endoscopic Subscore (MES) in Predicting Patients' Response to Biological Therapy and the Need for Colectomy. Digestion 2021;102:534-45. [PMID: 32739919 DOI: 10.1159/000509512] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 271 |
Lee SH, Walshe M, Oh EH, Hwang SW, Park SH, Yang DH, Byeon JS, Myung SJ, Yang SK, Greener T, Weizman AV, Silverberg MS, Ye BD. Early Changes in Serum Albumin Predict Clinical and Endoscopic Outcomes in Patients With Ulcerative Colitis Starting Anti-TNF Treatment. Inflamm Bowel Dis 2021;27:1452-61. [PMID: 33269403 DOI: 10.1093/ibd/izaa309] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 272 |
Singh V, Johnson K, Yin J, Lee S, Lin R, Yu H, In J, Foulke-Abel J, Zachos NC, Donowitz M, Rong Y. Chronic Inflammation in Ulcerative Colitis Causes Long-Term Changes in Goblet Cell Function. Cell Mol Gastroenterol Hepatol 2022;13:219-32. [PMID: 34418586 DOI: 10.1016/j.jcmgh.2021.08.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 273 |
Weisel K, Scott N, Berger S, Wang S, Brown K, Powell M, Broer M, Watts C, Tompson DJ, Burriss SW, Hawkins S, Abbott-Banner K, Tak PP. A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis. BMJ Open Gastroenterol 2021;8:e000680. [PMID: 34389633 DOI: 10.1136/bmjgast-2021-000680] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 274 |
Miyoshi J, Maeda T, Matsuoka K, Saito D, Miyoshi S, Matsuura M, Okamoto S, Tamura S, Hisamatsu T. Machine learning using clinical data at baseline predicts the efficacy of vedolizumab at week 22 in patients with ulcerative colitis. Sci Rep 2021;11:16440. [PMID: 34385588 DOI: 10.1038/s41598-021-96019-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 275 |
Smith BJ, Piceno Y, Zydek M, Zhang B, Syriani LA, Terdiman JP, Kassam Z, Ma A, Lynch SV, Pollard KS, El-nachef N. Strain-resolved analysis in a randomized trial of antibiotic pretreatment and maintenance dose delivery mode with fecal microbiota transplant for ulcerative colitis.. [DOI: 10.1101/2021.08.07.21261556] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 276 |
Ishida N, Tamura S, Miyazu T, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. Comparison between Prostaglandin E-major urinary metabolite and C-reactive protein levels to reflect endoscopic scores in patients with ulcerative colitis. Sci Rep 2021;11:16205. [PMID: 34376764 DOI: 10.1038/s41598-021-95761-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 277 |
Madarame A, Fukuzawa M, Yamauchi Y, Kono S, Sugimoto A, Yamaguchi H, Morise T, Koyama Y, Uchida K, Suguro M, Matsumoto T, Yasuyuki K, Kawai T, Itoi T. Predictive factors of relapse after dose reduction of oral 5-aminosalicylic acid in patients with ulcerative colitis in the remission phase. PLoS One 2021;16:e0255620. [PMID: 34347848 DOI: 10.1371/journal.pone.0255620] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 278 |
Lo SW, Connell W, Kamm MA, Lust M, Wright EK. Letter: tofacitinib in biologic-experienced ulcerative colitis-a single-centre real-world experience in Australia. Aliment Pharmacol Ther 2021;54:532-3. [PMID: 34331806 DOI: 10.1111/apt.16468] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 279 |
He XX, Li YH, Yan PG, Meng XC, Chen CY, Li KM, Li JN. Relationship between clinical features and intestinal microbiota in Chinese patients with ulcerative colitis. World J Gastroenterol 2021; 27(28): 4722-4737 [PMID: 34366632 DOI: 10.3748/wjg.v27.i28.4722] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 280 |
González-Bernardo O, Riestra S, Vivas S, de Francisco R, Pérez-Martínez I, Castaño-García A, Jiménez-Beltrán V, Rollé V, Suárez P, Suárez A. Chromoendoscopy With Indigo Carmine vs Virtual Chromoendoscopy (iSCAN 1) for Neoplasia Screening in Patients With Inflammatory Bowel Disease: A Prospective Randomized Study. Inflamm Bowel Dis 2021;27:1256-62. [PMID: 33169787 DOI: 10.1093/ibd/izaa291] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 281 |
Knyazev OV, Kagramanova АV, Veselov AV, Skurko TV. Effectiveness of treatment moderate ulcerative colitis with prolonged-release ethylcellulose-coated mesalazine in real clinical practice in Moscow. City Healthcare 2021;2:65-74. [DOI: 10.47619/2713-2617.zm.2021.v2i2;65-74] [Reference Citation Analysis]
|
| 282 |
Lindholm M, Godskesen LE, Manon-Jensen T, Kjeldsen J, Krag A, Karsdal MA, Mortensen JH. Endotrophin and C6Ma3, serological biomarkers of type VI collagen remodelling, reflect endoscopic and clinical disease activity in IBD. Sci Rep 2021;11:14713. [PMID: 34282237 DOI: 10.1038/s41598-021-94321-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 283 |
Yanai S, Shinzaki S, Matsuoka K, Mizuno S, Iijima H, Naka T, Kanai T, Matsumoto T. Leucine-Rich Alpha-2 Glycoprotein May Be Predictive of the Adalimumab Trough Level and Antidrug Antibody Development for Patients with Inflammatory Bowel Disease: A Sub-Analysis of the PLANET Study. Digestion 2021;102:929-37. [PMID: 34350873 DOI: 10.1159/000517339] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 284 |
Водовозов А. Современный подход к терапии язвенного колита: обновленные рекомендации Американской гастроэнтерологической ассоциации. jour 2021. [DOI: 10.21518/1561-5936-2021-2-62-68] [Reference Citation Analysis]
|
| 285 |
Lim HJ, Do Kim H, Soh JS, Kim SY, Jung YJ, Lim H, Kang HS, Kim JH. Discrete terminal ileal ulcers in patients diagnosed with ulcerative colitis: clinical significance and natural course. BMC Gastroenterol 2021;21:285. [PMID: 34247574 DOI: 10.1186/s12876-021-01866-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 286 |
Carrillo-Palau M, Hernández-Camba A, Hernández Alvarez-Buylla N, Ramos L, Alonso-Abreu I, Hernández-Pérez A, Vela M, Arranz L, Hernández-Guerra M, González-Gay MÁ, Ferraz-Amaro I. Insulin Resistance Is Not Increased in Inflammatory Bowel Disease Patients but Is Related to Non-Alcoholic Fatty Liver Disease. J Clin Med 2021;10:3062. [PMID: 34300227 DOI: 10.3390/jcm10143062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 287 |
El Megeed KHA, Saleh SAB, Mohamed AE, Alphonse Anwar C. Predictors of surgical intervention in patients with inflammatory bowel disease (two-center study). Egypt J Intern Med 2021;33. [DOI: 10.1186/s43162-021-00050-3] [Reference Citation Analysis]
|
| 288 |
Nishikawa Y, Sato N, Tsukinaga S, Uchiyama K, Koido S, Ishikawa D, Ohkusa T. Long-term outcomes of antibiotic combination therapy for ulcerative colitis. Ther Adv Chronic Dis 2021;12:20406223211028790. [PMID: 34285790 DOI: 10.1177/20406223211028790] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 289 |
Barberio B, Segal JP, Quraishi MN, Black CJ, Savarino EV, Ford AC. Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-analysis. J Crohns Colitis 2021;15:1184-96. [PMID: 33433562 DOI: 10.1093/ecco-jcc/jjab010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 290 |
Eriksson C, Rundquist S, Lykiardopoulos V, Udumyan R, Karlén P, Grip O, Söderman C, Almer S, Hertervig E, Marsal J, Gunnarsson J, Malmgren C, Delin J, Strid H, Sjöberg M, Öberg D, Bergemalm D, Hjortswang H, Halfvarson J; SWIBREG SVEAH Study Group. Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study. Therap Adv Gastroenterol 2021;14:17562848211023386. [PMID: 34276808 DOI: 10.1177/17562848211023386] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 291 |
Holubar SD, Lightner AL, Poylin V, Vogel JD, Gaertner W, Davis B, Davis KG, Mahadevan U, Shah SA, Kane SV, Steele SR, Paquette IM, Feingold DL; Prepared on behalf of the Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Ulcerative Colitis. Dis Colon Rectum 2021;64:783-804. [PMID: 33853087 DOI: 10.1097/DCR.0000000000002037] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 292 |
Kronsten VT, Colwill MJ, Nayeemuddin S, Limdi JK, Selinger C, Scott G, Al‐hillawi L, Salehi S, Blaker P, Chung‐faye G, Kent AJ, Dubois P, Hayee B. A ‘real‐world’ retrospective multi‐centre cohort study comparing infliximab and adalimumab for the maintenance of remission in ulcerative colitis. GastroHep 2021;3:229-235. [DOI: 10.1002/ygh2.467] [Reference Citation Analysis]
|
| 293 |
Chen L, Xu CJ, Wu W, Ding BJ, Liu ZJ. Anti-TNF and immunosuppressive combination therapy is preferential to inducing clinical remission in patients with active inflammatory bowel disease: A systemic review and meta-analysis. J Dig Dis 2021;22:408-18. [PMID: 34048629 DOI: 10.1111/1751-2980.13026] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 294 |
Neri B, Scarozza P, Giannarelli D, Sena G, Mossa M, Lolli E, Calabrese E, Biancone L, Grasso E, Di Iorio L, Troncone E, Monteleone G, Paoluzi OA, Del Vecchio Blanco G. Efficacy and tolerability of very low-volume bowel preparation in patients with inflammatory bowel diseases. Eur J Gastroenterol Hepatol 2021;33:977-82. [PMID: 34034275 DOI: 10.1097/MEG.0000000000002167] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 295 |
Norsa L, Ferrari A, Arrigo S, Bramuzzo M, Deganello Saccomani M, Di Nardo G, Illiceto MT, Miele E, Paci M, Romano C, Romeo E, Daperno M, Oliva S; Endoscopy group of the Italian society of pediatric Gastroenterology Hepatology and Nutrition (SIGENP). Scoring Endoscopy in Pediatric Inflammatory Bowel Disease: A Way to Improve Quality. J Pediatr Gastroenterol Nutr 2021;73:48-53. [PMID: 33720096 DOI: 10.1097/MPG.0000000000003090] [Reference Citation Analysis]
|
| 296 |
Sedano R, Nguyen TM, Almradi A, Rieder F, Parker CE, Shackelton LM, D'Haens G, Sandborn WJ, Feagan BG, Ma C, Jairath V. Disease Activity Indices for Pouchitis: A Systematic Review. Inflamm Bowel Dis 2022;28:622-38. [PMID: 34180986 DOI: 10.1093/ibd/izab124] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 297 |
Fossmark R, Olaisen M, Martinsen TC, Melberg HO. Factors associated with the persistence of oral 5-aminosalicylic acid monotherapy in ulcerative colitis: a nationwide Norwegian cohort study. Therap Adv Gastroenterol 2021;14:17562848211021760. [PMID: 34262610 DOI: 10.1177/17562848211021760] [Reference Citation Analysis]
|
| 298 |
Massimi D, Barberio B, Bertani L, Costa F, Ferronato A, Facchin S, Cardin R, Cingolani L, Casadei C, D'Incà R, Zingone F, Savarino EV. Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study. Therap Adv Gastroenterol 2021;14:17562848211023384. [PMID: 34249147 DOI: 10.1177/17562848211023384] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 299 |
Ventin-Holmberg R, Eberl A, Saqib S, Korpela K, Virtanen S, Sipponen T, Salonen A, Saavalainen P, Nissilä E. Bacterial and Fungal Profiles as Markers of Infliximab Drug Response in Inflammatory Bowel Disease. J Crohns Colitis 2021;15:1019-31. [PMID: 33300552 DOI: 10.1093/ecco-jcc/jjaa252] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 300 |
Morosi LG, Cutine AM, Cagnoni AJ, Manselle-Cocco MN, Croci DO, Merlo JP, Morales RM, May M, Pérez-Sáez JM, Girotti MR, Méndez-Huergo SP, Pucci B, Gil AH, Huernos SP, Docena GH, Sambuelli AM, Toscano MA, Rabinovich GA, Mariño KV. Control of intestinal inflammation by glycosylation-dependent lectin-driven immunoregulatory circuits. Sci Adv 2021;7:eabf8630. [PMID: 34144987 DOI: 10.1126/sciadv.abf8630] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 301 |
Yang S, Park JS, Hwang SH, Cho KH, Na HS, Choi J, Jhun J, Kim SJ, Lee BI, Park SH, Cho ML. Metformin-Inducible Small Heterodimer Partner Interacting Leucine Zipper Protein Ameliorates Intestinal Inflammation. Front Immunol 2021;12:652709. [PMID: 34211461 DOI: 10.3389/fimmu.2021.652709] [Reference Citation Analysis]
|
| 302 |
Yoshida A, Matsuoka K, Ueno F, Morizane T, Endo Y, Hibi T. Serum PR3-ANCA Is a Predictor of Primary Nonresponse to Anti-TNF-α Agents in Patients with Ulcerative Colitis. Inflamm Intest Dis 2021;6:117-22. [PMID: 34124183 DOI: 10.1159/000515361] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 303 |
Ishida N, Higuchi T, Miyazu T, Tamura S, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. C-reactive protein is superior to fecal biomarkers for evaluating colon-wide active inflammation in ulcerative colitis. Sci Rep 2021;11:12431. [PMID: 34127687 DOI: 10.1038/s41598-021-90558-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 304 |
Ishida N, Miyazu T, Tamura S, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. Early serum albumin changes in patients with ulcerative colitis treated with tacrolimus will predict clinical outcome. World J Gastroenterol 2021; 27(22): 3109-3120 [PMID: 34168412 DOI: 10.3748/wjg.v27.i22.3109] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 305 |
Maasfeh L, Härtlova A, Isaksson S, Sundin J, Mavroudis G, Savolainen O, Strid H, Öhman L, Magnusson MK. Impaired Luminal Control of Intestinal Macrophage Maturation in Patients With Ulcerative Colitis During Remission. Cell Mol Gastroenterol Hepatol 2021;12:1415-32. [PMID: 34126236 DOI: 10.1016/j.jcmgh.2021.06.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 306 |
Yagi S, Furukawa S, Shiraishi K, Hashimoto Y, Tange K, Mori K, Ninomiya T, Suzuki S, Shibata N, Murakami H, Ohashi K, Hasebe A, Tomida H, Yamamoto Y, Takeshita E, Ikeda Y, Hiasa Y. Effect of disease duration on the association between serum albumin and mucosal healing in patients with ulcerative colitis. BMJ Open Gastroenterol 2021;8:e000662. [PMID: 34099464 DOI: 10.1136/bmjgast-2021-000662] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 307 |
Chaparro M, Donday MG, Abad-Santos F, Martín de Carpi FJ, Maciá-Martínez MÁ, Montero D, Acosta D, Brenes Y, Gisbert JP. The safety of drugs for inflammatory bowel disease during pregnancy and breastfeeding: the DUMBO registry study protocol of GETECCU. Therap Adv Gastroenterol 2021;14:17562848211018097. [PMID: 34158835 DOI: 10.1177/17562848211018097] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 308 |
Smith SCL, Banbury C, Zardo D, Cannatelli R, Nardone OM, Shivaji UN, Ghosh S, Oppenheimer PG, Iacucci M. Raman spectroscopy accurately differentiates mucosal healing from non-healing and biochemical changes following biological therapy in inflammatory bowel disease. PLoS One 2021;16:e0252210. [PMID: 34077453 DOI: 10.1371/journal.pone.0252210] [Reference Citation Analysis]
|
| 309 |
Rath T, Atreya R, Neurath MF. Is histological healing a feasible endpoint in ulcerative colitis? Expert Rev Gastroenterol Hepatol 2021;15:665-74. [PMID: 33481635 DOI: 10.1080/17474124.2021.1880892] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 310 |
Chen H, Wu L, Wang M, Shao B, Ye L, Zhang Y, Cao Q. Use of the ulcerative colitis endoscopic index of severity and Mayo endoscopic score for predicting the therapeutic effect of mesalazine in patients with ulcerative colitis. Laparoscopic, Endoscopic and Robotic Surgery 2021;4:33-9. [DOI: 10.1016/j.lers.2021.04.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 311 |
Kuwada T, Shiokawa M, Kodama Y, Ota S, Kakiuchi N, Nannya Y, Yamazaki H, Yoshida H, Nakamura T, Matsumoto S, Muramoto Y, Yamamoto S, Honzawa Y, Kuriyama K, Okamoto K, Hirano T, Okada H, Marui S, Sogabe Y, Morita T, Matsumori T, Mima A, Nishikawa Y, Ueda T, Matsumura K, Uza N, Chiba T, Seno H. Identification of an Anti-Integrin αvβ6 Autoantibody in Patients With Ulcerative Colitis. Gastroenterology 2021;160:2383-2394.e21. [PMID: 33582126 DOI: 10.1053/j.gastro.2021.02.019] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 10.5] [Reference Citation Analysis]
|
| 312 |
Sakamoto A, Izutsu K, Yoshida H, Abe Y, Inoue D, Sugano K. Simple bicarbonate buffer system for dissolution testing: Floating lid method and its application to colonic drug delivery system. Journal of Drug Delivery Science and Technology 2021;63:102447. [DOI: 10.1016/j.jddst.2021.102447] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 313 |
Triantafyllou C, Nikolaou M, Ikonomidis I, Bamias G, Kouretas D, Andreadou I, Tsoumani M, Thymis J, Papaconstantinou I. Effects of Anti-Inflammatory Treatment and Surgical Intervention on Endothelial Glycocalyx, Peripheral and Coronary Microcirculatory Function and Myocardial Deformation in Inflammatory Bowel Disease Patients: A Two-Arms Two-Stage Clinical Trial. Diagnostics (Basel) 2021;11:993. [PMID: 34070768 DOI: 10.3390/diagnostics11060993] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 314 |
Paniz GR, Arroyo-mercado FM, Ling CL, Choi EE, Snow HE, Rakov NE, Castillo EF. Assessment of mesalamine in the alterations of metabolic parameters in comorbid ulcerative colitis and metabolic syndrome patients: A retrospective study.. [DOI: 10.1101/2021.05.27.21257690] [Reference Citation Analysis]
|
| 315 |
Yasutomi E, Inokuchi T, Hiraoka S, Takei K, Igawa S, Yamamoto S, Ohmori M, Oka S, Yamasaki Y, Kinugasa H, Takahara M, Harada K, Furukawa M, Itoshima K, Okada K, Otsuka F, Tanaka T, Mitsuhashi T, Kato J, Okada H. Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease. Sci Rep 2021;11:11086. [PMID: 34045529 DOI: 10.1038/s41598-021-90441-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 316 |
Stapersma L, van den Brink G, van der Ende J, Szigethy EM, Groeneweg M, de Bruijne FH, Hillegers MHJ, Escher JC, Utens EMWJ. Psychological Outcomes of a Cognitive Behavioral Therapy for Youth with Inflammatory Bowel Disease: Results of the HAPPY-IBD Randomized Controlled Trial at 6- and 12-Month Follow-Up. J Clin Psychol Med Settings 2020;27:490-506. [PMID: 31506853 DOI: 10.1007/s10880-019-09649-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 317 |
Iacucci M, Jeffery L, Acharjee A, Nardone OM, Zardo D, Smith SCL, Bazarova A, Cannatelli R, Shivaji UN, Williams J, Gkoutos G, Ghosh S. Ultra-high Magnification Endocytoscopy and Molecular Markers for Defining Endoscopic and Histologic Remission in Ulcerative Colitis-An Exploratory Study to Define Deep Remission. Inflamm Bowel Dis 2021;27:1719-30. [PMID: 34019073 DOI: 10.1093/ibd/izab059] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 318 |
Bromke MA, Neubauer K, Kempiński R, Krzystek-Korpacka M. Faecal Calprotectin in Assessment of Mucosal Healing in Adults with Inflammatory Bowel Disease: A Meta-Analysis. J Clin Med 2021;10:2203. [PMID: 34069684 DOI: 10.3390/jcm10102203] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 319 |
Cordes F, Lenker E, Weinhage T, Spille LJ, Bettenworth D, Varga G, Schmidt HH, Foell D. Impaired IFN-γ-dependent STAT3 Activation Is Associated With Dysregulation of Regulatory and Inflammatory Signaling in Monocytes of Ulcerative Colitis Patients. Inflamm Bowel Dis 2021;27:887-901. [PMID: 33165509 DOI: 10.1093/ibd/izaa280] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 320 |
Knyazev OV, Kagramanova AV, Lishchinskaya AA. Evaluation of the efficacy of MMX mesalazine therapy for moderate ulcerative colitis. Medicinskij sovet 2021. [DOI: 10.21518/2079-701x-2021-5-113-123] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 321 |
Pagnini C, Di Paolo MC, Mariani BM, Urgesi R, Pallotta L, Vitale MA, Villotti G, d’Alba L, De Cesare MA, Di Giulio E, Graziani MG. Mayo Endoscopic Score and Ulcerative Colitis Endoscopic Index Are Equally Effective for Endoscopic Activity Evaluation in Ulcerative Colitis Patients in a Real Life Setting. Gastroenterology Insights 2021;12:217-24. [DOI: 10.3390/gastroent12020019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 322 |
Tiong MK, Smith ER, Toussaint ND, Al-Khayyat HF, Holt SG. Reduction of Calciprotein Particles in Adults Receiving Infliximab for Chronic Inflammatory Disease. JBMR Plus 2021;5:e10497. [PMID: 34189386 DOI: 10.1002/jbm4.10497] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 323 |
Tadbiri S, Nachury M, Bouhnik Y, Serrero M, Hébuterne X, Roblin X, Kirchgesner J, Bouguen G, Franchimont D, Savoye G, Buisson A, Louis E, Nancey S, ABitbol V, Reimund JM, DeWit O, Vuitton L, Matthieu N, Peyrin-Biroulet L, Gilletta C, Allez M, Viennot S, Trang-Poisson C, Dib N, Brixi H, Boualit M, Plastaras L, Boivineau L, Fumery M, Caillo L, Laharie D, Amiot A; GETAID-IBD-disk study group. The IBD-disk Is a Reliable Tool to Assess the Daily-life Burden of Patients with Inflammatory Bowel Disease. J Crohns Colitis 2021;15:766-73. [PMID: 33246337 DOI: 10.1093/ecco-jcc/jjaa244] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 324 |
Bonnaud G, Haennig A, Altwegg R, Caron B, Boivineau L, Zallot C, Gilleta de Saint-Joseph C, Moreau J, Gonzalez F, Reynaud D, Faure P, Aygalenq P, Combis JM, Peyrin-Biroulet L. Real-life pilot study on the impact of the telemedicine platform EasyMICI-MaMICI(®) on quality of life and quality of care in patients with inflammatory bowel disease. Scand J Gastroenterol 2021;56:530-6. [PMID: 33691075 DOI: 10.1080/00365521.2021.1894602] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 325 |
Tursi A, Mocci G, Lorenzetti R, Allegretta L, Brandimarte G, Cassieri C, Colucci R, De Medici A, Faggiani R, Ferronato A, Fiorella S, Forti G, Franceschi M, Gallina S, Giorgetti G, Grasso G, Larussa T, Luzza F, Penna A, Pica R, Piergallini S, Porciello S, Pranzo G, Rodino' S, Scorza S, Sebkova L, Zampaletta C, Elisei W, Picchio M. Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients. Eur J Gastroenterol Hepatol 2021;33:670-9. [PMID: 33741797 DOI: 10.1097/MEG.0000000000002087] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 326 |
Sagami S, Kobayashi T, Miyatani Y, Okabayashi S, Yamazaki H, Takada T, Kinoshita K, Allocca M, Kunisaki R, Ramaswamy PK, Shiraki M, Hibi T, Kataoka Y. Accuracy of Ultrasound for Evaluation of Colorectal Segments in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2021;19:908-921.e6. [PMID: 32777549 DOI: 10.1016/j.cgh.2020.07.067] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 327 |
Hisabe T, Matsui T, Yamasaki K, Morokuma T, Aomi K, Yoshizawa N, Takatsu N, Yao K, Ueki T, Futami K, Tanabe H, Iwashita A. Possible Earlier Diagnosis of Ulcerative Colitis-Associated Neoplasia: A Retrospective Analysis of Interval Cases during Surveillance. J Clin Med 2021;10:1927. [PMID: 33946906 DOI: 10.3390/jcm10091927] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 328 |
Hyams JS, Brimacombe M, Haberman Y, Walters T, Gibson G, Mo A, Mack D, Griffiths A, Boyle B, LeLeiko N, Markowitz J, Rosh J, Patel A, Shah S, Baldassano R, Pfefferkorn M, Sauer C, Dailey J, Venkateswaran S, Kugathasan S, Denson LA. Clinical and Host Biological Factors Predict Colectomy Risk in Children Newly Diagnosed With Ulcerative Colitis. Inflamm Bowel Dis 2022;28:151-60. [PMID: 33904583 DOI: 10.1093/ibd/izab061] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 329 |
Kakuta K, Dohi K, Yamamoto T, Fujimoto N, Shimoyama T, Umegae S, Ito M. Coronary Microvascular Dysfunction Restored After Surgery in Inflammatory Bowel Disease: A Prospective Observational Study. J Am Heart Assoc 2021;10:e019125. [PMID: 33899514 DOI: 10.1161/JAHA.120.019125] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 330 |
Oliva S, Thomson M, Wilson D, Turner D. Role of endoscopy in inflammatory bowel disease including scoring systems. Practical Pediatric Gastrointestinal Endoscopy 2021. [DOI: 10.1002/9781119423492.ch24] [Reference Citation Analysis]
|
| 331 |
Cannatelli R, Bazarova A, Zardo D, Nardone OM, Shivaji U, Smith SCL, Gkoutos G, Ricci C, Gui XS, Ghosh S, Iacucci M. Fecal Calprotectin Thresholds to Predict Endoscopic Remission Using Advanced Optical Enhancement Techniques and Histological Remission in IBD Patients. Inflamm Bowel Dis 2021;27:647-54. [PMID: 32592477 DOI: 10.1093/ibd/izaa163] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 332 |
Coelho-Prabhu N, Bruining DH, Faubion WA, Kane SV, Kisiel JB, Papadakis KA, Pardi DS, Raffals LE, Schroeder KW, Tremaine WJ, Fruth K, Harmsen WS, Loftus EV. A 1-Year Cross-sectional Inflammatory Bowel Disease Surveillance Colonoscopy Cohort Comparing High-definition White Light Endoscopy and Chromoendoscopy. Inflamm Bowel Dis 2021;27:594-602. [PMID: 32529198 DOI: 10.1093/ibd/izaa146] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 333 |
Hernández-Camba A, Carrillo-Palau M, Ramos L, Hernández Alvarez-Buylla N, Alonso-Abreu I, Hernández-Pérez A, Vela M, Arranz L, Hernández-Guerra M, González-Gay MÁ, Ferraz-Amaro I. Carotid Plaque Assessment Reclassifies Patients with Inflammatory Bowel Disease into Very-High Cardiovascular Risk. J Clin Med 2021;10:1671. [PMID: 33924727 DOI: 10.3390/jcm10081671] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 334 |
Mo A, Nagpal S, Gettler K, Haritunians T, Giri M, Haberman Y, Karns R, Prince J, Arafat D, Hsu N, Chuang L, Argmann C, Kasarskis A, Suarez-farinas M, Gotman N, Mengesha E, Venkateswaran S, Rufo PA, Baker SS, Sauer CG, Markowitz J, Pfefferkorn MD, Rosh JR, Boyle BM, Mack DR, Baldassano RN, Shah S, Leleiko NS, Heyman MB, Griffiths AM, Patel AS, Noe JD, Thomas SD, Aronow BJ, Walters TD, Mcgovern DPB, Hyams JS, Kugathasan S, Cho JH, Denson LA, Gibson G. Stratification of Risk of Progression to Colectomy in Ulcerative Colitis using Measured and Predicted Gene Expression.. [DOI: 10.1101/2021.04.02.438187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 335 |
Yamamoto-furusho J. Evaluación del estado nutricional y su asociación con el grado de actividad en pacientes mexicanos con colitis ulcerosa crónica idiopática (CUCI). Revista de Gastroenterología de México 2021;86:107-109. [DOI: 10.1016/j.rgmx.2020.08.004] [Reference Citation Analysis]
|
| 336 |
Yamamoto-furusho J. Evaluation of nutritional status and its association with the grade of activity of ulcerative colitis in Mexican patients. Revista de Gastroenterología de México (English Edition) 2021;86:107-109. [DOI: 10.1016/j.rgmxen.2020.08.003] [Reference Citation Analysis]
|
| 337 |
Devlin JC, Axelrad J, Hine AM, Chang S, Sarkar S, Lin JD, Ruggles KV, Hudesman D, Cadwell K, Loke P. Single-Cell Transcriptional Survey of Ileal-Anal Pouch Immune Cells From Ulcerative Colitis Patients. Gastroenterology 2021;160:1679-93. [PMID: 33359089 DOI: 10.1053/j.gastro.2020.12.030] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 338 |
Fiorino G, Danese S, Giacobazzi G, Spinelli A. Medical therapy versus surgery in moderate-to-severe ulcerative colitis. Dig Liver Dis 2021;53:403-8. [PMID: 33051163 DOI: 10.1016/j.dld.2020.09.022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 339 |
Iacucci M, Smith SCL, Bazarova A, Shivaji UN, Bhandari P, Cannatelli R, Daperno M, Ferraz J, Goetz M, Gui X, Hayee B, De Hertogh G, Lazarev M, Li J, Nardone OM, Parra-Blanco A, Pastorelli L, Panaccione R, Occhipinti V, Rath T, Tontini GE, Vieth M, Villanacci V, Zardo D, Bisschops R, Kiesslich R, Ghosh S. An International Multicenter Real-Life Prospective Study of Electronic Chromoendoscopy Score PICaSSO in Ulcerative Colitis. Gastroenterology 2021;160:1558-1569.e8. [PMID: 33347880 DOI: 10.1053/j.gastro.2020.12.024] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 12.5] [Reference Citation Analysis]
|
| 340 |
Hu JE, Weiß F, Bojarski C, Branchi F, Schulzke JD, Fromm M, Krug SM. Expression of tricellular tight junction proteins and the paracellular macromolecule barrier are recovered in remission of ulcerative colitis. BMC Gastroenterol 2021;21:141. [PMID: 33789594 DOI: 10.1186/s12876-021-01723-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 341 |
Hagan M, Hayee BH, Rodriguez-Mateos A. (Poly)phenols in Inflammatory Bowel Disease and Irritable Bowel Syndrome: A Review. Molecules 2021;26:1843. [PMID: 33805938 DOI: 10.3390/molecules26071843] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 342 |
Pang L, Liu H, Liu Z, Tan J, Zhou L, Qiu Y, Lin X, He J, Li X, Lin S, Ghosh S, Mao R, Chen M. Role of Telemedicine in Inflammatory Bowel Disease: a Systematic Review and Meta-analysis of Randomized Clinical Trials (Preprint).. [DOI: 10.2196/preprints.28978] [Reference Citation Analysis]
|
| 343 |
Singh V, Johnson K, Yin J, Lee S, Lin R, Yu H, In JG, Foulke-abel J, Zachos N. Chronic inflammation in ulcerative colitis causes long term changes in gobletcell function.. [DOI: 10.1101/2021.03.17.435871] [Reference Citation Analysis]
|
| 344 |
El Sharawy S, El-horany H, Amer I. Corrected ESR/Albumin Ratio as a Simple, Practical Marker Predicts the Severity in Egyptian Ulcerative Colitis Patients. TOBIOMJ 2021;11:8-16. [DOI: 10.2174/1875318302111010008] [Reference Citation Analysis]
|
| 345 |
Caio G, Lungaro L, Caputo F, Muccinelli M, Marcello MC, Zoli E, Volta U, De Giorgio R, Zoli G. Recurrent myocarditis in a patient with active ulcerative colitis: a case report and review of the literature. BMJ Open Gastroenterol 2021;8:e000587. [PMID: 33722804 DOI: 10.1136/bmjgast-2020-000587] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 346 |
Farias e Silva K, Nanini HF, Cascabulho CM, Rosas SLB, Santana PT, Carneiro AJV, Anaissie E, Nucci M, de Souza HSP. Serum 1,3-beta-D-glucan as a noninvasive test to predict histologic activity in patients with inflammatory bowel disease. World J Gastroenterol 2021; 27(9): 866-885 [PMID: 33727775 DOI: 10.3748/wjg.v27.i9.866] [Reference Citation Analysis]
|
| 347 |
Aloi M, Bramuzzo M, Norsa L, Arrigo S, Distante M, Miele E, Romano C, Giobbi C, Panceri R, Cucchiara S, Alvisi P; SIGENP IBD Working Group. IBD Working group. Disease Activity Patterns in the First 5 Years After Diagnosis in Children With Ulcerative Colitis: A Population-Based Study. J Crohns Colitis 2021;15:367-74. [PMID: 33022055 DOI: 10.1093/ecco-jcc/jjaa203] [Reference Citation Analysis]
|
| 348 |
Mavroudis G, Strid H, Jonefjäll B, Simrén M. Visceral hypersensitivity is together with psychological distress and female gender associated with severity of IBS-like symptoms in quiescent ulcerative colitis. Neurogastroenterol Motil 2021;33:e13998. [PMID: 33034406 DOI: 10.1111/nmo.13998] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 349 |
Brynza M, V. N. Karazin Kharkiv National University, Uvarova K, V. N. Karazin Kharkiv National University. Issues of inflammatory bowel disease management in primary care. Shidnoevr z vnutr simejnoi med 2021;2021:109-115. [DOI: 10.15407/internalmed2021.01.109] [Reference Citation Analysis]
|
| 350 |
Yao H, Najarian K, Gryak J, Bishu S, Rice MD, Waljee AK, Wilkins HJ, Stidham RW. Fully automated endoscopic disease activity assessment in ulcerative colitis. Gastrointest Endosc 2021;93:728-736.e1. [PMID: 32810479 DOI: 10.1016/j.gie.2020.08.011] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 15.5] [Reference Citation Analysis]
|
| 351 |
Ran Z, Wu K, Matsuoka K, Jeen YT, Wei SC, Ahuja V, Chen M, Hu PJ, Andoh A, Kim HJ, Yang SK, Watanabe M, Ng SC, Hibi T, Hilmi IN, Suzuki Y, Han DS, Leung WK, Sollano J, Ooi CJ, Qian J. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia. J Gastroenterol Hepatol 2021;36:637-45. [PMID: 32672839 DOI: 10.1111/jgh.15185] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 352 |
Pugliese D, Privitera G, Rogai F, Variola A, Viola A, Laterza L, Privitera AC, Allocca M, Bossa F, Cappello M, Daperno M, Lorenzon G, Mazzuoli S, Principi M, Sablich R, Moser L, Ferronato A, Traini S, Tapete G, Bodini G, Di Girolamo M, Grossi L, Mocci G, Ricci C, Saibeni S, Festa S, Spagnuolo R, Cortelezzi CC, Mocciaro F, Rizzello F, Armuzzi A; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study. United European Gastroenterol J 2021;9:102-9. [PMID: 33203342 DOI: 10.1177/2050640620974308] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 353 |
Gutierrez Becker B, Arcadu F, Thalhammer A, Gamez Serna C, Feehan O, Drawnel F, Oh YS, Prunotto M. Training and deploying a deep learning model for endoscopic severity grading in ulcerative colitis using multicenter clinical trial data. Ther Adv Gastrointest Endosc. 2021;14:2631774521990623. [PMID: 33718871 DOI: 10.1177/2631774521990623] [Cited by in Crossref: 9] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 354 |
Naegeli AN, Hunter T, Dong Y, Hoskin B, Middleton-Dalby C, Hetherington J, Stefani-Hunyady D, Canavan JB. Full, Partial, and Modified Permutations of the Mayo Score: Characterizing Clinical and Patient-Reported Outcomes in Ulcerative Colitis Patients. Crohns Colitis 360 2021;3:otab007. [PMID: 36777063 DOI: 10.1093/crocol/otab007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 355 |
Chimenti MS, Conigliaro P, Biancone L, Perricone R. Update on the therapeutic management of patients with either psoriatic arthritis or ulcerative colitis: focus on the JAK inhibitor tofacitinib. Ther Adv Musculoskelet Dis 2021;13:1759720X20977777. [PMID: 33680096 DOI: 10.1177/1759720X20977777] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 356 |
Allocca M, Filippi E, Costantino A, Bonovas S, Fiorino G, Furfaro F, Peyrin-Biroulet L, Fraquelli M, Caprioli F, Danese S. Milan ultrasound criteria are accurate in assessing disease activity in ulcerative colitis: external validation. United European Gastroenterol J 2021;9:438-42. [PMID: 33349199 DOI: 10.1177/2050640620980203] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 357 |
Festa S, Scribano ML, Pugliese D, Bezzio C, Principi M, Ribaldone DG, Allocca M, Mocci G, Bodini G, Spagnuolo R, Vernia P, Mazzuoli S, Costa F, Barberio B, Cosintino R, Zerboni G, Aratari A, Armuzzi A, Papi C. Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study. United European Gastroenterol J 2021;9:507-16. [PMID: 33259773 DOI: 10.1177/2050640620977405] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 358 |
Magnusson MK, Isaksson S, Öhman L. The Anti-inflammatory Immune Regulation Induced by Butyrate Is Impaired in Inflamed Intestinal Mucosa from Patients with Ulcerative Colitis. Inflammation 2020;43:507-17. [PMID: 31797122 DOI: 10.1007/s10753-019-01133-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 359 |
Ledergerber M, Lang BM, Heinrich H, Biedermann L, Begré S, Zeitz J, Krupka N, Rickenbacher A, Turina M, Greuter T, Schreiner P, Roth R, Siebenhüner A, Vavricka SR, Rogler G, Beerenwinkel N, Misselwitz B; Swiss IBD Cohort Study Group. Abdominal pain in patients with inflammatory bowel disease: association with single-nucleotide polymorphisms prevalent in irritable bowel syndrome and clinical management. BMC Gastroenterol 2021;21:53. [PMID: 33546600 DOI: 10.1186/s12876-021-01622-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 360 |
Adamkova P, Hradicka P, Gancarcikova S, Kassayova M, Ambro L, Bertkova I, Maronek M, Farkasova Iannaccone S, Demeckova V. Single Donor FMT Reverses Microbial/Immune Dysbiosis and Induces Clinical Remission in a Rat Model of Acute Colitis. Pathogens 2021;10:152. [PMID: 33540919 DOI: 10.3390/pathogens10020152] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 361 |
Boland K, Bedrani L, Turpin W, Kabakchiev B, Stempak J, Borowski K, Nguyen G, Steinhart AH, Smith MI, Croitoru K, Silverberg MS. Persistent Diarrhea in Patients With Crohn's Disease After Mucosal Healing Is Associated With Lower Diversity of the Intestinal Microbiome and Increased Dysbiosis. Clin Gastroenterol Hepatol 2021;19:296-304.e3. [PMID: 32220613 DOI: 10.1016/j.cgh.2020.03.044] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 362 |
Belvis Jiménez M, Hergueta-Delgado P, Gómez Rodríguez B, Maldonado Pérez B, Castro Laria L, Rodríguez-Téllez M, Morales Barroso ML, Galván Fernández MD, Guerra Veloz M, Jiménez García VA, Romero-Castro R, Benítez-Roladán A, Castro Márquez C, Aparcero López R, Garrido-Serrano A, Caunedo-Álvarez Á, Argüelles-Arias F. Comparison of the Mayo Endoscopy Score and the Ulcerative Colitis Endoscopy Index of Severity and the Ulcerative Colitis Colonoscopy Index of Severity. Endosc Int Open 2021;9:E130-6. [PMID: 33532549 DOI: 10.1055/a-1313-6968] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 363 |
Yoshimura T, Mitsuyama K, Sakemi R, Takedatsu H, Yoshioka S, Kuwaki K, Mori A, Fukunaga S, Araki T, Morita M, Tsuruta K, Yamasaki H, Torimura T. Evaluation of Serum Leucine-Rich Alpha-2 Glycoprotein as a New Inflammatory Biomarker of Inflammatory Bowel Disease. Mediators Inflamm 2021;2021:8825374. [PMID: 33623482 DOI: 10.1155/2021/8825374] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 364 |
Gottlieb K, Daperno M, Usiskin K, Sands BE, Ahmad H, Howden CW, Karnes W, Oh YS, Modesto I, Marano C, Stidham RW, Reinisch W. Endoscopy and central reading in inflammatory bowel disease clinical trials: achievements, challenges and future developments. Gut 2021;70:418-26. [PMID: 32699100 DOI: 10.1136/gutjnl-2020-320690] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 365 |
Gottlieb K, Requa J, Karnes W, Chandra Gudivada R, Shen J, Rael E, Arora V, Dao T, Ninh A, McGill J. Central Reading of Ulcerative Colitis Clinical Trial Videos Using Neural Networks. Gastroenterology 2021;160:710-719.e2. [PMID: 33098883 DOI: 10.1053/j.gastro.2020.10.024] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 20.5] [Reference Citation Analysis]
|
| 366 |
Yokoyama M, Kimura MY, Ito T, Hayashizaki K, Endo Y, Wang Y, Yagi R, Nakagawa T, Kato N, Matsubara H, Nakayama T. Myosin Light Chain 9/12 Regulates the Pathogenesis of Inflammatory Bowel Disease. Front Immunol 2020;11:594297. [PMID: 33584659 DOI: 10.3389/fimmu.2020.594297] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 367 |
Malvão LDR, Madi K, Esberard BC, de Amorim RF, Silva KDS, Farias E Silva K, de Souza HSP, Carvalho ATP. Fecal calprotectin as a noninvasive test to predict deep remission in patients with ulcerative colitis. Medicine (Baltimore) 2021;100:e24058. [PMID: 33546007 DOI: 10.1097/MD.0000000000024058] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 368 |
Osterman MT, Scott FI, Fogt FF, Gilroy ED, Parrott S, Galanko J, Cross R, Moss A, Herfarth HH, Higgins PDR. Endoscopic and Histological Assessment, Correlation, and Relapse in Clinically Quiescent Ulcerative Colitis (MARQUEE). Inflamm Bowel Dis 2021;27:207-14. [PMID: 32170946 DOI: 10.1093/ibd/izaa048] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 369 |
Zhang MH, Wang H, Wang HG, Wen X, Yang XZ. Effective immune-inflammation index for ulcerative colitis and activity assessments. World J Clin Cases 2021; 9(2): 334-343 [PMID: 33521101 DOI: 10.12998/wjcc.v9.i2.334] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 370 |
Goodsall TM, Nguyen TM, Parker CE, Ma C, Andrews JM, Jairath V, Bryant RV. Systematic Review: Gastrointestinal Ultrasound Scoring Indices for Inflammatory Bowel Disease. J Crohns Colitis 2021;15:125-42. [PMID: 32614386 DOI: 10.1093/ecco-jcc/jjaa129] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 371 |
Sandborn WJ, Feagan BG, Hanauer S, Vermeire S, Ghosh S, Liu WJ, Petersen A, Charles L, Huang V, Usiskin K, Wolf DC, D'Haens G. Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study. J Crohns Colitis 2021;15:1120-9. [PMID: 33438008 DOI: 10.1093/ecco-jcc/jjab012] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 16.5] [Reference Citation Analysis]
|
| 372 |
Bots S, Nylund K, Löwenberg M, Gecse K, D'Haens G. Intestinal Ultrasound to Assess Disease Activity in Ulcerative Colitis: Development of a novel UC-Ultrasound Index. J Crohns Colitis 2021;15:1264-71. [PMID: 33411887 DOI: 10.1093/ecco-jcc/jjab002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 10.5] [Reference Citation Analysis]
|
| 373 |
Capolupo GT, Carannante F, Mascianà G, Lauricella S, Mazzotta E, Caricato M. Transanal proctocolectomy and ileal pouch-anal anastomosis (TaIPAA) for ulcerative colitis: medium term functional outcomes in a single centre. BMC Surg 2021;21:17. [PMID: 33407354 DOI: 10.1186/s12893-020-01007-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 374 |
Zeng F, Li X, Deng X, Yao L, Lian G. An image classification model based on transfer learning for ulcerative proctitis. Multimedia Systems 2021;27:627-36. [DOI: 10.1007/s00530-020-00722-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 375 |
Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M, Sugimoto K, Fuji T, Watanabe K, Nakamura S, Inoue N, Itoh T, Naganuma M, Hisamatsu T, Watanabe M, Miwa H, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol 2021;56:489-526. [PMID: 33885977 DOI: 10.1007/s00535-021-01784-1] [Cited by in Crossref: 89] [Cited by in F6Publishing: 78] [Article Influence: 44.5] [Reference Citation Analysis]
|
| 376 |
Shinzaki S, Matsuoka K, Tanaka H, Takeshima F, Kato S, Torisu T, Ohta Y, Watanabe K, Nakamura S, Yoshimura N, Kobayashi T, Shiotani A, Hirai F, Hiraoka S, Watanabe M, Matsuura M, Nishimoto S, Mizuno S, Iijima H, Takehara T, Naka T, Kanai T, Matsumoto T. Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study. J Gastroenterol 2021;56:560-9. [PMID: 33942166 DOI: 10.1007/s00535-021-01793-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 377 |
Bitton S, Markowitz JF. Ulcerative Colitis in Children and Adolescents. Pediatric Gastrointestinal and Liver Disease 2021. [DOI: 10.1016/b978-0-323-67293-1.00043-8] [Reference Citation Analysis]
|
| 378 |
Kato M, Sugiyama K, Miyakawa M, Nasuno M, Tanaka H, Motoya S. Efficacy of Multi Matrix System Mesalazine for the Induction of Remission in Patients with Ulcerative Colitis who Insufficiently Respond toother Mesalazine Formulations: A Japanese Single-center Study. Journal of Japan Society of Coloproctology 2021;74:357-363. [DOI: 10.3862/jcoloproctology.74.357] [Reference Citation Analysis]
|
| 379 |
Passarella A, Grewal P, Vrabie R. Diagnosis and Monitoring in Inflammatory Bowel Disease: Who, When, Where, and How. Clinical Gastroenterology 2021. [DOI: 10.1007/978-3-030-81780-0_2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 380 |
Кручинина МВ, Светлова ИО, Азгалдян АВ, Осипенко МФ, Валуйских ЕЮ, Шашков МВ, Соколова АС, Кручинин ВН, Яковина ИН, Осипенко ИВ. Профиль жирных кислот мембран эритроцитов и сыворотки крови у пациентов с воспалительными заболеваниями кишечника в зависимости от стадии заболевания. Естественные и Технические Науки 2021. [DOI: 10.37882/2223-2966.2021.05.18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 381 |
Fenton CG, Taman H, Florholmen J, Sørbye SW, Paulssen RH. Transcriptional Signatures That Define Ulcerative Colitis in Remission. Inflamm Bowel Dis 2021;27:94-105. [PMID: 32322884 DOI: 10.1093/ibd/izaa075] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 382 |
Ishida N, Onoue S, Miyazu T, Tamura S, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. Further research on the clinical relevance of the ulcerative colitis colonoscopic index of severity for predicting 5-year relapse. Int J Colorectal Dis 2021;36:2661-70. [PMID: 34409500 DOI: 10.1007/s00384-021-04009-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 383 |
Ohmori T. Efficacy of Budesonide Foam in Patients with Mild-to-Moderate Ulcerative Colitis Treated with a Maximum Dose of Oral Mesalazine. Journal of Japan Society of Coloproctology 2021;74:153-161. [DOI: 10.3862/jcoloproctology.74.153] [Reference Citation Analysis]
|
| 384 |
Stefanovic S, Detrez I, Compernolle G, Brouwers E, Sever N, Stabuc B, Smrekar N, Kurent T, Novak G, Kozelj M, Ferrante M, Gils A, Drobne D. Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed label. Eur J Gastroenterol Hepatol 2021;33:54-61. [PMID: 32804854 DOI: 10.1097/MEG.0000000000001843] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 385 |
Stallard L, Hussey S. Endoscopic and Histologic Predictors of Outcomes in Pediatric Ulcerative Colitis-Caveat Emptor. Front Pediatr 2021;9:678132. [PMID: 34249815 DOI: 10.3389/fped.2021.678132] [Reference Citation Analysis]
|
| 386 |
Shaoul R, Day AS. An Overview of Tools to Score Severity in Pediatric Inflammatory Bowel Disease. Front Pediatr 2021;9:615216. [PMID: 33912519 DOI: 10.3389/fped.2021.615216] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 387 |
Conti C, Rosa I, Zito L, Grossi L, Efthymakis K, Neri M, Porcelli P. Influence of the COVID-19 Outbreak on Disease Activity and Quality of Life in Inflammatory Bowel Disease Patients. Front Psychiatry 2021;12:664088. [PMID: 33967864 DOI: 10.3389/fpsyt.2021.664088] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 388 |
Iacucci M, Cannatelli R. Advanced Colonoscopy Techniques in Inflammatory Bowel Diseases. Gastrointestinal and Pancreatico-Biliary Diseases: Advanced Diagnostic and Therapeutic Endoscopy 2021. [DOI: 10.1007/978-3-030-29964-4_29-1] [Reference Citation Analysis]
|
| 389 |
Sultan K, Becher N. Ulcerative Colitis Diagnosis and Management: Past, Present, and Future Directions. Clinical Gastroenterology 2021. [DOI: 10.1007/978-3-030-81780-0_3] [Reference Citation Analysis]
|
| 390 |
Chen L, Yang J, Fang L, Wu W, Feng B, Shi Y, Sun M, Sun X, Liu Z. The Degree of Ulcerative Colitis Burden of Luminal Inflammation score is superior to predicting medium- to long-term prognosis in patients with active ulcerative colitis. Therap Adv Gastroenterol 2020;13:1756284820981210. [PMID: 33425012 DOI: 10.1177/1756284820981210] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 391 |
Kosmachova ED, Iakovenko MS, Yumukian KA. A clinical case of ulcerative colitis in a patient with viral hepatitis. jour 2020;1:95-102. [DOI: 10.21886/2712-8156-2020-1-3-95-102] [Reference Citation Analysis]
|
| 392 |
Dan N, Samanta K, Almoazen H. An Update on Pharmaceutical Strategies for Oral Delivery of Therapeutic Peptides and Proteins in Adults and Pediatrics. Children (Basel) 2020;7:E307. [PMID: 33352795 DOI: 10.3390/children7120307] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 393 |
Rodrigues BL, Mazzaro MC, Nagasako CK, Ayrizono MLS, Fagundes JJ, Leal RF. Assessment of disease activity in inflammatory bowel diseases: Non-invasive biomarkers and endoscopic scores. World J Gastrointest Endosc 2020; 12(12): 504-520 [PMID: 33362904 DOI: 10.4253/wjge.v12.i12.504] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 394 |
Dwadasi S, Zafer M, Goens D, Paknikar R, Dalal S, Cohen RD, Pekow J, Rubin DT, Sakuraba A, Micic D. Inpatient Therapy With Calcineurin Inhibitors in Severe Ulcerative Colitis. Inflamm Bowel Dis 2021;27:1620-5. [PMID: 33319248 DOI: 10.1093/ibd/izaa326] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 395 |
Alekseeva OP, Krishtopenko SV, Alekseeva AA. Using Dose-Effect Relationship for Optimising Systemic Corticosteroid Dosage in Treatment of Inflammatory Bowel Diseases. Rossijskij žurnal gastroènterologii, gepatologii, koloproktologii 2020;30:18-25. [DOI: 10.22416/1382-4376-2020-30-5-18-25] [Reference Citation Analysis]
|
| 396 |
Marutani Y, Mizoshita T, Sugiyama T, Togawa S, Katano T, Yamada T, Hirata Y, Kimura Y, Miyaki T, Inoue Y, Suzuki E, Sasaki M, Kataoka H. Efficacies of first and second tumor necrosis factor inhibitors in refractory ulcerative colitis patients in real-world practice. Indian J Gastroenterol 2020;39:565-75. [PMID: 33106991 DOI: 10.1007/s12664-020-01092-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 397 |
Pabla BS, Schwartz DA. Assessing Severity of Disease in Patients with Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:671-88. [PMID: 33121688 DOI: 10.1016/j.gtc.2020.08.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 398 |
Li K, Marano C, Zhang H, Yang F, Sandborn WJ, Sands BE, Feagan BG, Rubin DT, Peyrin-Biroulet L, Friedman JR, De Hertogh G. Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis. Gastroenterology 2020;159:2052-64. [PMID: 32853634 DOI: 10.1053/j.gastro.2020.08.037] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
|
| 399 |
Abreu MT, Sandborn WJ; IOIBD Defining Endpoints and Biomarkers in Inflammatory Bowel Disease Writing Group. Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design. Gastroenterology 2020;159:2013-2018.e7. [PMID: 32961246 DOI: 10.1053/j.gastro.2020.07.064] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 400 |
Stojkovic Lalosevic M, Toncev L, Stankovic S, Dragasevic S, Stojkovic S, Jovicic I, Stulic M, Culafic D, Milovanovic T, Stojanovic M, Aleksic M, Stjepanovic M, Lalosevic J, Kiurski S, Oluic B, Pavlovic Markovic A, Stojkovic M. Hepcidin Is a Reliable Marker of Iron Deficiency Anemia in Newly Diagnosed Patients with Inflammatory Bowel Disease. Dis Markers 2020;2020:8523205. [PMID: 33354248 DOI: 10.1155/2020/8523205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 401 |
Sznurkowska K, Luty J, Bryl E, Witkowski JM, Hermann-Okoniewska B, Landowski P, Kosek M, Szlagatys-Sidorkiewicz A. Enhancement of Circulating and Intestinal T Regulatory Cells and Their Expression of Helios and Neuropilin-1 in Children with Inflammatory Bowel Disease. J Inflamm Res 2020;13:995-1005. [PMID: 33273840 DOI: 10.2147/JIR.S268484] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 402 |
Liu J, Gao X, Chen Y, Mei Q, Zhu L, Qian J, Hu P, Cao Q. Incidence and risk factors for venous thrombosis among patients with inflammatory bowel disease in China: a multicenter retrospective study. Intest Res 2021;19:313-22. [PMID: 33232589 DOI: 10.5217/ir.2020.00017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 403 |
Murasugi S, Ito A, Omori T, Nakamura S, Tokushige K. Clinical Characterization of Ulcerative Colitis in Patients with Primary Sclerosing Cholangitis. Gastroenterol Res Pract 2020;2020:7969628. [PMID: 33224192 DOI: 10.1155/2020/7969628] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 404 |
Alkhatry M, Al-Rifai A, Annese V, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Nathwani R, Taha MS, Limdi JK. First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World J Gastroenterol 2020; 26(43): 6710-6769 [PMID: 33268959 DOI: 10.3748/wjg.v26.i43.6710] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 405 |
Furukawa S, Yagi S, Shiraishi K, Mori K, Ninomiya T, Kawasaki K, Mizukami Y, Suzuki S, Uraoka M, Shibata N, Nakamura S, Imamine S, Murakami H, Ohashi K, Torisu M, Hasebe A, Yano H, Murakami M, Takeshita E, Ikeda Y, Hiasa Y. Association between platelet count and mucosal healing in Japanese patients with ulcerative colitis: a cross-sectional study. BMC Gastroenterol 2020;20:384. [PMID: 33198664 DOI: 10.1186/s12876-020-01538-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 406 |
Fukuda T, Naganuma M, Takabayashi K, Hagihara Y, Tanemoto S, Nomura E, Yoshimatsu Y, Sugimoto S, Nanki K, Mizuno S, Mikami Y, Fukuhara K, Sujino T, Mutaguchi M, Inoue N, Ogata H, Iwao Y, Abe T, Kanai T. Mucosal concentrations of N-acetyl-5-aminosalicylic acid related to endoscopic activity in ulcerative colitis patients with mesalamine. J Gastroenterol Hepatol 2020;35:1878-85. [PMID: 32250471 DOI: 10.1111/jgh.15059] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 407 |
Axelrad JE, Sachs MC, Ludvigsson JF, Olén O; SWIBREG Study Group. A Novel Method for Quantifying Intestinal Inflammatory Burden in Inflammatory Bowel Disease Using Register Data. Clin Epidemiol 2020;12:1059-72. [PMID: 33116900 DOI: 10.2147/CLEP.S265404] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 408 |
Cheung VTF, Brain O. Immunotherapy induced enterocolitis and gastritis - What to do and when? Best Pract Res Clin Gastroenterol 2020;48-49:101703. [PMID: 33317787 DOI: 10.1016/j.bpg.2020.101703] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 409 |
Pinto-lopes P, Afonso J, Pinto-lopes R, Rocha C, Lago P, Gonçalves R, Tavares De Sousa H, Macedo G, Camila Dias C, Magro F. Serum Dipeptidyl Peptidase 4: A Predictor of Disease Activity and Prognosis in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2020;26:1707-1719. [DOI: 10.1093/ibd/izz319] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 410 |
Attauabi M, Poulsen A, Theede K, Pedersen N, Larsen L, Jess T, Rosager Hansen M, Verner-Andersen MK, V Haderslev K, Berg Lødrup A, Molazahi A, Neumann A, Wase A, Seidelin JB, Burisch J. Prevalence and Outcomes of COVID-19 Among Patients With Inflammatory Bowel Disease-A Danish Prospective Population-based Cohort Study. J Crohns Colitis 2021;15:540-50. [PMID: 33035299 DOI: 10.1093/ecco-jcc/jjaa205] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 411 |
Matsuda K, Okada Y, Hashiguchi Y, Asako K, Ohno K, Tsukamoto M, Fukushima Y, Shimada R, Ozawa T, Hayama T, Nozawa K, Fukagawa T, Sasajima Y. Ulcerative colitis that developed during radiotherapy for prostate cancer, deteriorated rapidly and required emergency surgery. Surg Case Rep 2020;6:250. [PMID: 33001266 DOI: 10.1186/s40792-020-01024-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 412 |
Silva JC, Fernandes C, Rodrigues J, Fernandes S, Ponte A, Rodrigues A, Silva AP, Gomes AC, Afecto E, Correia J, Carvalho J. Endoscopic and histologic activity assessment considering disease extent and prediction of treatment failure in ulcerative colitis. Scand J Gastroenterol 2020;55:1157-62. [PMID: 32772587 DOI: 10.1080/00365521.2020.1803397] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 413 |
Bossuyt P, Nakase H, Vermeire S, de Hertogh G, Eelbode T, Ferrante M, Hasegawa T, Willekens H, Ikemoto Y, Makino T, Bisschops R. Automatic, computer-aided determination of endoscopic and histological inflammation in patients with mild to moderate ulcerative colitis based on red density. Gut 2020;69:1778-86. [PMID: 31915237 DOI: 10.1136/gutjnl-2019-320056] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 16.3] [Reference Citation Analysis]
|
| 414 |
Gundersen MD, Goll R, Fenton CG, Anderssen E, Sørbye SW, Florholmen JR, Paulssen RH. Fibrosis Mediators in the Colonic Mucosa of Acute and Healed Ulcerative Colitis. Clin Transl Gastroenterol 2019;10:e00082. [PMID: 31584460 DOI: 10.14309/ctg.0000000000000082] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 415 |
Kim SY, An S, Park DK, Kwon KA, Kim KO, Chung JW, Kim JH, Kim YJ. Efficacy of iron supplementation in patients with inflammatory bowel disease treated with anti-tumor necrosis factor-alpha agents. Therap Adv Gastroenterol 2020;13:1756284820961302. [PMID: 33029199 DOI: 10.1177/1756284820961302] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 416 |
Kakimoto K, Matsuura M, Fukuchi T, Hongo H, Kimura T, Aoyama N, Okuda Y, Aomatsu K, Kamata N, Yokoyama Y, Mizuno C, Inoue T, Miyazaki T, Nakamura S, Higuchi K, Nakase H. Exploratory Study of the Effectiveness of Granulocyte and Monocyte Adsorptive Apheresis Before Initiation of Steroids in Patients With Active Ulcerative Colitis (EXPECT Study): A Multicenter Prospective Clinical Trial. Crohns Colitis 360 2020;2:otaa073. [PMID: 34192247 DOI: 10.1093/crocol/otaa073] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 417 |
Foulquier N, Chevet B, Carvajal G, Saraux L, Devauchelle-pensec V, Redou P, Saraux A. Towards a universal definition of disease activity score thresholds: The AS135 score (Preprint). JMIR Medical Informatics 2020. [DOI: 10.2196/24493] [Reference Citation Analysis]
|
| 418 |
Foulquier N, Chevet B, Carvajal G, Saraux L, Devauchelle-pensec V, Redou P, Saraux A. Towards a universal definition of disease activity score thresholds: The AS135 score (Preprint).. [DOI: 10.2196/preprints.24493] [Reference Citation Analysis]
|
| 419 |
Tkachev AV, Mazovka KE, Mkrtchyan LS, Makarenko AS, Takidze LT. Optimization of prediction of UC relapse and adjustment of adequate therapy in patient with ulcerative colitiss. jour 2020;1:65-71. [DOI: 10.21886/2712-8156-2020-1-2-65-71] [Reference Citation Analysis]
|
| 420 |
Veny M, Garrido-Trigo A, Corraliza AM, Masamunt MC, Bassolas-Molina H, Esteller M, Arroyes M, Tristán E, Fernández-Clotet A, Ordás I, Ricart E, Esteve M, Panés J, Salas A. Dissecting Common and Unique Effects of Anti-α4β7 and Anti-Tumor Necrosis Factor Treatment in Ulcerative Colitis. J Crohns Colitis 2021;15:441-52. [PMID: 32926095 DOI: 10.1093/ecco-jcc/jjaa178] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 421 |
Kanı HT, Ergenç İ, Arıkan H, Kömesli Z, Seyrek B, Demirtaş CÖ, Özen Alahdab Y, İmeryüz N, Atuğ Ö. Validation and reliability of the Turkish version of the inflammatory bowel disease questionnaire for ulcerative colitis and Crohn's disease. Turk J Gastroenterol 2020;31:566-72. [PMID: 32915144 DOI: 10.5152/tjg.2020.19553] [Reference Citation Analysis]
|
| 422 |
Hart L, Chavannes M, Lakatos PL, Afif W, Bitton A, Bressler B, Bessissow T. Do You See What I See? An Assessment of Endoscopic Lesions Recognition and Description by Gastroenterology Trainees and Staff Physicians. J Can Assoc Gastroenterol 2020;3:216-21. [PMID: 32905160 DOI: 10.1093/jcag/gwz022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 423 |
Sochal M, Małecka-Panas E, Gabryelska A, Talar-Wojnarowska R, Szmyd B, Krzywdzińska M, Białasiewicz P. Determinants of Sleep Quality in Inflammatory Bowel Diseases. J Clin Med 2020;9:E2921. [PMID: 32927760 DOI: 10.3390/jcm9092921] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 424 |
Mack DR, Saul B, Boyle B, Griffiths A, Sauer C, Markowitz J, LeLeiko N, Keljo D, Rosh JR, Baker SS, Steiner S, Heyman MB, Patel AS, Baldassano R, Noe J, Rufo P, Kugathasan S, Walters T, Marquis A, Thomas SM, Denson L, Hyams J; PROTECT STUDY GROUP. Analysis of Using the Total White Blood Cell Count to Define Severe New-onset Ulcerative Colitis in Children. J Pediatr Gastroenterol Nutr 2020;71:354-60. [PMID: 32520830 DOI: 10.1097/MPG.0000000000002797] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 425 |
Shashi P, Gopalakrishnan D, Parikh MP, Shen B, Kochhar G. Efficacy and safety of vedolizumab in elderly patients with inflammatory bowel disease: a matched case-control study. Gastroenterol Rep (Oxf) 2020;8:306-11. [PMID: 32843978 DOI: 10.1093/gastro/goz041] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 426 |
Borgli H, Thambawita V, Smedsrud PH, Hicks S, Jha D, Eskeland SL, Randel KR, Pogorelov K, Lux M, Nguyen DTD, Johansen D, Griwodz C, Stensland HK, Garcia-Ceja E, Schmidt PT, Hammer HL, Riegler MA, Halvorsen P, de Lange T. HyperKvasir, a comprehensive multi-class image and video dataset for gastrointestinal endoscopy. Sci Data. 2020;7:283. [PMID: 32859981 DOI: 10.1038/s41597-020-00622-y] [Cited by in Crossref: 76] [Cited by in F6Publishing: 83] [Article Influence: 25.3] [Reference Citation Analysis]
|
| 427 |
Aleksandrov TL, Shapina MV, Kisteneva LB, Sukhina MA, Kuznetsov AN. CYTOMEGALOVIRUS INFECTION IN PATIENTS WITH MODERATE AND SEVERE ULCERATIVE COLITIS. Koloproktologiâ 2020;19:26-36. [DOI: 10.33878/2073-7556-2020-19-3-26-36] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 428 |
Jalanka J, Cheng J, Hiippala K, Ritari J, Salojärvi J, Ruuska T, Kalliomäki M, Satokari R. Colonic Mucosal Microbiota and Association of Bacterial Taxa with the Expression of Host Antimicrobial Peptides in Pediatric Ulcerative Colitis. Int J Mol Sci 2020;21:E6044. [PMID: 32842596 DOI: 10.3390/ijms21176044] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 429 |
Oh SJ, Shin GY, Soh H, Lee JG, Im JP, Eun CS, Lee KM, Park DI, Han DS, Kim HJ, Lee CK. Long-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis. Intest Res 2021;19:323-31. [PMID: 32806875 DOI: 10.5217/ir.2020.00039] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 430 |
Sood A, Kaur K, Singh A, Midha V, Mahajan R, Bansal N, Mehta V, Singh D. Trends of inflammatory bowel disease at a tertiary care center in northern India. Intest Res 2021;19:282-90. [PMID: 32806872 DOI: 10.5217/ir.2020.00010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 431 |
Morita T, Mitsuyama K, Yamasaki H, Mori A, Yoshimura T, Araki T, Morita M, Tsuruta K, Yamasaki S, Kuwaki K, Yoshioka S, Takedatsu H, Torimura T. Gene Expression of Transient Receptor Potential Channels in Peripheral Blood Mononuclear Cells of Inflammatory Bowel Disease Patients. J Clin Med 2020;9:E2643. [PMID: 32823895 DOI: 10.3390/jcm9082643] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 432 |
Murray A, Nguyen TM, Parker CE, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2020;8:CD000543. [PMID: 32786164 DOI: 10.1002/14651858.CD000543.pub5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 433 |
Ayelén R, Pablo A, Sofía Q, Jimena C, Renata S, Carolina C, Claudia M, Iraola G, Federico CL, Alberto P, Belforte Fiorella S. New insights in Ulcerative Colitis Associated Gut Microbiota in South American Population: Akkermansia and Collinsella, two distinctive genera found in Argentine subjects.. [DOI: 10.1101/2020.07.29.20164764] [Reference Citation Analysis]
|
| 434 |
Gökden Y, Hot S, Gönen C, Kalyon S, Akkan Çetinkaya Z. The value of adenosine deaminase level in assessing activation of inflammatory bowel disease. Journal of Surgery and Medicine 2020;4:654-659. [DOI: 10.28982/josam.769877] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 435 |
Gu P, Patel D, Lakhoo K, Ko J, Liu X, Chang B, Pan D, Lentz G, Sonesen M, Estiandan R, Lin E, Pimentel M, Rezaie A. Breath Test Gas Patterns in Inflammatory Bowel Disease with Concomitant Irritable Bowel Syndrome-Like Symptoms: A Controlled Large-Scale Database Linkage Analysis. Dig Dis Sci 2020;65:2388-96. [PMID: 31754993 DOI: 10.1007/s10620-019-05967-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 436 |
Negroni A, Fiaschini N, Palone F, Vitali R, Colantoni E, Laudadio I, Oliva S, Aloi M, Cucchiara S, Stronati L. Intestinal Inflammation Alters the Expression of Hepatic Bile Acid Receptors Causing Liver Impairment. J Pediatr Gastroenterol Nutr 2020;71:189-96. [PMID: 32404746 DOI: 10.1097/MPG.0000000000002759] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 437 |
Devlin JC, Axelrad J, Hine AM, Chang S, Sarkar S, Lin J, Ruggles KV, Hudesman D, Cadwell K, Loke P. Transcriptional Atlas of Ileal-Anal Pouch Immune Cells from Ulcerative Colitis Patients.. [DOI: 10.1101/2020.07.31.231308] [Reference Citation Analysis]
|
| 438 |
Viscido A, Capannolo A, Petroni R, Stefanelli G, Zerboni G, De Martinis M, Necozione S, Penco M, Frieri G, Latella G, Romano S. Association between Corrected QT Interval and C-Reactive Protein in Patients with Inflammatory Bowel Diseases. Medicina (Kaunas) 2020;56:E382. [PMID: 32751480 DOI: 10.3390/medicina56080382] [Reference Citation Analysis]
|
| 439 |
Long Y, Zhao X, Liu C, Xia C, Liu C. Activated inducible co-stimulator-positive programmed cell death 1-positive follicular helper T cells indicate disease activity and severity in ulcerative colitis patients. Clin Exp Immunol 2020;202:106-18. [PMID: 32621310 DOI: 10.1111/cei.13485] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 440 |
Lee HS, Vancamelbeke M, Verstockt S, Wilms T, Verstockt B, Sabino J, Ferrante M, Vermeire S, Cleynen I. Molecular Changes in the Non-Inflamed Terminal Ileum of Patients with Ulcerative Colitis. Cells 2020;9:E1793. [PMID: 32731480 DOI: 10.3390/cells9081793] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 441 |
Jentzer A, Veyrard P, Roblin X, Saint-Sardos P, Rochereau N, Paul S, Bourlet T, Pozzetto B, Pillet S. Cytomegalovirus and Inflammatory Bowel Diseases (IBD) with a Special Focus on the Link with Ulcerative Colitis (UC). Microorganisms 2020;8:E1078. [PMID: 32698383 DOI: 10.3390/microorganisms8071078] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 442 |
Okamoto D, Kawai Y, Kakuta Y, Naito T, Torisu T, Hirano A, Umeno J, Fuyuno Y, Li D, Nakano T, Izumiyama Y, Ichikawa R, Hiramoto K, Moroi R, Kuroha M, Kanazawa Y, Shiga H, Tokunaga K, Nakamura M, Esaki M, Matsumoto T, McGovern DPB, Nagasaki M, Kinouchi Y, Masamune A. Genetic Analysis of Ulcerative Colitis in Japanese Individuals Using Population-specific SNP Array. Inflamm Bowel Dis 2020;26:1177-87. [PMID: 32072174 DOI: 10.1093/ibd/izaa033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 443 |
Leung K, Rhee G, Parlow S, Bollu A, Sabri E, McCurdy JD, Murthy SK. Absence of Day 3 Steroid Response Predicts Colitis-Related Complications and Colectomy in Hospitalized Ulcerative Colitis Patients. J Can Assoc Gastroenterol 2020;3:169-76. [PMID: 32671326 DOI: 10.1093/jcag/gwz005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 444 |
Sood A, Kaur K, Mahajan R, Midha V, Singh A, Sharma S, Puri AS, Goswami B, Desai D, Pai CG, Peddi K, Philip M, Kochhar R, Nijhawan S, Bhatia S, Rao NS. Colitis and Crohn's Foundation (India): a first nationwide inflammatory bowel disease registry. Intest Res 2021;19:206-16. [PMID: 32646197 DOI: 10.5217/ir.2019.09169] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 445 |
Ma C, Sandborn WJ, D'Haens GR, Zou G, Stitt LW, Singh S, Ananthakrishnan AN, Dulai PS, Khanna R, Jairath V, Feagan BG. Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis. Clin Gastroenterol Hepatol 2020;18:1760-1768.e1. [PMID: 31546056 DOI: 10.1016/j.cgh.2019.09.021] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 446 |
Hiyama S, Iijima H, Sakakibara Y, Yamada T, Mukai A, Otake Y, Yamaguchi T, Araki M, Kawai S, Tsujii Y, Inoue T, Hayashi Y, Shinzaki S, Takehara T. Endoscopic alterations in Peyer's patches in patients with ulcerative colitis: A prospective, multicenter study. J Gastroenterol Hepatol 2020;35:1143-9. [PMID: 31734952 DOI: 10.1111/jgh.14933] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 447 |
Xu Y, Xu F, Li W, Li M, Dong S, Zhang Y, Norman GL, Zhao Q, Liu L. The diagnostic role and clinical association of serum proteinase 3 anti-neutrophil cytoplasmic antibodies in Chinese patients with inflammatory bowel disease. Scand J Gastroenterol 2020;55:806-13. [PMID: 32568566 DOI: 10.1080/00365521.2020.1781926] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 448 |
Katinios G, Casado-Bedmar M, Walter SA, Vicario M, González-Castro AM, Bednarska O, Söderholm JD, Hjortswang H, Keita ÅV. Increased Colonic Epithelial Permeability and Mucosal Eosinophilia in Ulcerative Colitis in Remission Compared With Irritable Bowel Syndrome and Health. Inflamm Bowel Dis 2020;26:974-84. [PMID: 31944236 DOI: 10.1093/ibd/izz328] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 449 |
Powell N, Ibraheim H, Raine T, Speight RA, Papa S, Brain O, Green M, Samaan MA, Spain L, Yousaf N, Hunter N, Eldridge L, Pavlidis P, Irving P, Hayee B, Turajlic S, Larkin J, Lindsay JO, Gore M. British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. Lancet Gastroenterol Hepatol 2020;5:679-97. [PMID: 32553146 DOI: 10.1016/S2468-1253(20)30014-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 450 |
Vachon A, Scott FI. The treatment approach to inflammatory bowel disease in 2020. Curr Opin Gastroenterol 2020;36:247-56. [PMID: 32452863 DOI: 10.1097/MOG.0000000000000653] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 451 |
Kimura K, Yoshida A, Katagiri F, Takayanagi R, Yamada Y. Prediction of treatment failure during infliximab induction therapy in inflammatory bowel disease patients based on pharmacokinetic and pharmacodynamic modeling. Eur J Pharm Sci 2020;150:105317. [PMID: 32205229 DOI: 10.1016/j.ejps.2020.105317] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 452 |
Ito A, Murasugi S, Omori T, Nakamura S, Tokushige K. Relationship between mucosal healing by tacrolimus and relapse of refractory ulcerative colitis: a retrospective study. BMC Gastroenterol 2020;20:203. [PMID: 32590945 DOI: 10.1186/s12876-020-01317-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 453 |
Chen YH, Wang L, Feng SY, Cai WM, Chen XF, Huang ZM. The Relationship between C-Reactive Protein/Albumin Ratio and Disease Activity in Patients with Inflammatory Bowel Disease. Gastroenterol Res Pract 2020;2020:3467419. [PMID: 32655630 DOI: 10.1155/2020/3467419] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 454 |
D'Amico F, Baumann C, Rousseau H, Danese S, Peyrin-Biroulet L. Phase I, II and III Trials in Inflammatory Bowel Diseases: A Practical Guide for the Non-specialist. J Crohns Colitis 2020;14:710-8. [PMID: 31901097 DOI: 10.1093/ecco-jcc/jjz214] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 455 |
Kelsen JR, Dawany N, Conrad MA, Karakasheva TA, Maurer K, Wei JM, Uman S, Dent MH, Behera R, Bryant LM, Ma X, Moreira L, Chatterji P, Shraim R, Merz A, Mizuno R, Simon LA, Muir AB, Giraudo C, Behrens EM, Whelan KA, Devoto M, Russo PA, Andres SF, Sullivan KE, Hamilton KE. Colonoids From Patients With Pediatric Inflammatory Bowel Disease Exhibit Decreased Growth Associated With Inflammation Severity and Durable Upregulation of Antigen Presentation Genes. Inflamm Bowel Dis 2021;27:256-67. [PMID: 32556182 DOI: 10.1093/ibd/izaa145] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 456 |
Godskesen LE, Lassen TR, Jespersen NR, Siersbæk M, Yan Y, Nielsen MM, Tjønnfjord SK, Grøntved L, Madsen G, Kjems J, Bøtker HE, Schmidt MR, Krag A, Kjeldsen J. Remote ischemic conditioning in active ulcerative colitis: An explorative randomized clinical trial. Sci Rep 2020;10:9537. [PMID: 32533085 DOI: 10.1038/s41598-020-65692-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 457 |
Shindo Y, Mitsuyama K, Yamasaki H, Imai T, Yoshioka S, Kuwaki K, Yamauchi R, Yoshimura T, Araki T, Morita M, Tsuruta K, Yamasaki S, Fukami K, Torimura T. Safety and efficacy of single-needle leukocyte apheresis for treatment of ulcerative colitis. Ther Apher Dial 2020;24:503-10. [PMID: 32526089 DOI: 10.1111/1744-9987.13539] [Reference Citation Analysis]
|
| 458 |
Shimizu H, Fujii T, Hibiya S, Motobayashi M, Suzuki K, Takenaka K, Saito E, Nagahori M, Ohtsuka K, Watanabe M. Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis. Intest Res 2021;19:115-8. [PMID: 32516866 DOI: 10.5217/ir.2020.00030] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 459 |
Kierkus J, Pesegova M, Klopocka M, Brankovic M, Kasai N, Efuni S, Kong J, Nakajima Y, Jordan C, Matsui T, Feagan BG, Strout V. Randomized, Ascending Dose, Phase 2 Study of KHK4083, an Anti-OX40 Monoclonal Antibody, in Moderately Active Ulcerative Colitis. Crohns Colitis 360 2020;2:otaa049. [PMID: 36776497 DOI: 10.1093/crocol/otaa049] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 460 |
Langer V, Vivi E, Regensburger D, Winkler TH, Waldner MJ, Rath T, Schmid B, Skottke L, Lee S, Jeon NL, Wohlfahrt T, Kramer V, Tripal P, Schumann M, Kersting S, Handtrack C, Geppert CI, Suchowski K, Adams RH, Becker C, Ramming A, Naschberger E, Britzen-Laurent N, Stürzl M. IFN-γ drives inflammatory bowel disease pathogenesis through VE-cadherin-directed vascular barrier disruption. J Clin Invest 2019;129:4691-707. [PMID: 31566580 DOI: 10.1172/JCI124884] [Cited by in Crossref: 74] [Cited by in F6Publishing: 77] [Article Influence: 24.7] [Reference Citation Analysis]
|
| 461 |
Haga K, Shibuya T, Nomura K, Okahara K, Nomura O, Ishikawa D, Sakamoto N, Osada T, Nagahara A. Effectiveness and Nephrotoxicity of Long-Term Tacrolimus Administration in Patients with Ulcerative Colitis. J Clin Med 2020;9:E1771. [PMID: 32517388 DOI: 10.3390/jcm9061771] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 462 |
Małgorzata Krzystek-Korpacka, Radosław Kempiński, Mariusz Bromke, Katarzyna Neubauer. Biochemical Biomarkers of Mucosal Healing for Inflammatory Bowel Disease in Adults. Diagnostics (Basel) 2020;10:367. [PMID: 32498475 DOI: 10.3390/diagnostics10060367] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 9.7] [Reference Citation Analysis]
|
| 463 |
Wen Y, Niu J, Zhang F, Wu J, Li M, Sun Y, Wang W, Xia S, Tan Y, Wang K, Miao Y. Heat shock transcription factor 2 predicts mucosal healing and promotes mucosal repair of ulcerative colitis. Scand J Gastroenterol 2020;55:677-86. [PMID: 32538201 DOI: 10.1080/00365521.2020.1774924] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 464 |
Sagami S, Kobayashi T, Aihara K, Umeda M, Morikubo H, Matsubayashi M, Kiyohara H, Nakano M, Ohbu M, Hibi T. Transperineal ultrasound predicts endoscopic and histological healing in ulcerative colitis. Aliment Pharmacol Ther 2020;51:1373-83. [PMID: 32383166 DOI: 10.1111/apt.15767] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 465 |
Bossa F, Biscaglia G, Valvano MR, Costantino G, Lauria A, Clemente R, Ferracane C, Shahini E, Mendolaro M, Grossi L, Mazzuoli S, Rispo A, Pranzo G, Sebkova L, Tursi A, Miranda A, Patturelli M, Spagnuolo R, Ricciardelli C, Sgarro C, Paese P, Inserra G, Azzarone A, Nardone O, Fries W, Buccianti N, Privitera AC, Principi MB, Cappello M, Guglielmi FW, Romano M, Riegler G, Fanigliulo L, Melina R, Andriulli A. Real-Life Effectiveness and Safety of Golimumab and Its Predictors of Response in Patients with Ulcerative Colitis. Dig Dis Sci 2020;65:1767-76. [PMID: 31722059 DOI: 10.1007/s10620-019-05904-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 466 |
Moraes L, Magnusson MK, Mavroudis G, Polster A, Jonefjäll B, Törnblom H, Sundin J, Simrén M, Strid H, Öhman L. Systemic Inflammatory Protein Profiles Distinguish Irritable Bowel Syndrome (IBS) and Ulcerative Colitis, Irrespective of Inflammation or IBS-Like Symptoms. Inflamm Bowel Dis 2020;26:874-84. [PMID: 31901089 DOI: 10.1093/ibd/izz322] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 467 |
Takenaka K, Ohtsuka K, Fujii T, Negi M, Suzuki K, Shimizu H, Oshima S, Akiyama S, Motobayashi M, Nagahori M, Saito E, Matsuoka K, Watanabe M. Development and Validation of a Deep Neural Network for Accurate Evaluation of Endoscopic Images From Patients With Ulcerative Colitis. Gastroenterology 2020;158:2150-2157. [DOI: 10.1053/j.gastro.2020.02.012] [Cited by in Crossref: 117] [Cited by in F6Publishing: 111] [Article Influence: 39.0] [Reference Citation Analysis]
|
| 468 |
Dulai PS, Jairath V, Khanna R, Ma C, McCarrier KP, Martin ML, Parker CE, Morris J, Feagan BG, Sandborn WJ. Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther 2020;51:1047-66. [PMID: 32319120 DOI: 10.1111/apt.15726] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 469 |
Curciarello R, Sobande T, Jones S, Giuffrida P, Di Sabatino A, Docena GH, MacDonald TT, Kok K. Human Neutrophil Elastase Proteolytic Activity in Ulcerative Colitis Favors the Loss of Function of Therapeutic Monoclonal Antibodies. J Inflamm Res 2020;13:233-43. [PMID: 32547155 DOI: 10.2147/JIR.S234710] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 470 |
Shen Y, Shi L, Zhang J, Zhu H, Yao Y, Liu Z, Zou X, Zhang X. Thromboelastography in Patients with Inflammatory Bowel Disease. Gastroenterol Res Pract 2020;2020:3245657. [PMID: 32565780 DOI: 10.1155/2020/3245657] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 471 |
Mooradian MJ, Wang DY, Coromilas A, Lumish M, Chen T, Giobbie-Hurder A, Johnson DB, Sullivan RJ, Dougan M. Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis. J Immunother Cancer 2020;8. [PMID: 32414860 DOI: 10.1136/jitc-2019-000451] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 472 |
Jeong Y, Jeon SR, Kim HG, Moon JR, Lee TH, Jang JY, Cho JH, Park JS, Park H, Lee KH, Kim JO, Lee JS, Ko BM, Park S. The role of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio in ulcerative colitis. Intest Res 2021;19:62-70. [PMID: 32375208 DOI: 10.5217/ir.2019.09156] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 473 |
Li N, Mao J, Tang H, Zhu L, Tan X, Bi J, Wu H, Chen X, Wang Y. Efficacy and safety of adsorptive granulomonocytapheresis in Chinese patients with ulcerative colitis: A retrospective analysis of 50 cases with focus on factors impacting clinical efficacy. J Clin Apher 2020;35:271-80. [PMID: 32378240 DOI: 10.1002/jca.21787] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 474 |
Lahat A, Fidder HH, Ben-Horin S. Development and validation of a diverticular clinical score for symptomatic uncomplicated diverticular disease after acute diverticulitis in a prospective patient cohort. Therap Adv Gastroenterol 2020;13:1756284820913210. [PMID: 32523619 DOI: 10.1177/1756284820913210] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 475 |
Troncone E, Marafini I, Del Vecchio Blanco G, Di Grazia A, Monteleone G. Novel Therapeutic Options for People with Ulcerative Colitis: An Update on Recent Developments with Janus Kinase (JAK) Inhibitors. Clin Exp Gastroenterol 2020;13:131-9. [PMID: 32440190 DOI: 10.2147/CEG.S208020] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 476 |
Chandrakumar A, Wang A, Grover K, El-Matary W. Obesity Is More Common in Children Newly Diagnosed With Ulcerative Colitis as Compared to Those With Crohn Disease. J Pediatr Gastroenterol Nutr 2020;70:593-7. [PMID: 31977953 DOI: 10.1097/MPG.0000000000002639] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 477 |
Rodríguez-Lago I, Castro-Poceiro J, Fernández-Clotet A, Mesonero F, López-Sanromán A, López-García A, Márquez L, Clos-Parals A, Cañete F, Vicuña M, Nantes Ó, Merino O, Matallana V, Gordillo J, Elorza A, Vicente R, Casanova MJ, Ferreiro-Iglesias R, Pérez-Galindo P, Benítez JM, Taxonera C, García MJ, Martín E, Aguirre U, Gisbert JP; Young GETECCU Group. Tacrolimus induces short-term but not long-term clinical response in inflammatory bowel disease. Aliment Pharmacol Ther 2020;51:870-9. [PMID: 32181930 DOI: 10.1111/apt.15687] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 478 |
Smith SCL, Cannatelli R, Bazarova A, Sharma N, McCulloch A, Mak J, Shivaji UN, Iqbal T, Kane K, Ghosh S, Cooney R, Iacucci M. Performance measures in inflammatory bowel disease surveillance colonoscopy: Implementing changes to practice improves performance. Dig Endosc 2020;32:592-9. [PMID: 31479541 DOI: 10.1111/den.13521] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 479 |
Schmitt H, Ulmschneider J, Billmeier U, Vieth M, Scarozza P, Sonnewald S, Reid S, Atreya I, Rath T, Zundler S, Langheinrich M, Schüttler J, Hartmann A, Winkler T, Admyre C, Knittel T, Dieterich Johansson C, Zargari A, Neurath MF, Atreya R. The TLR9 Agonist Cobitolimod Induces IL10-Producing Wound Healing Macrophages and Regulatory T Cells in Ulcerative Colitis. J Crohns Colitis 2020;14:508-24. [PMID: 31630153 DOI: 10.1093/ecco-jcc/jjz170] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 9.7] [Reference Citation Analysis]
|
| 480 |
Yeshi K, Ruscher R, Hunter L, Daly NL, Loukas A, Wangchuk P. Revisiting Inflammatory Bowel Disease: Pathology, Treatments, Challenges and Emerging Therapeutics Including Drug Leads from Natural Products. J Clin Med 2020;9:E1273. [PMID: 32354192 DOI: 10.3390/jcm9051273] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 15.3] [Reference Citation Analysis]
|
| 481 |
Yarlas A, Maher S, Bayliss M, Lovley A, Cappelleri JC, Bushmakin AG, DiBonaventura MD. The Inflammatory Bowel Disease Questionnaire in Randomized Controlled Trials of Treatment for Ulcerative Colitis: Systematic Review and Meta-Analysis. J Patient Cent Res Rev 2020;7:189-205. [PMID: 32377552 DOI: 10.17294/2330-0698.1722] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 482 |
Zezos P, Kabakchiev B, Weizman AV, Nguyen GC, Narula N, Croitoru K, Steinhart AH, Silverberg MS. Ulcerative Colitis Patients Continue to Improve Over the First Six Months of Vedolizumab Treatment: 12-Month Clinical and Mucosal Healing Effectiveness. J Can Assoc Gastroenterol 2020;3:74-82. [PMID: 32328546 DOI: 10.1093/jcag/gwy065] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 483 |
Naguib R, El-Shikh WM. Clinical Significance of Hepatocyte Growth Factor and Transforming Growth Factor-Beta-1 Levels in Assessing Disease Activity in Inflammatory Bowel Disease. Can J Gastroenterol Hepatol 2020;2020:2104314. [PMID: 32377513 DOI: 10.1155/2020/2104314] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 484 |
Biondi RB, Salmazo PS, Bazan SGZ, Hueb JC, de Paiva SAR, Sassaki LY. Cardiovascular Risk in Individuals with Inflammatory Bowel Disease. Clin Exp Gastroenterol 2020;13:107-13. [PMID: 32425576 DOI: 10.2147/CEG.S243478] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 485 |
Yamamoto-Furusho JK, Mendieta-Escalante EA. Diagnostic utility of the neutrophil-platelet ratio as a novel marker of activity in patients with Ulcerative Colitis. PLoS One 2020;15:e0231988. [PMID: 32315368 DOI: 10.1371/journal.pone.0231988] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 486 |
Ishida N, Miyazu T, Takano R, Tamura S, Tani S, Kagami T, Yamade M, Hamaya Y, Iwaizumi M, Osawa S, Furuta T, Miyajima H, Sugimoto K. Prostaglandin E-major urinary metabolite versus fecal immunochemical occult blood test as a biomarker for patient with ulcerative colitis. BMC Gastroenterol 2020;20:114. [PMID: 32306914 DOI: 10.1186/s12876-020-01256-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 487 |
Principi M, Contaldo A, Bianchi FP, Losurdo G, Iannone A, Ierardi E, Tafuri S, Di Leo A, IBD Endoscopy Team Work IBD Endoscopy Team Work. Inter-Observer Agreement of a New Endoscopic Score for Ulcerative Colitis Activity: Preliminary Experience. Diagnostics 2020;10:213. [DOI: 10.3390/diagnostics10040213] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 488 |
Dulic S, Toldi G, Sava F, Kovács L, Molnár T, Milassin Á, Farkas K, Rutka M, Balog A. Specific T-Cell Subsets Can Predict the Efficacy of Anti-TNF Treatment in Inflammatory Bowel Diseases. Arch Immunol Ther Exp (Warsz) 2020;68:12. [PMID: 32248339 DOI: 10.1007/s00005-020-00575-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 489 |
Limdi JK, Picco M, Farraye FA. A review of endoscopic scoring systems and their importance in a treat-to-target approach in inflammatory bowel disease (with videos). Gastrointest Endosc 2020;91:733-45. [PMID: 31786161 DOI: 10.1016/j.gie.2019.11.032] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 490 |
Takatsu N, Hisabe T, Higashi D, Ueki T, Matsui T. Vedolizumab in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Safety, Efficacy, and Place of Therapy. Core Evid 2020;15:7-20. [PMID: 32280316 DOI: 10.2147/CE.S179053] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 491 |
Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S; AGA Institute Clinical Guidelines Committee. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology 2020;158:1450-61. [PMID: 31945371 DOI: 10.1053/j.gastro.2020.01.006] [Cited by in Crossref: 216] [Cited by in F6Publishing: 218] [Article Influence: 72.0] [Reference Citation Analysis]
|
| 492 |
Singh S, Allegretti JR, Siddique SM, Terdiman JP. AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology 2020;158:1465-1496.e17. [PMID: 31945351 DOI: 10.1053/j.gastro.2020.01.007] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 17.7] [Reference Citation Analysis]
|
| 493 |
Naganuma M, Yokoyama Y, Motoya S, Watanabe K, Sawada K, Hirai F, Yamamoto T, Hanai H, Omori T, Kanai T, Hibi T; CAPTAIN study Group. Efficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open-label prospective multicenter randomised controlled trial. J Gastroenterol 2020;55:390-400. [PMID: 31811562 DOI: 10.1007/s00535-019-01651-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 494 |
Bezzio C, Saibeni S, Variola A, Allocca M, Massari A, Gerardi V, Casini V, Ricci C, Zingone F, Amato A, Caprioli F, Lenti MV, Viganò C, Ascolani M, Bossa F, Castiglione F, Cortelezzi C, Grossi L, Milla M, Morganti D, Pastorelli L, Ribaldone DG, Sartini A, Soriano A, Manes G, Danese S, Fantini MC, Armuzzi A, Daperno M, Fiorino G; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut 2020;69:1213-7. [PMID: 32354990 DOI: 10.1136/gutjnl-2020-321411] [Cited by in Crossref: 236] [Cited by in F6Publishing: 252] [Article Influence: 78.7] [Reference Citation Analysis]
|
| 495 |
Tian C, Huang Y, Wu X, Xu C, Bu H, Wang H. The Efficacy and Safety of Mesalamine and Probiotics in Mild-to-Moderate Ulcerative Colitis: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med 2020;2020:6923609. [PMID: 32308714 DOI: 10.1155/2020/6923609] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 496 |
Kanmura S, Tanaka A, Yutsudou K, Kuwazuru K, Komaki F, Komaki Y, Iwaya H, Arima S, Sasaki F, Tanoue S, Hashimoto S, Ido A. Significance of Linked Color Imaging for Predicting the Risk of Clinical Relapse in Ulcerative Colitis. Gastroenterol Res Pract 2020;2020:3108690. [PMID: 32211040 DOI: 10.1155/2020/3108690] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 497 |
van Andel EM, Koopmann BDM, Crouwel F, Noomen CG, de Boer NKH, van Asseldonk DP, Mokkink LB. Systematic Review of Development and Content Validity of Patient-reported Outcome Measures in Inflammatory Bowel Disease: Do We Measure What We Measure? J Crohns Colitis 2020;14:1299-315. [PMID: 32211749 DOI: 10.1093/ecco-jcc/jjaa057] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 498 |
Dang X, Xu M, Liu D, Zhou D, Yang W. Assessing the efficacy and safety of fecal microbiota transplantation and probiotic VSL#3 for active ulcerative colitis: A systematic review and meta-analysis. PLoS One. 2020;15:e0228846. [PMID: 32182248 DOI: 10.1371/journal.pone.0228846] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
|
| 499 |
Coenen S, Nijns E, Weyts E, Geens P, Van den Bosch B, Vermeire S, Ferrante M, Vanhaecht K, Van Assche G. Development and feasibility of a telemonitoring tool with full integration in the electronic medical record: a proof of concept study for patients with inflammatory bowel disease in remission on biological therapy. Scand J Gastroenterol 2020;55:287-93. [PMID: 32180470 DOI: 10.1080/00365521.2020.1735506] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 500 |
Battat R, Dulai PS, Ma C, Jairath V, Feagan BG, Sandborn WJ, Khanna R. Current Endpoints of Clinical Trials in Ulcerative Colitis: Are They Valid? Curr Treat Options Gastro 2020;18:15-32. [DOI: 10.1007/s11938-019-00259-w] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 501 |
Lair-Mehiri L, Stefanescu C, Vaysse T, Laharie D, Roblin X, Rosa I, Treton X, Abitbol V, Amiot A, Bouguen G, Dib N, Fumery M, Pariente B, Carbonnel F, Peyrin-Biroulet L, Simon M, Viennot S, Bouhnik Y. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis. Dig Liver Dis 2020;52:268-73. [PMID: 31732444 DOI: 10.1016/j.dld.2019.10.003] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 11.3] [Reference Citation Analysis]
|
| 502 |
Nielsen OH, Steenholdt C, Juhl CB, Rogler G. Efficacy and safety of methotrexate in the management of inflammatory bowel disease: A systematic review and meta-analysis of randomized, controlled trials. EClinicalMedicine 2020;20:100271. [PMID: 32300735 DOI: 10.1016/j.eclinm.2020.100271] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 503 |
Abu-Sbeih H, Faleck DM, Ricciuti B, Mendelsohn RB, Naqash AR, Cohen JV, Sellers MC, Balaji A, Ben-Betzalel G, Hajir I, Zhang J, Awad MM, Leonardi GC, Johnson DB, Pinato DJ, Owen DH, Weiss SA, Lamberti G, Lythgoe MP, Manuzzi L, Arnold C, Qiao W, Naidoo J, Markel G, Powell N, Yeung SJ, Sharon E, Dougan M, Wang Y. Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. J Clin Oncol 2020;38:576-83. [PMID: 31800340 DOI: 10.1200/JCO.19.01674] [Cited by in Crossref: 89] [Cited by in F6Publishing: 93] [Article Influence: 29.7] [Reference Citation Analysis]
|
| 504 |
Bertolini E, Macchioni P, Rizzello F, Salice M, Vukatana G, Sandri G, Bertani A, Ciancio G, Govoni M, Zelante A, Malavolta N, Beltrami M, Salvarani C. Ultrasonographic and clinical assessment of peripheral enthesitis and arthritis in an Italian cohort of inflammatory bowel disease patients. Semin Arthritis Rheum 2020;50:436-43. [PMID: 32061429 DOI: 10.1016/j.semarthrit.2020.01.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 505 |
Long Y, Xia C, Xu L, Liu C, Fan C, Bao H, Zhao X, Liu C. The Imbalance of Circulating Follicular Helper T Cells and Follicular Regulatory T Cells Is Associated With Disease Activity in Patients With Ulcerative Colitis. Front Immunol 2020;11:104. [PMID: 32117258 DOI: 10.3389/fimmu.2020.00104] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 506 |
Chen HT, Huang HL, Xu HM, Luo QL, He J, Li YQ, Zhou YL, Nie YQ, Zhou YJ. Fecal microbiota transplantation ameliorates active ulcerative colitis. ExpTher Med. 2020;19:2650-2660. [PMID: 32256746 DOI: 10.3892/etm.2020.8512] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 507 |
Cordes F, Lenker E, Spille LJ, Weinhage T, Bettenworth D, Kessel C, Schmidt HH, Foell D, Varga G. Tofacitinib Reprograms Human Monocytes of IBD Patients and Healthy Controls Toward a More Regulatory Phenotype. Inflamm Bowel Dis 2020;26:391-406. [PMID: 31560043 DOI: 10.1093/ibd/izz213] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 508 |
deZoeten EF, Battista KD, Colson SB, Lovell MA, Kessler BE, Isfort RW, Fennimore BP, Onyiah JC, Kao DJ, Yeckes A, Keely S, Murray M, Hoffenberg EJ, Colgan SP, Gerich ME. Markers of Hypoxia Correlate with Histologic and Endoscopic Severity of Colitis in Inflammatory Bowel Disease. Hypoxia (Auckl) 2020;8:1-12. [PMID: 32104717 DOI: 10.2147/HP.S219049] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 509 |
Sugiyama T, Sasaki M, Nakagawa S, Inoue S, Adachi K, Yoshimine T, Yamaguchi Y, Tamura Y, Izawa S, Hijikata Y, Ebi M, Mizuno M, Yamamoto S, Funaki Y, Ogasawara N, Goto C, Kasugai K. The association among enterobacterial flora, dietary factors, and prognosis in patients with ulcerative colitis. J Clin Biochem Nutr 2020;66:152-7. [PMID: 32231412 DOI: 10.3164/jcbn.19-90] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 510 |
Tanida S, Ozeki K, Mizoshita T, Kitagawa M, Ozeki T, Tanaka M, Nishie H, Shimura T, Kubota E, Kataoka H. Combination Therapy With Tofacitinib Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis as Induction Therapy for Refractory Ulcerative Colitis. J Clin Med Res 2020;12:36-40. [PMID: 32010420 DOI: 10.14740/jocmr4037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 511 |
Hibi T, Ishibashi T, Ikenoue Y, Yoshihara R, Nihei A, Kobayashi T. Ulcerative Colitis: Disease Burden, Impact on Daily Life, and Reluctance to Consult Medical Professionals: Results from a Japanese Internet Survey. Inflamm Intest Dis 2020;5:27-35. [PMID: 32232052 DOI: 10.1159/000505092] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 512 |
Marinelli C, Zingone F, Inferrera M, Lorenzon G, Rigo A, Facchin S, Caccaro R, D'Incà R, Savarino EV. Factors associated with disability in patients with ulcerative colitis: A cross-sectional study. J Dig Dis 2020;21:81-7. [PMID: 31859432 DOI: 10.1111/1751-2980.12837] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 513 |
Sandborn WJ, Peyrin-Biroulet L, Zhang J, Chiorean M, Vermeire S, Lee SD, Kühbacher T, Yacyshyn B, Cabell CH, Naik SU, Klassen P, Panés J. Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology 2020;158:550-61. [PMID: 31711921 DOI: 10.1053/j.gastro.2019.10.035] [Cited by in Crossref: 91] [Cited by in F6Publishing: 91] [Article Influence: 30.3] [Reference Citation Analysis]
|
| 514 |
Arkteg CB, Goll R, Gundersen MD, Anderssen E, Fenton C, Florholmen J. Mucosal gene transcription of ulcerative colitis in endoscopic remission. Scand J Gastroenterol 2020;55:139-47. [PMID: 31918598 DOI: 10.1080/00365521.2019.1710245] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 515 |
Sandborn WJ, Baert F, Danese S, Krznarić Ž, Kobayashi T, Yao X, Chen J, Rosario M, Bhatia S, Kisfalvi K, D'Haens G, Vermeire S. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology 2020;158:562-572.e12. [PMID: 31470005 DOI: 10.1053/j.gastro.2019.08.027] [Cited by in Crossref: 105] [Cited by in F6Publishing: 105] [Article Influence: 35.0] [Reference Citation Analysis]
|
| 516 |
Naganuma M, Sugimoto S, Fukuda T, Mitsuyama K, Kobayashi T, Yoshimura N, Ohi H, Tanaka S, Andoh A, Ohmiya N, Saigusa K, Yamamoto T, Morohoshi Y, Ichikawa H, Matsuoka K, Hisamatsu T, Watanabe K, Mizuno S, Abe T, Suzuki Y, Kanai T; INDIGO Study Group. Indigo naturalis is effective even in treatment-refractory patients with ulcerative colitis: a post hoc analysis from the INDIGO study. J Gastroenterol 2020;55:169-80. [PMID: 31529220 DOI: 10.1007/s00535-019-01625-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 517 |
Singh S, Proudfoot JA, Dulai PS, Xu R, Feagan BG, Sandborn WJ, Jairath V. Comparative Efficacy and Speed of Onset of Action of Infliximab vs Golimumab in Ulcerative Colitis. Clin Gastroenterol Hepatol 2020;18:424-431.e7. [PMID: 31108227 DOI: 10.1016/j.cgh.2019.05.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 518 |
Cornish JS, Wirthgen E, Däbritz J. Biomarkers Predictive of Response to Thiopurine Therapy in Inflammatory Bowel Disease.Front Med (Lausanne). 2020;7:8. [PMID: 32064265 DOI: 10.3389/fmed.2020.00008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 519 |
Szemes K, Soós A, Hegyi P, Farkas N, Erős A, Erőss B, Mezősi E, Szakács Z, Márta K, Sarlós P. Comparable Long-Term Outcomes of Cyclosporine and Infliximab in Patients With Steroid-Refractory Acute Severe Ulcerative Colitis: A Meta-Analysis. Front Med (Lausanne) 2019;6:338. [PMID: 32039218 DOI: 10.3389/fmed.2019.00338] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 520 |
Choi JH, Kim JH, Lee DH, Byun S, Jung K, Kim SE, Moon W, Park MI, Park SJ. The clinical significance of simple endoscopic scoring of patients with rectal cancer after concurrent chemoradiotherapy. J Gastrointest Oncol 2019;10:1073-9. [PMID: 31949924 DOI: 10.21037/jgo.2019.08.05] [Reference Citation Analysis]
|
| 521 |
Camarillo GF, Goyon EI, Zuñiga RB, Salas LAS, Escárcega AEP, Yamamoto-Furusho JK. Gene Expression Profiling of Mediators Associated with the Inflammatory Pathways in the Intestinal Tissue from Patients with Ulcerative Colitis. Mediators Inflamm 2020;2020:9238970. [PMID: 32410873 DOI: 10.1155/2020/9238970] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 522 |
Marinelli C, Savarino EV, Marsilio I, Lorenzon G, Gavaruzzi T, D'Incà R, Zingone F. Sleep disturbance in Inflammatory Bowel Disease: prevalence and risk factors - A cross-sectional study. Sci Rep 2020;10:507. [PMID: 31949257 DOI: 10.1038/s41598-020-57460-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 523 |
Han Y, Zhao J, Huang H, Liu F, Sun X, Sun L, Lu Y, Chen L, Liu X. Characteristics of Hemorheology in Patients with Acute Severe Ulcerative Colitis and the Clinical Study of Rivaroxaban Anticoagulant Therapy. Hepat Mon 2020;19. [DOI: 10.5812/hepatmon.92536] [Reference Citation Analysis]
|
| 524 |
Takahashi N, Kitazawa C, Itani Y, Awaga Y, Hama A, Hayashi I, Takamatsu H. Exploratory clinical characterization of experimentally-induced ulcerative colitis nonhuman primates. Heliyon 2020;6:e03178. [PMID: 31938753 DOI: 10.1016/j.heliyon.2020.e03178] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 525 |
Lee SD, Clark-snustad KD. Colitis, Ulcerative. Encyclopedia of Gastroenterology 2020. [DOI: 10.1016/b978-0-12-801238-3.65948-2] [Reference Citation Analysis]
|
| 526 |
Torres J, Hu J, Seki A, Eisele C, Nair N, Huang R, Tarassishin L, Jharap B, Cote-Daigneault J, Mao Q, Mogno I, Britton GJ, Uzzan M, Chen CL, Kornbluth A, George J, Legnani P, Maser E, Loudon H, Stone J, Dubinsky M, Faith JJ, Clemente JC, Mehandru S, Colombel JF, Peter I. Infants born to mothers with IBD present with altered gut microbiome that transfers abnormalities of the adaptive immune system to germ-free mice. Gut 2020;69:42-51. [PMID: 31036757 DOI: 10.1136/gutjnl-2018-317855] [Cited by in Crossref: 89] [Cited by in F6Publishing: 88] [Article Influence: 29.7] [Reference Citation Analysis]
|
| 527 |
Ma C, Liu X. Histologic evaluation of disease activity in inflammatory bowel disease. Atlas of Endoscopy Imaging in Inflammatory Bowel Disease 2020. [DOI: 10.1016/b978-0-12-814811-2.00015-3] [Reference Citation Analysis]
|
| 528 |
Rogler G, Biedermann L. Klassifikationen, Indizes, Aktivitätsbeurteilung. Chronisch-entzündliche Darmerkrankungen 2020. [DOI: 10.1007/978-3-662-59104-8_8] [Reference Citation Analysis]
|
| 529 |
Kimura N, Hiraki M, Miyoshi A, Tominaga N, Akutagawa K, Tanaka T, Kitahara K. A Case of Cytomegalovirus Enteritis following Ulcerative Colitis with Spontaneous Pneumoperitoneum. Nihon Rinsho Geka Gakkai Zasshi (J Jpn Surg Assoc) 2020;81:513-518. [DOI: 10.3919/jjsa.81.513] [Reference Citation Analysis]
|
| 530 |
Zhang JJ, Lou DN, Ma H, Yu CH, Chen LH, Li YM. Development of a validated Chinese version of the inflammatory bowel disease disability index. J Dig Dis 2020;21:52-8. [PMID: 31837189 DOI: 10.1111/1751-2980.12836] [Reference Citation Analysis]
|
| 531 |
Honzawa Y, Matsuura M, Higuchi H, Sakurai T, Seno H, Nakase H. A novel endoscopic imaging system for quantitative evaluation of colonic mucosal inflammation in patients with quiescent ulcerative colitis. Endosc Int Open 2020;8:E41-9. [PMID: 31921983 DOI: 10.1055/a-0990-9375] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 532 |
Iwamoto M, Kato K, Moriyama M, Yamaguchi K, Takahashi S. Remission of ulcerative colitis flare-up induced by nivolumab. Int J Colorectal Dis 2020;35:1791-5. [PMID: 32458394 DOI: 10.1007/s00384-020-03638-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 533 |
Molander P, Kemppainen H, Ilus T, Sipponen T. Long-term deep remission during maintenance therapy with biological agents in inflammatory bowel diseases. Scand J Gastroenterol 2020;55:34-40. [PMID: 31841064 DOI: 10.1080/00365521.2019.1701070] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 534 |
Ferrer-Picón E, Dotti I, Corraliza AM, Mayorgas A, Esteller M, Perales JC, Ricart E, Masamunt MC, Carrasco A, Tristán E, Esteve M, Salas A. Intestinal Inflammation Modulates the Epithelial Response to Butyrate in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis 2020;26:43-55. [PMID: 31211831 DOI: 10.1093/ibd/izz119] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 19.0] [Reference Citation Analysis]
|
| 535 |
Lynch KD, Chapman RW, Keshav S, Montano-Loza AJ, Mason AL, Kremer AE, Vetter M, de Krijger M, Ponsioen CY, Trivedi P, Hirschfield G, Schramm C, Liu CH, Bowlus CL, Estes DJ, Pratt D, Hedin C, Bergquist A, de Vries AC, van der Woude CJ, Yu L, Assis DN, Boyer J, Ytting H, Hallibasic E, Trauner M, Marschall HU, Daretti LM, Marzioni M, Yimam KK, Perin N, Floreani A, Beretta-Piccoli BT, Rogers JK, Levy C; International Primary Sclerosing Cholangitis Study Group (IPSCSG). Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2020;18:179-187.e6. [PMID: 31100458 DOI: 10.1016/j.cgh.2019.05.013] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 11.7] [Reference Citation Analysis]
|
| 536 |
Melendez-rosado J, Shen B. Endoscopic scores in inflammatory bowel disease. Atlas of Endoscopy Imaging in Inflammatory Bowel Disease 2020. [DOI: 10.1016/b978-0-12-814811-2.00014-1] [Reference Citation Analysis]
|
| 537 |
Kim S, Park S, Kang Y, Koh H. Combining faecal calprotectin and sigmoidoscopy can predict mucosal healing in paediatric ulcerative colitis. Eur J Gastroenterol Hepatol 2020;32:17-21. [PMID: 31651657 DOI: 10.1097/MEG.0000000000001550] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 538 |
Nyman M, Nguyen TD, Wikman O, Hjortswang H, Hallert C. Oat Bran Increased Fecal Butyrate and Prevented Gastrointestinal Symptoms in Patients With Quiescent Ulcerative Colitis-Randomized Controlled Trial. Crohns Colitis 360 2020;2:otaa005. [PMID: 36777965 DOI: 10.1093/crocol/otaa005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 539 |
Kayal M, Shah S. Ulcerative Colitis: Current and Emerging Treatment Strategies. J Clin Med 2019;9:E94. [PMID: 31905945 DOI: 10.3390/jcm9010094] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 540 |
Kevans D, Kirsch R, Dargavel C, Kabakchiev B, Riddell R, Silverberg MS. Histological Markers of Clinical Relapse in Endoscopically Quiescent Ulcerative Colitis. Inflamm Bowel Dis 2020;26:1722-9. [PMID: 31883337 DOI: 10.1093/ibd/izz308] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 541 |
Xu M, Cen M, Chen X, Chen H, Liu X, Cao Q. Correlation between Serological Biomarkers and Disease Activity in Patients with Inflammatory Bowel Disease. Biomed Res Int 2019;2019:6517549. [PMID: 31950048 DOI: 10.1155/2019/6517549] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 542 |
Shibuya T, Nomura K, Okahara K, Haga K, Nomura O, Murakami T, Uchida S, Kodani T, Ishikawa D, Sakamoto N, Ogihara T, Osada T, Nagahara A. Budesonide Foam for Ulcerative Colitis Patients Experiencing Inadequate Response to Biological Therapy. Med Sci Monit 2019;25:9855-63. [PMID: 31865359 DOI: 10.12659/MSM.918562] [Reference Citation Analysis]
|
| 543 |
Ochsenkühn T, Tillack C, Szokodi D, Janelidze S, Schnitzler F. Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis. United European Gastroenterol J 2020;8:91-8. [PMID: 32213052 DOI: 10.1177/2050640619895361] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 544 |
Ivashkin VT, Shelygin YA, Belousova EA, Abdulganieva DI, Alekseeva OA, Achkasov SI, Valuiskikh EY, Vardanyan AV, Veselov AV, Veselov VV, Golovenko OV, Gubonina IV, Zhigalova TN, Kashnikov VN, Knyazev OV, Makarchuk PA, Moskaliev AI, Nanaeva BA, Nizov AA, Nikitina NV, Nikolaeva NN, Pavlenko VV, Poluektova EA, Svetlova IO, Tarasova LV, Tkachev AV, Frolov SA, Khlynova OV, Chashkova EY, Shapina MV, Sheptulin AA, Shifrin OS, Shchukina OB. PROJECT: CLINICAL GUIDELINES FOR THE DIAGNOSTICS AND TREATMENT OF ULCERATIVE COLITIS. Koloproktologiâ 2019;18:7-36. [DOI: 10.33878/2073-7556-2019-18-4-7-36] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 545 |
Shah J, Dutta U, Rudramurthy S, Chakrabarti A, Sinha SK, Sharma V, Mandavdhare H, Sharma P, Kalsi D, Popli P, Radhika S, Das A, Kochhar R. Colonic mucosa-associated candida assessed by biopsy culture is associated with disease severity in ulcerative colitis: A prospective study. J Dig Dis 2019;20:642-8. [PMID: 31626384 DOI: 10.1111/1751-2980.12825] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 546 |
Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H, Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB; IBD guidelines eDelphi consensus group. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019;68:s1-s106. [PMID: 31562236 DOI: 10.1136/gutjnl-2019-318484] [Cited by in Crossref: 885] [Cited by in F6Publishing: 863] [Article Influence: 221.3] [Reference Citation Analysis]
|
| 547 |
Ito A, Omori T, Nakamura S, Tokushige K. Retrospective investigation of tacrolimus combined with an anti‐tumor necrosis factorα antibody as remission induction therapy for refractory ulcerative colitis: Efficacy, safety, and relapse rate. JGH Open 2019;3:525-531. [DOI: 10.1002/jgh3.12197] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 548 |
van der Post S, Jabbar KS, Birchenough G, Arike L, Akhtar N, Sjovall H, Johansson MEV, Hansson GC. Structural weakening of the colonic mucus barrier is an early event in ulcerative colitis pathogenesis. Gut 2019;68:2142-51. [PMID: 30914450 DOI: 10.1136/gutjnl-2018-317571] [Cited by in Crossref: 177] [Cited by in F6Publishing: 180] [Article Influence: 44.3] [Reference Citation Analysis]
|
| 549 |
Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H, Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB; IBD guidelines eDelphi consensus group. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019;68:s1-s106. [PMID: 31562236 DOI: 10.1136/gutjnl-2019-318484] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 550 |
Chandan S, Mohan BP, Chandan OC, Ahmad R, Challa A, Tummala H, Singh S, Dhawan P, Ponnada S, Singh AB, Adler DG. Curcumin use in ulcerative colitis: is it ready for prime time? A systematic review and meta-analysis of clinical trials. Ann Gastroenterol 2020;33:53-8. [PMID: 31892798 DOI: 10.20524/aog.2019.0439] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 551 |
Takenaka K, Tominaga K, Kanazawa M, Fukushi K, Tanaka T, Kanamori A, Sugaya T, Tsuchida K, Iijima M, Goda K, Irisawa A. Endoscopic score vs blood cell indices for determining timing of immunomodulator withdrawal in quiescent ulcerative colitis. Sci Rep 2019;9:17751. [PMID: 31780764 DOI: 10.1038/s41598-019-54369-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 552 |
Klingberg E, Magnusson MK, Strid H, Deminger A, Ståhl A, Sundin J, Simrén M, Carlsten H, Öhman L, Forsblad-d'Elia H. A distinct gut microbiota composition in patients with ankylosing spondylitis is associated with increased levels of fecal calprotectin. Arthritis Res Ther 2019;21:248. [PMID: 31771630 DOI: 10.1186/s13075-019-2018-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 37] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 553 |
Sayar S, Kurbuz K, Kahraman R, Caliskan Z, Atalay R, Ozturk O, Doganay HL, Ozdil K. A practical marker to determining acute severe ulcerative colitis: CRP/albumin ratio. North Clin Istanb. 2020;7:49-55. [PMID: 32232203 DOI: 10.14744/nci.2018.78800] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 554 |
Ishikawa K, Takesue Y, Ichiki K, Tsuchida T, Nakajima K, Ueda T, Yamada K, Takahashi Y. Risk Factors for Central Line Associated Bloodstream Infection in Patients with Inflammatory Bowel Disease. Nihon Kankyou Kansen Gakkaishi 2019;34:296-301. [DOI: 10.4058/jsei.34.296] [Reference Citation Analysis]
|
| 555 |
Motoya S, Tanaka H, Shibuya T, Osada T, Yamamoto T, Hongo H, Mizuno C, Saito D, Aoyama N, Kobayashi T, Ito H, Tanida S, Nojima M, Kokuma S, Hosoi E. Safety and effectiveness of granulocyte and monocyte adsorptive apheresis in patients with inflammatory bowel disease in special situations: a multicentre cohort study. BMC Gastroenterol. 2019;19:196. [PMID: 31752695 DOI: 10.1186/s12876-019-1110-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 556 |
Stapersma L, van den Brink G, van der Ende J, Szigethy EM, Beukers R, Korpershoek TA, Theuns-Valks SDM, Hillegers MHJ, Escher JC, Utens EMWJ. Effectiveness of Disease-Specific Cognitive Behavioral Therapy on Anxiety, Depression, and Quality of Life in Youth With Inflammatory Bowel Disease: A Randomized Controlled Trial. J Pediatr Psychol 2018;43:967-80. [PMID: 29850915 DOI: 10.1093/jpepsy/jsy029] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 557 |
Hughes MS, Molina GE, Chen ST, Zheng H, Deshpande V, Fadden R, Sullivan RJ, Dougan M. Budesonide treatment for microscopic colitis from immune checkpoint inhibitors. J Immunother Cancer 2019;7:292. [PMID: 31699151 DOI: 10.1186/s40425-019-0756-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 8.8] [Reference Citation Analysis]
|
| 558 |
Bourgonje AR, von Martels JZH, Gabriëls RY, Blokzijl T, Buist-Homan M, Heegsma J, Jansen BH, van Dullemen HM, Festen EAM, Ter Steege RWF, Visschedijk MC, Weersma RK, de Vos P, Faber KN, Dijkstra G. A Combined Set of Four Serum Inflammatory Biomarkers Reliably Predicts Endoscopic Disease Activity in Inflammatory Bowel Disease. Front Med (Lausanne) 2019;6:251. [PMID: 31772929 DOI: 10.3389/fmed.2019.00251] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 559 |
Rodríguez-lago I, Merino O, López de Goicoechea MJ, Aranzamendi M, Zubiaurre L, Muro N, Ortiz de Zárate J, Cilla G, Cabriada JL. Immunosuppression for inflammatory bowel disease does not influence Epstein–Barr viral load in the short-term. Gastroenterología y Hepatología (English Edition) 2019;42:542-547. [DOI: 10.1016/j.gastre.2019.03.022] [Reference Citation Analysis]
|
| 560 |
Earley H, Lennon G, Balfe Á, Coffey JC, Winter DC, O'Connell PR. The abundance of Akkermansia muciniphila and its relationship with sulphated colonic mucins in health and ulcerative colitis. Sci Rep 2019;9:15683. [PMID: 31666581 DOI: 10.1038/s41598-019-51878-3] [Cited by in Crossref: 91] [Cited by in F6Publishing: 95] [Article Influence: 22.8] [Reference Citation Analysis]
|
| 561 |
Rowan CR, Cullen G, Mulcahy HE, Sheridan J, Moss AC, Ryan EJ, Doherty GA. DUBLIN [Degree of Ulcerative colitis Burden of Luminal Inflammation] Score, a Simple Method to Quantify Inflammatory Burden in Ulcerative Colitis. J Crohns Colitis 2019;13:1365-71. [PMID: 30911757 DOI: 10.1093/ecco-jcc/jjz067] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 562 |
Mansour R, Beattie M, Miller J, Haus C. Diffuse Large B-Cell Lymphoma Mimicking an Ulcerative Colitis Flare. ACG Case Rep J 2019;6:1-3. [PMID: 31620491 DOI: 10.14309/crj.0000000000000031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 563 |
Tajiri H, Arai K, Kagimoto S, Kunisaki R, Hida N, Sato N, Yamada H, Nagano M, Susuta Y, Ozaki K, Kondo K, Hibi T. Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan. BMC Pediatr 2019;19:351. [PMID: 31607268 DOI: 10.1186/s12887-019-1739-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 564 |
Knyazev OV, Kagramanova AV, Lishchinskaya AA, Parfenov AI. The effectiveness of mesalazine therapy of ulcerative colitis of moderate severity in real clinical practice. Medicinskij sovet 2019. [DOI: 10.21518/2079-701x-2019-14-80-86] [Reference Citation Analysis]
|
| 565 |
Shah J, Dutta U, Das A, Sharma V, Mandavdhare H, Sharma P, Kalsi D, Popli P, Kochhar R. Relationship between Mayo endoscopic score and histological scores in ulcerative colitis: A prospective study. JGH Open 2020;4:382-6. [PMID: 32514441 DOI: 10.1002/jgh3.12260] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 566 |
Yanartaş Ö, Kani HT, Kani AS, Akça ZND, Akça E, Ergün S, Tezcan N, Atug Ö, İmeryüz N, Sayar K. Depression and anxiety have unique contributions to somatic complaints in depression, irritable bowel syndrome and inflammatory bowel diseases. Psychiatry and Clinical Psychopharmacology 2019;29:418-26. [DOI: 10.1080/24750573.2019.1589177] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 567 |
Yang DH, Park SJ, Kim HS, Park YS, Park DI, Lee KM, Jung SA, Choi CH, Koo JS, Cheon JH, Yang SK, Kim WH, Kim J, Kim H, Ryan Choi CH; Korean Association for the Study of the Intestinal Diseases (KASID) study. High-Definition Chromoendoscopy Versus High-Definition White Light Colonoscopy for Neoplasia Surveillance in Ulcerative Colitis: A Randomized Controlled Trial. Am J Gastroenterol 2019;114:1642-8. [PMID: 31567166 DOI: 10.14309/ajg.0000000000000341] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 568 |
. UEG Week 2019 Poster Presentations. United European Gastroenterol J 2019;7:189-1030. [PMID: 32213001 DOI: 10.1177/2050640619854671] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 569 |
Chaparro M, Donday MG, Barreiro-de Acosta M, Domènech E, Esteve M, García-Sánchez V, Nos P, Panés J, Martínez C, Gisbert JP. Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial. Therap Adv Gastroenterol 2019;12:1756284819874202. [PMID: 35154384 DOI: 10.1177/1756284819874202] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 570 |
Guidi L, Pugliese D, Panici Tonucci T, Bertani L, Costa F, Privitera G, Tolusso B, Di Mario C, Albano E, Tapete G, Gremese E, Papa A, Gasbarrini A, Rapaccini GL, Armuzzi A. Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease. United European Gastroenterol J 2019;7:1189-97. [PMID: 31700632 DOI: 10.1177/2050640619873784] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 571 |
Røer MJ, Småstuen MC, Røseth AG. Usability of IBDoc, a Novel Fecal Calprotectin Home-Based Rapid Test in Clinical Practice. Point of Care 2019;18:85-91. [DOI: 10.1097/poc.0000000000000192] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 572 |
Sands BE, Cheifetz AS, Nduaka CI, Quirk D, Wang W, Maller E, Friedman GS, Su C, Higgins PDR. The Impact of Raising the Bar for Clinical Trials in Ulcerative Colitis. J Crohns Colitis 2019;13:1217-26. [PMID: 30879034 DOI: 10.1093/ecco-jcc/jjz038] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 573 |
Mutaguchi M, Naganuma M, Sugimoto S, Fukuda T, Nanki K, Mizuno S, Hosoe N, Shimoda M, Ogata H, Iwao Y, Kanai T. Difference in the clinical characteristic and prognosis of colitis-associated cancer and sporadic neoplasia in ulcerative colitis patients. Dig Liver Dis 2019;51:1257-64. [PMID: 31151895 DOI: 10.1016/j.dld.2019.05.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 574 |
Bourgonje AR, Gabriëls RY, de Borst MH, Bulthuis MLC, Faber KN, van Goor H, Dijkstra G. Serum Free Thiols Are Superior to Fecal Calprotectin in Reflecting Endoscopic Disease Activity in Inflammatory Bowel Disease. Antioxidants (Basel) 2019;8:E351. [PMID: 31480545 DOI: 10.3390/antiox8090351] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 575 |
Ludvigsson JF, Andersson M, Bengtsson J, Eberhardson M, Fagerberg UL, Grip O, Halfvarson J, Hjortswang H, Jäghult S, Karling P, Nordenvall C, Olén O, Olsson M, Rejler M, Strid H, Myrelid P. Swedish Inflammatory Bowel Disease Register (SWIBREG) - a nationwide quality register. Scand J Gastroenterol 2019;54:1089-101. [PMID: 31498717 DOI: 10.1080/00365521.2019.1660799] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 576 |
Ollech JE, Weisshof R, Rubin DT. PREVENTION OF INFLAMMATORY BOWEL DISEASE COMPLICATIONS AND RECURRENCE. Revista Médica Clínica Las Condes 2019;30:339-343. [DOI: 10.1016/j.rmclc.2019.08.001] [Reference Citation Analysis]
|
| 577 |
Magro F, Lopes S, Silva M, Coelho R, Portela F, Branquinho D, Correia L, Fernandes S, Cravo M, Caldeira P, Tavares de Sousa H, Patita M, Lago P, Ramos J, Afonso J, Redondo I, Machado P, Philip G, Lopes J, Carneiro F. Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab. Therap Adv Gastroenterol 2019;12:1756284819869141. [PMID: 31516554 DOI: 10.1177/1756284819869141] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 578 |
Dalal RS, Osterman MT, Buchner AM, Praestgaard A, Lewis JD, Lichtenstein GR. A User-Friendly Prediction Tool to Identify Colectomy Risk in Patients With Ulcerative Colitis. Inflamm Bowel Dis 2019;25:1550-8. [PMID: 30753443 DOI: 10.1093/ibd/izz014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 579 |
Rodríguez-Lago I, Merino O, López de Goicoechea MJ, Aranzamendi M, Zubiaurre L, Muro N, Ortiz de Zárate J, Cilla G, Cabriada JL. Immunosuppression for inflammatory bowel disease does not influence Epstein-Barr viral load in the short-term. Gastroenterol Hepatol 2019;42:542-7. [PMID: 31402179 DOI: 10.1016/j.gastrohep.2019.03.016] [Reference Citation Analysis]
|
| 580 |
Church PC, Ho S, Sharma A, Tomalty D, Frost K, Muise A, Walters TD, Griffiths AM. Intensified Infliximab Induction is Associated with Improved Response and Decreased Colectomy in Steroid-Refractory Paediatric Ulcerative Colitis. J Crohns Colitis 2019;13:982-9. [PMID: 30715240 DOI: 10.1093/ecco-jcc/jjz019] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 581 |
Nakayama LF, Bergamo VC, Conti ML, Fares NT, Costa LA, Ambrogini O Jr, de Moraes NSB. The retinal foveal avascular zone as a systemic biomarker to evaluate inflammatory bowel disease control. Int J Retina Vitreous 2019;5:16. [PMID: 31406581 DOI: 10.1186/s40942-019-0168-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 582 |
Klenske E, Atreya R, Hartmann A, Fischer S, Hirschmann S, Zundler S, Iaccuci M, Neurath MF, Rath T. Magnification endoscopy with optical chromoendoscopy shows strong correlation with histologic inflammation in patients with inflammatory bowel disease. Endosc Int Open 2019;7:E1018-26. [PMID: 31404439 DOI: 10.1055/a-0953-1334] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 583 |
Biasci D, Lee JC, Noor NM, Pombal DR, Hou M, Lewis N, Ahmad T, Hart A, Parkes M, McKinney EF, Lyons PA, Smith KGC. A blood-based prognostic biomarker in IBD. Gut 2019;68:1386-95. [PMID: 31030191 DOI: 10.1136/gutjnl-2019-318343] [Cited by in Crossref: 103] [Cited by in F6Publishing: 103] [Article Influence: 25.8] [Reference Citation Analysis]
|
| 584 |
Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, Makharia GK, Pisespongsa P, Chen MH, Ran ZH, Ye BD, Park DI, Ling KL, Ong D, Ahuja V, Goh KL, Sollano J, Lim WC, Leung WK, Ali RAR, Wu DC, Ong E, Mustaffa N, Limsrivilai J, Hisamatsu T, Yang SK, Ouyang Q, Geary R, De Silva JH, Rerknimitr R, Simadibrata M, Abdullah M, Leong RWL; Asia-Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn's and Colitis. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. J Gastroenterol Hepatol 2019;34:1296-315. [PMID: 30848854 DOI: 10.1111/jgh.14648] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 585 |
Fofaria RK, Barber S, Adeleke Y, Woodcock T, Kamperidis N, Mohamed A, Misra R, Shah A, Bailey-Fee S, Bluston H, Robinson D, Tyrrell T, Arebi N. Stratification of inflammatory bowel disease outpatients by disease activity and risk of complications to guide out-of-hospital monitoring: a patient-centred quality improvement project. BMJ Open Qual. 2019;8:e000546. [PMID: 31428704 DOI: 10.1136/bmjoq-2018-000546] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 586 |
Kanmura S, Hamamoto H, Tanaka A, Arima S, Sasaki F, Tanoue S, Nasu Y, Hashimoto S, Higashi M, Ido A. Diagnostic utility of linked color imaging in the evaluation of colonic mucosal inflammation in ulcerative colitis: a pilot study. Endosc Int Open 2019;7:E937-43. [PMID: 31367672 DOI: 10.1055/a-0810-0398] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 587 |
Lo Presti E, Di Mitri R, Mocciaro F, Di Stefano AB, Scibetta N, Unti E, Cicero G, Pecoraro G, Conte E, Dieli F, Meraviglia S. Characterization of γδ T Cells in Intestinal Mucosa From Patients With Early-Onset or Long-Standing Inflammatory Bowel Disease and Their Correlation With Clinical Status. J Crohns Colitis 2019;13:873-83. [PMID: 30689780 DOI: 10.1093/ecco-jcc/jjz015] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 588 |
Greenberg S, Herfarth HH, Barnes EL. Predictors of Inadequate Response to Budesonide Multimatrix in Real-World Patients with Ulcerative Colitis. Inflamm Intest Dis 2019;4:115-22. [PMID: 31559263 DOI: 10.1159/000501004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 589 |
Annese V. An update on treatment of ulcerative colitis. Expert Opinion on Orphan Drugs 2019;7:295-304. [DOI: 10.1080/21678707.2019.1638249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 590 |
Pugliese D, Daperno M, Fiorino G, Savarino E, Mosso E, Biancone L, Testa A, Sarpi L, Cappello M, Bodini G, Caprioli F, Festa S, Laino G, Maconi G, Mazzuoli S, Mocci G, Sartini A, D'Amore A, Alivernini S, Gremese E, Armuzzi A. Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study. Dig Liver Dis 2019;51:972-7. [PMID: 30992173 DOI: 10.1016/j.dld.2019.03.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 591 |
Yamamoto-furusho J, Bozada-gutiérrez K, Sánchez-rodríguez A, Bojalil-romano F, Barreto-zuñiga R, Martínez-benitez B. Validation of a novel integral disease index for evaluating the grade of activity in Mexican patients with ulcerative colitis: A prospective cohort study. Revista de Gastroenterología de México (English Edition) 2019;84:317-25. [DOI: 10.1016/j.rgmxen.2019.02.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 592 |
Kimura K, Yoshida A, Katagiri F, Takayanagi R, Yamada Y. Prediction of clinical effects of infliximab administered for inflammatory bowel disease based on pharmacokinetic and pharmacodynamic modeling. Biopharm Drug Dispos 2019;40:250-61. [PMID: 31256430 DOI: 10.1002/bdd.2198] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 593 |
Ma C, Lee JK, Mitra AR, Teriaky A, Choudhary D, Nguyen TM, Vande Casteele N, Khanna R, Panaccione R, Feagan BG, Jairath V. Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease. Aliment Pharmacol Ther 2019;50:5-23. [PMID: 31119766 DOI: 10.1111/apt.15297] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 594 |
Fluxa D, Abreu MT. Therapeutic targets in inflammatory bowel disease. Revista Médica Clínica Las Condes 2019;30:315-322. [DOI: 10.1016/j.rmclc.2019.06.008] [Reference Citation Analysis]
|
| 595 |
Xu W, Ou W, Guo Y, Gu Y, Cui L, Zhong J, Du P. Clinical outcomes and risk factors of secondary extraintestinal manifestation in ulcerative colitis: results of a multicenter and long-term follow-up retrospective study. PeerJ 2019;7:e7194. [PMID: 31304061 DOI: 10.7717/peerj.7194] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 596 |
Boden EK, Canavan JB, Moran CJ, McCann K, Dunn WA, Farraye FA, Ananthakrishnan AN, Yajnik V, Gandhi R, Nguyen DD, Bhan AK, Weiner HL, Korzenik JR, Snapper SB. Immunologic Alterations Associated With Oral Delivery of Anti-CD3 (OKT3) Monoclonal Antibodies in Patients With Moderate-to-Severe Ulcerative Colitis. Crohns Colitis 360 2019;1:otz009. [PMID: 31423487 DOI: 10.1093/crocol/otz009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 597 |
Scaioli E, Belluzzi A, Ricciardiello L, Del Rio D, Rotondo E, Mena P, Derlindati E, Danesi F. Pomegranate juice to reduce fecal calprotectin levels in inflammatory bowel disease patients with a high risk of clinical relapse: Study protocol for a randomized controlled trial. Trials 2019;20:327. [PMID: 31171016 DOI: 10.1186/s13063-019-3321-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 598 |
Mahdipour M, Shafaghi A, Mansour-ghanaei F, Hojati A, Joukar F, Mavaddati S. Fecal calprotectin role in diagnosis of ulcerative colitis and treatment follow-up. Journal of Coloproctology 2019;39:115-120. [DOI: 10.1016/j.jcol.2018.10.012] [Reference Citation Analysis]
|
| 599 |
Aladrén BS, González-Lama Y, García-Alvarado M, Sierra M, Barrio JA, Vicente VP, Hernández L, Velayos B, Garcia LA, Relea L, Suarez P, Atienza R, Vásquez M, Fernández-Salazar L, Muñoz F; GEICYL (group of inflammatory bowel disease of Castilla y León). Even non-experts identify non-dysplastic lesions in inflammatory bowel disease via chromoendoscopy: results of a screening program in real-life. Endosc Int Open 2019;7:E743-50. [PMID: 31157291 DOI: 10.1055/a-0839-4514] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 600 |
Motobayashi M, Matsuoka K, Takenaka K, Fujii T, Nagahori M, Ohtsuka K, Iwamoto F, Tsuchiya K, Negi M, Eishi Y, Watanabe M. Predictors of mucosal healing during induction therapy in patients with acute moderate-to-severe ulcerative colitis. J Gastroenterol Hepatol 2019;34:1004-10. [PMID: 30551266 DOI: 10.1111/jgh.14565] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 601 |
Yarur AJ, Bruss A, Naik S, Beniwal-Patel P, Fox C, Jain A, Berens B, Patel A, Ungaro R, Bahur B, Dubinsky M, Stein DJ. Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases. Dig Dis Sci 2019;64:1651-9. [PMID: 30835029 DOI: 10.1007/s10620-019-05570-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 602 |
Restellini S, Chao CY, Martel M, Barkun A, Kherad O, Seidman E, Wild G, Bitton A, Afif W, Bessissow T, Lakatos PL. Clinical Parameters Correlate With Endoscopic Activity of Ulcerative Colitis: A Systematic Review. Clin Gastroenterol Hepatol 2019;17:1265-1275.e8. [PMID: 30583048 DOI: 10.1016/j.cgh.2018.12.021] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 603 |
Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, Makharia GK, Pisespongsa P, Chen MH, Ran ZH, Ye BD, Park DI, Ling KL, Ong D, Ahuja V, Goh KL, Sollano J, Lim WC, Leung WK, Ali RAR, Wu DC, Ong E, Mustaffa N, Limsrivilai J, Hisamatsu T, Yang SK, Ouyang Q, Geary R, De Silva JH, Rerknimitr R, Simadibrata M, Abdullah M, Leong RW; Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn’s and Colitis. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. Intest Res 2019;17:285-310. [PMID: 31146509 DOI: 10.5217/ir.2019.00026] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 16.3] [Reference Citation Analysis]
|
| 604 |
Kelly OB, Li N, Smith M, Chan J, Inman RD, Silverberg MS. The Prevalence and Clinical Associations of Subclinical Sacroiliitis in Inflammatory Bowel Disease. Inflamm Bowel Dis 2019;25:1066-71. [PMID: 30428061 DOI: 10.1093/ibd/izy339] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 605 |
Stidham RW, Liu W, Bishu S, Rice MD, Higgins PDR, Zhu J, Nallamothu BK, Waljee AK. Performance of a Deep Learning Model vs Human Reviewers in Grading Endoscopic Disease Severity of Patients With Ulcerative Colitis. JAMA Netw Open 2019;2:e193963. [PMID: 31099869 DOI: 10.1001/jamanetworkopen.2019.3963] [Cited by in Crossref: 116] [Cited by in F6Publishing: 100] [Article Influence: 29.0] [Reference Citation Analysis]
|
| 606 |
Olaisen M, Spigset O, Flatberg A, Granlund AVB, Brede WR, Albrektsen G, Røyset ES, Gilde B, Sandvik AK, Martinsen TC, Fossmark R. Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis. Aliment Pharmacol Ther 2019;49:1301-13. [PMID: 30895635 DOI: 10.1111/apt.15227] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 607 |
Burrelli Scotti G, Afferri MT, De Carolis A, Vaiarello V, Fassino V, Ferrone F, Minisola S, Nieddu L, Vernia P. Factors affecting vitamin D deficiency in active inflammatory bowel diseases. Dig Liver Dis 2019;51:657-62. [PMID: 30587439 DOI: 10.1016/j.dld.2018.11.036] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 608 |
Coenen S, Weyts E, Geens P, Vermeire S, Ferrante M, Vanhaecht K, Van Assche G. Short Health Scale: a valid and reliable measure of quality of life in Dutch speaking patients with inflammatory bowel disease. Scand J Gastroenterol 2019;54:592-6. [PMID: 31106617 DOI: 10.1080/00365521.2019.1616214] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 609 |
Tripathi K, Feuerstein JD. New developments in ulcerative colitis: latest evidence on management, treatment, and maintenance. Drugs Context 2019;8:212572. [PMID: 31065290 DOI: 10.7573/dic.212572] [Cited by in Crossref: 52] [Cited by in F6Publishing: 58] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 610 |
Hyams JS, Davis Thomas S, Gotman N, Haberman Y, Karns R, Schirmer M, Mo A, Mack DR, Boyle B, Griffiths AM, LeLeiko NS, Sauer CG, Keljo DJ, Markowitz J, Baker SS, Rosh J, Baldassano RN, Patel A, Pfefferkorn M, Otley A, Heyman M, Noe J, Oliva-Hemker M, Rufo PA, Strople J, Ziring D, Guthery SL, Sudel B, Benkov K, Wali P, Moulton D, Evans J, Kappelman MD, Marquis MA, Sylvester FA, Collins MH, Venkateswaran S, Dubinsky M, Tangpricha V, Spada KL, Saul B, Wang J, Serrano J, Hommel K, Marigorta UM, Gibson G, Xavier RJ, Kugathasan S, Walters T, Denson LA. Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study. Lancet 2019;393:1708-20. [PMID: 30935734 DOI: 10.1016/S0140-6736(18)32592-3] [Cited by in Crossref: 85] [Cited by in F6Publishing: 79] [Article Influence: 21.3] [Reference Citation Analysis]
|
| 611 |
Ateş Bulut E, Törüner M. The influence of disease type and activity to sexual life and health quality in inflammatory bowel disease. Turk J Gastroenterol 2019;30:33-9. [PMID: 30644362 DOI: 10.5152/tjg.2018.18250] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 612 |
Tursi A, Mocci G, Faggiani R, Allegretta L, Valle ND, Forti G, Franceschi M, Ferronato A, Gallina S, Larussa T, Luzza F, Lorenzetti R, Penna A, Rodino S, Sebkova L, Lauria A, Piergallini S, Pranzo G, Ricciardelli C, Zampaletta C, Elisei W, Picchio M. Infliximab biosimilar CT-P13 is effective and safe in treating inflammatory bowel diseases: a real-life multicenter, observational study in Italian primary inflammatory bowel disease centers. Ann Gastroenterol 2019;32:392-9. [PMID: 31263362 DOI: 10.20524/aog.2019.0377] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 613 |
Huguet JM, Ferrer-Barceló L, Suárez P, Albert C, Gonzalez L, Castillo G, Boix C, García L, Gallego J, Sempere J. Endoscopic progression of ulcerative proctitis to proximal disease. Can we identify predictors of progression? Scand J Gastroenterol 2018;53:1286-90. [PMID: 30351984 DOI: 10.1080/00365521.2018.1524026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 614 |
Goertz RS, Lueke C, Schellhaas B, Pfeifer L, Wildner D, Neurath MF, Strobel D. Acoustic radiation force impulse (ARFI) shear wave elastography of the bowel wall in healthy volunteers and in ulcerative colitis. Acta Radiol Open 2019;8:2058460119840969. [PMID: 31024741 DOI: 10.1177/2058460119840969] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 615 |
de Jong DC, Löwenberg M, Koumoutsos I, Ray S, Mawdsley J, Anderson S, Sanderson JD, Gecse K, Ponsioen CY, D'Haens GR, Irving PM, Samaan MA. Validation and Investigation of the Operating Characteristics of the Ulcerative Colitis Endoscopic Index of Severity. Inflamm Bowel Dis 2019;25:937-44. [PMID: 30329045 DOI: 10.1093/ibd/izy325] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 616 |
Wuensch T, Wizenty J, Quint J, Spitz W, Bosma M, Becker O, Adler A, Veltzke-Schlieker W, Stockmann M, Weiss S, Biebl M, Pratschke J, Aigner F. Expression Analysis of Fibronectin Type III Domain-Containing (FNDC) Genes in Inflammatory Bowel Disease and Colorectal Cancer. Gastroenterol Res Pract 2019;2019:3784172. [PMID: 31093274 DOI: 10.1155/2019/3784172] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 617 |
Hoffmann P, Wehling C, Krisam J, Pfeiffenberger J, Belling N, Gauss A. Performance of tacrolimus in hospitalized patients with steroid-refractory acute severe ulcerative colitis. World J Gastroenterol 2019; 25(13): 1603-1617 [PMID: 30983820 DOI: 10.3748/wjg.v25.i13.1603] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 618 |
Perler BK, Ungaro R, Baird G, Mallette M, Bright R, Shah S, Shapiro J, Sands BE. Presenting symptoms in inflammatory bowel disease: descriptive analysis of a community-based inception cohort. BMC Gastroenterol 2019;19:47. [PMID: 30940072 DOI: 10.1186/s12876-019-0963-7] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 619 |
Kanazawa M, Takahashi F, Tominaga K, Abe K, Izawa N, Fukushi K, Nagashima K, Kanamori A, Takenaka K, Sugaya T, Iijima M, Takada A, Imai Y, Hiraishi H, Irisawa A. Relationship between endoscopic mucosal healing and histologic inflammation during remission maintenance phase in ulcerative colitis: a retrospective study. Endosc Int Open 2019;7:E568-75. [PMID: 30957007 DOI: 10.1055/a-0869-7619] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 620 |
Magro F, Lopes J, Borralho P, Lopes S, Coelho R, Cotter J, Castro FD, Sousa HT, Salgado M, Andrade P, Vieira AI, Figueiredo P, Caldeira P, Sousa A, Duarte MA, Ávila F, Silva J, Moleiro J, Mendes S, Giestas S, Ministro P, Sousa P, Gonçalves R, Gonçalves B, Oliveira A, Rosa I, Rodrigues M, Chagas C, Dias CC, Afonso J, Geboes K, Carneiro F; Portuguese IBD Study Group (GEDII). Comparison of different histological indexes in the assessment of UC activity and their accuracy regarding endoscopic outcomes and faecal calprotectin levels. Gut 2019;68:594-603. [PMID: 29437913 DOI: 10.1136/gutjnl-2017-315545] [Cited by in Crossref: 64] [Cited by in F6Publishing: 68] [Article Influence: 16.0] [Reference Citation Analysis]
|
| 621 |
Testa A, Giannetti E, Rispo A, Rea M, Miele E, Scarpato E, Opramolla A, Nardone OM, Imperatore N, Di Luna I, Staiano A, Castiglione F. Successful outcome of the transitional process of inflammatory bowel disease from pediatric to adult age: A five years experience. Dig Liver Dis 2019;51:524-8. [PMID: 30704905 DOI: 10.1016/j.dld.2018.11.034] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 622 |
Cassinotti A, Buffoli F, Fociani P, Staiano T, Villanacci V, Nebuloni M, Duca P, Fichera M, Grassia R, Manes G, Salemme M, Molteni P, Sampietro G, Foschi D, de Franchis R, Ardizzone S. Virtual Chromoendoscopy With FICE for the Classification of Polypoid and Nonpolypoid Raised Lesions in Ulcerative Colitis. J Clin Gastroenterol 2019;53:269-76. [PMID: 29394176 DOI: 10.1097/MCG.0000000000000974] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 623 |
Tow KE, Rogge C, Lee T, Caputi P, Knowles SR. Validation of a Digital Support App to Assess Inflammatory Disease Activity and Mental Health Patient-Reported Outcomes (PROs): A Pilot Investigation. Gastroenterol Res Pract 2019;2019:7618468. [PMID: 30911295 DOI: 10.1155/2019/7618468] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 624 |
Sturm A, Maaser C, Calabrese E, Annese V, Fiorino G, Kucharzik T, Vavricka SR, Verstockt B, van Rheenen P, Tolan D, Taylor SA, Rimola J, Rieder F, Limdi JK, Laghi A, Krustiņš E, Kotze PG, Kopylov U, Katsanos K, Halligan S, Gordon H, González Lama Y, Ellul P, Eliakim R, Castiglione F, Burisch J, Borralho Nunes P, Bettenworth D, Baumgart DC, Stoker J; European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR]. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. J Crohns Colitis 2019;13:273-84. [PMID: 30137278 DOI: 10.1093/ecco-jcc/jjy114] [Cited by in Crossref: 166] [Cited by in F6Publishing: 172] [Article Influence: 41.5] [Reference Citation Analysis]
|
| 625 |
Szakács Z, Csiszár B, Kenyeres P, Sarlós P, Erőss B, Hussain A, Nagy Á, Kőszegi B, Veczák I, Farkas N, Bódis E, Márta K, Szentesi A, Tőkés-Füzesi M, Berki T, Vincze Á, Tóth K, Hegyi P, Bajor J. Haemorheological and haemostatic alterations in coeliac disease and inflammatory bowel disease in comparison with non-coeliac, non-IBD subjects (HERMES): a case-control study protocol. BMJ Open 2019;9:e026315. [PMID: 30904871 DOI: 10.1136/bmjopen-2018-026315] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 626 |
Hanžel J, Sever N, Ferkolj I, Štabuc B, Smrekar N, Kurent T, Koželj M, Novak G, Compernolle G, Tops S, Gils A, Drobne D. Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease. United European Gastroenterol J 2019;7:741-9. [PMID: 31316778 DOI: 10.1177/2050640619840211] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 627 |
Fukuda T, Naganuma M, Sugimoto S, Ono K, Nanki K, Mizuno S, Kimura K, Mutaguchi M, Nakazato Y, Takabayashi K, Inoue N, Ogata H, Iwao Y, Kanai T. Efficacy of Therapeutic Intervention for Patients With an Ulcerative Colitis Mayo Endoscopic Score of 1. Inflamm Bowel Dis 2019;25:782-8. [PMID: 30265308 DOI: 10.1093/ibd/izy300] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 628 |
Damião AOMC, Azevedo MFC, Carlos AS, Wada MY, Silva TVM, Feitosa FC. Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review. World J Gastroenterol 2019; 25(9): 1142-1157 [PMID: 30863001 DOI: 10.3748/wjg.v25.i9.1142] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 47] [Article Influence: 11.5] [Reference Citation Analysis]
|
| 629 |
Sonoyama H, Kawashima K, Ishihara S, Kotani S, Fukuba N, Oka A, Kusunoki R, Tada Y, Mishima Y, Oshima N, Moriyama I, Yuki T, Onishi K, Kinoshita Y. Capabilities of fecal calprotectin and blood biomarkers as surrogate endoscopic markers according to ulcerative colitis disease type. J Clin Biochem Nutr 2019;64:265-70. [PMID: 31138962 DOI: 10.3164/jcbn.18-92] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 630 |
Pararasa C, Zhang N, Tull TJ, Chong MHA, Siu JHY, Guesdon W, Chavele KM, Sanderson JD, Langmead L, Kok K, Spencer J, Vossenkamper A. Reduced CD27-IgD- B Cells in Blood and Raised CD27-IgD- B Cells in Gut-Associated Lymphoid Tissue in Inflammatory Bowel Disease. Front Immunol 2019;10:361. [PMID: 30891036 DOI: 10.3389/fimmu.2019.00361] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 631 |
Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol 2019;114:384-413. [PMID: 30840605 DOI: 10.14309/ajg.0000000000000152] [Cited by in Crossref: 612] [Cited by in F6Publishing: 559] [Article Influence: 153.0] [Reference Citation Analysis]
|
| 632 |
Iacucci M, Furfaro F, Matsumoto T, Uraoka T, Smith S, Ghosh S, Kiesslich R. Advanced endoscopic techniques in the assessment of inflammatory bowel disease: new technology, new era. Gut 2019;68:562-72. [PMID: 30580249 DOI: 10.1136/gutjnl-2017-315235] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 633 |
Kang HS, Koo JS, Lee KM, Kim DB, Lee JM, Kim YJ, Yoon H, Jang HJ. Two-year delay in ulcerative colitis diagnosis is associated with anti-tumor necrosis factor alpha use. World J Gastroenterol 2019; 25(8): 989-1001 [PMID: 30833804 DOI: 10.3748/wjg.v25.i8.989] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 634 |
Som A, Mandaliya R, Alsaadi D, Farshidpour M, Charabaty A, Malhotra N, Mattar MC. Immune checkpoint inhibitor-induced colitis: A comprehensive review. World J Clin Cases 2019;7:405-18. [PMID: 30842952 DOI: 10.12998/wjcc.v7.i4.405] [Cited by in CrossRef: 132] [Cited by in F6Publishing: 136] [Article Influence: 33.0] [Reference Citation Analysis]
|
| 635 |
Suzuki T, Mizoshita T, Tanida S, Sugimura N, Katano T, Nishie H, Kataoka H. The efficacy of maintenance therapy after remission induction with tacrolimus in ulcerative colitis with and without previous tumor necrosis factor-α inhibitor. JGH Open 2019;3:217-23. [PMID: 31276039 DOI: 10.1002/jgh3.12140] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 636 |
Mavroudis G, Simren M, Jonefjäll B, Öhman L, Strid H. Symptoms compatible with functional bowel disorders are common in patients with quiescent ulcerative colitis and influence the quality of life but not the course of the disease. Therap Adv Gastroenterol 2019;12:1756284819827689. [PMID: 30815033 DOI: 10.1177/1756284819827689] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 637 |
Thomas MG, Bayliss C, Bond S, Dowling F, Galea J, Jairath V, Lamb C, Probert C, Timperley-Preece E, Watson A, Whitehead L, Williams JG, Parkes M, Kaser A, Raine T. Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trial. BMJ Open 2019;9:e023765. [PMID: 30772849 DOI: 10.1136/bmjopen-2018-023765] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 638 |
Khanna R, Feagan BG. The Role of Biomarkers in Treatment Algorithms for Ulcerative Colitis (UC). Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases 2019. [DOI: 10.1002/9781119289234.ch2] [Reference Citation Analysis]
|
| 639 |
Hibi T, Motoya S, Ashida T, Sai S, Sameshima Y, Nakamura S, Maemoto A, Nii M, Sullivan BA, Gasser RA Jr, Suzuki Y. Efficacy and safety of abrilumab, an α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study. Intest Res 2019;17:375-86. [PMID: 30739435 DOI: 10.5217/ir.2018.00141] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 640 |
Vasudevan A, Arachchi A, Scanlon C, Greenhalgh J, Van Langenberg DR. A comparison of long-term healthcare utilization and costs in patients with acute severe ulcerative colitis receiving infliximab versus early colectomy. Ther Adv Chronic Dis 2019;10:2040622319825595. [PMID: 30728932 DOI: 10.1177/2040622319825595] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 641 |
Vinayaga-Pavan M, Frampton M, Pontikos N, Levine AP, Smith PJ, Jonasson JG, Björnsson ES, Segal AW, Smith AM. Elevation in Cell Cycle and Protein Metabolism Gene Transcription in Inactive Colonic Tissue From Icelandic Patients With Ulcerative Colitis. Inflamm Bowel Dis 2019;25:317-27. [PMID: 30452647 DOI: 10.1093/ibd/izy350] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 642 |
Spagnuolo R, Montalcini T, De Bonis D, Ferro Y, Cosco C, Mazza E, Romeo S, Doldo P, Pujia A. Weight Gain and Liver Steatosis in Patients with Inflammatory Bowel Diseases. Nutrients 2019;11:E303. [PMID: 30717085 DOI: 10.3390/nu11020303] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 643 |
Ma C, Guizzetti L, Cipriano LE, Parker CE, Nguyen TM, Gregor JC, Chande N, Feagan BG, Jairath V. Systematic review with meta-analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies. Aliment Pharmacol Ther 2019;49:364-74. [PMID: 30569460 DOI: 10.1111/apt.15090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 644 |
Ko CW, Singh S, Feuerstein JD, Falck-Ytter C, Falck-Ytter Y, Cross RK; American Gastroenterological Association Institute Clinical Guidelines Committee. AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis. Gastroenterology 2019;156:748-64. [PMID: 30576644 DOI: 10.1053/j.gastro.2018.12.009] [Cited by in Crossref: 129] [Cited by in F6Publishing: 130] [Article Influence: 32.3] [Reference Citation Analysis]
|
| 645 |
Singh S, Feuerstein JD, Binion DG, Tremaine WJ. AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis. Gastroenterology 2019;156:769-808.e29. [PMID: 30576642 DOI: 10.1053/j.gastro.2018.12.008] [Cited by in Crossref: 66] [Cited by in F6Publishing: 70] [Article Influence: 16.5] [Reference Citation Analysis]
|
| 646 |
Christensen B, Gibson PR, Micic D, Colman RJ, Goeppinger SR, Kassim O, Yarur A, Weber CR, Cohen RD, Rubin DT. Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2019;17:486-93. [PMID: 29751166 DOI: 10.1016/j.cgh.2018.04.060] [Cited by in Crossref: 59] [Cited by in F6Publishing: 59] [Article Influence: 14.8] [Reference Citation Analysis]
|
| 647 |
Maeda Y, Kudo SE, Mori Y, Misawa M, Ogata N, Sasanuma S, Wakamura K, Oda M, Mori K, Ohtsuka K. Fully automated diagnostic system with artificial intelligence using endocytoscopy to identify the presence of histologic inflammation associated with ulcerative colitis (with video). Gastrointest Endosc 2019;89:408-15. [PMID: 30268542 DOI: 10.1016/j.gie.2018.09.024] [Cited by in Crossref: 124] [Cited by in F6Publishing: 124] [Article Influence: 31.0] [Reference Citation Analysis]
|
| 648 |
Law AD, Dutta U, Kochhar R, Vaishnavi C, Kumar S, Noor T, Bhadada S, Singh K. Vitamin D deficiency in adult patients with ulcerative colitis: Prevalence and relationship with disease severity, extent, and duration. Indian J Gastroenterol 2019;38:6-14. [PMID: 30864011 DOI: 10.1007/s12664-019-00932-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 649 |
Biasci D, Lee J, Noor N, Pombal D, Lewis N, Ahmad T, Hart A, Parkes M, Mckinney E, Lyons P, Smith K. A blood-based prognostic biomarker in inflammatory bowel disease.. [DOI: 10.1101/535153] [Reference Citation Analysis]
|
| 650 |
Murthy SK, Shukla T, Antonova L, Belair MA, Ramsay T, Gallinger Z, Nguyen GC, Benchimol EI. Predictive models of disease burden at diagnosis in persons with adult-onset ulcerative colitis using health administrative data. BMC Gastroenterol 2019;19:13. [PMID: 30665357 DOI: 10.1186/s12876-018-0924-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 651 |
Xu H, Tang H, Xu T, Xiao M, Li J, Tan B, Yang H, Lv H, Li Y, Qian J. Retrospective analysis of Clostridium difficile infection in patients with ulcerative colitis in a tertiary hospital in China. BMC Gastroenterol 2019;19:3. [PMID: 30616563 DOI: 10.1186/s12876-018-0920-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 652 |
Neubauer K, Bednarz-Misa I, Walecka-Zacharska E, Wierzbicki J, Agrawal A, Gamian A, Krzystek-Korpacka M. Oversecretion and Overexpression of Nicotinamide Phosphoribosyltransferase/Pre-B Colony-Enhancing Factor/Visfatin in Inflammatory Bowel Disease Reflects the Disease Activity, Severity of Inflammatory Response and Hypoxia. Int J Mol Sci. 2019;20. [PMID: 30621173 DOI: 10.3390/ijms20010166] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 653 |
Chiba M, Nakane K, Tsuji T, Tsuda S, Ishii H, Ohno H, Watanabe K, Ito M, Komatsu M, Yamada K, Sugawara T. Relapse Prevention in Ulcerative Colitis by Plant-Based Diet Through Educational Hospitalization: A Single-Group Trial. Perm J 2018;22:17-167. [PMID: 30005726 DOI: 10.7812/TPP/17-167] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 654 |
Buchner AM, Lichtenstein GR. Endoscopic Diagnosis and Staging of Inflammatory Bowel Disease. Clinical Gastrointestinal Endoscopy 2019. [DOI: 10.1016/b978-0-323-41509-5.00038-4] [Reference Citation Analysis]
|
| 655 |
Zhang L, Wu T. Inflammatory Bowel Disease. Surgical Pathology of Non-neoplastic Gastrointestinal Diseases 2019. [DOI: 10.1007/978-3-030-15573-5_15] [Reference Citation Analysis]
|
| 656 |
Heinz A, Michael V, Gian Eugenio T, Helmut N. Accuracy of the Full Spectrum Endoscopy (FUSE) system for assessment of disease activity in Inflammatory Bowel Diseases (IBD) compared to high-definition endoscopy. Arch Clin Gastroenterol 2019;5:034-038. [DOI: 10.17352/2455-2283.000066] [Reference Citation Analysis]
|
| 657 |
Salvetto M, Daperno M. Endoscopy. Inflammatory Bowel Disease Nursing Manual 2019. [DOI: 10.1007/978-3-319-75022-4_5] [Reference Citation Analysis]
|
| 658 |
Hanauer S, Panaccione R, Danese S, Cheifetz A, Reinisch W, Higgins PDR, Woodworth DA, Zhang H, Friedman GS, Lawendy N, Quirk D, Nduaka CI, Su C. Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol 2019;17:139-47. [PMID: 30012431 DOI: 10.1016/j.cgh.2018.07.009] [Cited by in Crossref: 102] [Cited by in F6Publishing: 99] [Article Influence: 25.5] [Reference Citation Analysis]
|
| 659 |
Cheah M, Khanna R. Current Medical Therapies for Ulcerative Colitis. Pouchitis and Ileal Pouch Disorders 2019. [DOI: 10.1016/b978-0-12-809402-0.00001-0] [Reference Citation Analysis]
|
| 660 |
Vaughan R, Christensen B, Rubin DT. Chronic Active Ulcerative Colitis. Biomarkers in Inflammatory Bowel Diseases 2019. [DOI: 10.1007/978-3-030-11446-6_11] [Reference Citation Analysis]
|
| 661 |
Rizzello F, Salice M, Calabrese C, Mazza M, Calafiore A, Calandrini L, Hrustemovic HP, Campieri M, Gionchetti P. Medical Treatment of Ulcerative Colitis: Does Traditional Therapy Still Have a Role? Ulcerative Colitis 2019. [DOI: 10.1007/978-88-470-3977-3_6] [Reference Citation Analysis]
|
| 662 |
Poggioli G, Di Simone MP, Vittori L. Diagnosis of Ulcerative Colitis: the Role of Endoscopy. Ulcerative Colitis 2019. [DOI: 10.1007/978-88-470-3977-3_4] [Reference Citation Analysis]
|
| 663 |
Antonelli E, Villanacci V, Bassotti G. Novel oral-targeted therapies for mucosal healing in ulcerative colitis. World J Gastroenterol 2018; 24(47): 5322-5330 [PMID: 30598577 DOI: 10.3748/wjg.v24.i47.5322] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 664 |
Hiraoka S, Takashima S, Inokuchi T, Nakarai A, Takahara M, Harada K, Seki Y, Watanabe K, Kato J, Okada H. The novel latex agglutination turbidimetric immunoassay system for simultaneous measurements of calprotectin and hemoglobin in feces. Intest Res 2019;17:202-9. [PMID: 30541228 DOI: 10.5217/ir.2018.00086] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 665 |
Yarlas A, Maher SM, Bayliss MS, Lovley A, Cappelleri JC, DiBonaventura MD. Psychometric validation of the work productivity and activity impairment questionnaire in ulcerative colitis: results from a systematic literature review. J Patient Rep Outcomes. 2018;2:62. [PMID: 30547275 DOI: 10.1186/s41687-018-0088-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 666 |
Pierdomenico M, Palone F, Cesi V, Vitali R, Mancuso AB, Cucchiara S, Oliva S, Aloi M, Stronati L. Transcription Factor ZNF281: A Novel Player in Intestinal Inflammation and Fibrosis. Front Immunol 2018;9:2907. [PMID: 30619271 DOI: 10.3389/fimmu.2018.02907] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 667 |
Hood MM, Wilson R, Gorenz A, Jedel S, Raeisi S, Hobfoll S, Keshavarzian A. Sleep Quality in Ulcerative Colitis: Associations with Inflammation, Psychological Distress, and Quality of Life. Int J Behav Med 2018;25:517-25. [PMID: 30159665 DOI: 10.1007/s12529-018-9745-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 668 |
Leoncini G, Villanacci V, Marin MG, Crisafulli V, Cadei M, Antonelli E, Leoci C, Bassotti G. Colonic hypereosinophilia in ulcerative colitis may help to predict the failure of steroid therapy. Tech Coloproctol 2018;22:941-946. [DOI: 10.1007/s10151-018-1896-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 669 |
Miyazawa T, Shiga H, Kinouchi Y, Takahashi S, Tominaga G, Takahashi H, Takagi S, Obana N, Kikuchi T, Omori S, Sato Y, Takahashi S, Umemura K, Endo K, Kakuta Y, Matsuura M, Kimura T, Kuroha M, Shimosegawa T. Long-term course of inflammatory bowel disease after the Great East Japan Earthquake. J Gastroenterol Hepatol 2018;33:1956-60. [PMID: 29791048 DOI: 10.1111/jgh.14286] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 670 |
Pai RK, Jairath V, Vande Casteele N, Rieder F, Parker CE, Lauwers GY. The emerging role of histologic disease activity assessment in ulcerative colitis. Gastrointest Endosc 2018;88:887-98. [PMID: 30142351 DOI: 10.1016/j.gie.2018.08.018] [Cited by in Crossref: 68] [Cited by in F6Publishing: 68] [Article Influence: 13.6] [Reference Citation Analysis]
|
| 671 |
Bennet SMP, Sundin J, Magnusson MK, Strid H, Tap J, Derrien M, Le Nevé B, Doré J, Törnblom H, Simrén M, Öhman L. Altered intestinal antibacterial gene expression response profile in irritable bowel syndrome is linked to bacterial composition and immune activation. Neurogastroenterol Motil 2018;30:e13468. [PMID: 30230134 DOI: 10.1111/nmo.13468] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 672 |
Paschos P, Katsoula A, Salanti G, Giouleme O, Athanasiadou E, Tsapas A. Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life. Aliment Pharmacol Ther 2018;48:1174-85. [PMID: 30378141 DOI: 10.1111/apt.15005] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 673 |
Hosoe N, Nakano M, Takeuchi K, Endo Y, Matsuoka K, Abe T, Omori T, Hayashida M, Kobayashi T, Yoshida A, Mizuno S, Nakazato Y, Naganuma M, Kanai T, Watanabe M, Ueno F, Suzuki Y, Hibi T, Ogata H. Establishment of a Novel Scoring System for Colon Capsule Endoscopy to Assess the Severity of Ulcerative Colitis-Capsule Scoring of Ulcerative Colitis. Inflamm Bowel Dis 2018;24:2641-7. [PMID: 29846579 DOI: 10.1093/ibd/izy193] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 674 |
Bajer L, Slavcev A, Macinga P, Sticova E, Brezina J, Roder M, Janousek R, Trunecka P, Spicak J, Drastich P. Risk of recurrence of primary sclerosing cholangitis after liver transplantation is associated with de novo inflammatory bowel disease. World J Gastroenterol 2018; 24(43): 4939-4949 [PMID: 30487703 DOI: 10.3748/wjg.v24.i43.4939] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 675 |
Ninomiya K, Hisabe T, Okado Y, Takada Y, Yamaoka R, Sato Y, Kishi M, Takatsu N, Matsui T, Ueki T, Yao K, Hirai F. Comparison of Small Bowel Lesions Using Capsule Endoscopy in Ulcerative Colitis and Crohn's Disease: A Single-Center Retrospective Analysis. Digestion 2018;98:119-26. [PMID: 29698945 DOI: 10.1159/000487796] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 676 |
Knyazev OV, Kagramanova AV, Chernova ME, Koroleva IA, Parfenov AI. Clostridium difficile in ulcerative colitis; a retrospective study. Alʹm klin med 2018;46:474-481. [DOI: 10.18786/2072-0505-2018-46-5-474-481] [Reference Citation Analysis]
|
| 677 |
Grammatikopoulou MG, Gkiouras K, Theodoridis X, Asteriou E, Forbes A, Bogdanos DP. Oral Adjuvant Curcumin Therapy for Attaining Clinical Remission in Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients 2018;10:E1737. [PMID: 30424514 DOI: 10.3390/nu10111737] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 678 |
Jaeger SU, Klag T, Hoeger K, Klumpp S, Escher M, Malek N, Stange E, Wehkamp J. Tacrolimus Suppositories in Therapy-Resistant Ulcerative Proctitis. Inflamm Intest Dis 2019;3:116-24. [PMID: 30820433 DOI: 10.1159/000493979] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 679 |
Carlsen K, Riis LB, Elsberg H, Maagaard L, Thorkilgaard T, Sørbye SW, Jakobsen C, Wewer V, Florholmen J, Goll R, Munkholm P. The sensitivity of fecal calprotectin in predicting deep remission in ulcerative colitis. Scand J Gastroenterol 2018;53:825-30. [PMID: 29968483 DOI: 10.1080/00365521.2018.1482956] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 680 |
Nakarai A, Kato J, Hiraoka S, Takashima S, Inokuchi T, Takahara M, Sugihara Y, Harada K, Okada H. An Elevated Platelet Count Increases the Risk of Relapse in Ulcerative Colitis Patients with Mucosal Healing. Gut Liver. 2018;12:420-425. [PMID: 29945423 DOI: 10.5009/gnl17236] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 681 |
Valcheva R, Koleva P, Martínez I, Walter J, Gänzle MG, Dieleman LA. Inulin-type fructans improve active ulcerative colitis associated with microbiota changes and increased short-chain fatty acids levels. Gut Microbes 2019;10:334-57. [PMID: 30395776 DOI: 10.1080/19490976.2018.1526583] [Cited by in Crossref: 71] [Cited by in F6Publishing: 72] [Article Influence: 14.2] [Reference Citation Analysis]
|
| 682 |
Bieliński M, Lesiewska N, Bielińska J, Liebert A, Mieczkowski A, Sopońska-Brzoszczyk P, Brzoszczyk B, Kłopocka M, Borkowska A. Affective temperament in inflammatory bowel diseases: Another brick in the wall of differentiation. PLoS One 2018;13:e0205606. [PMID: 30383791 DOI: 10.1371/journal.pone.0205606] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 683 |
Chang JY, Cheon JH, Park Y, Park SJ, Kim TI, Kim WH. Does Medical Acceleration Improve Outcomes in Ulcerative Colitis Patients Who Are in Clinical Remission but Have Endoscopic Inflammation? Dig Dis Sci 2018;63:3041-8. [PMID: 29987626 DOI: 10.1007/s10620-018-5193-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 684 |
Shin DS, Cheon JH, Park YE, Park Y, Park SJ, Kim TI, Kim WH. Extensive Disease Subtypes in Adult Patients with Ulcerative Colitis: Non-pancolitis Versus Pancolitis. Dig Dis Sci 2018;63:3097-104. [PMID: 30145694 DOI: 10.1007/s10620-018-5218-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 685 |
Allocca M, Fiorino G, Bonovas S, Furfaro F, Gilardi D, Argollo M, Magnoni P, Peyrin-Biroulet L, Danese S. Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study. J Crohns Colitis 2018;12:1385-91. [PMID: 30085066 DOI: 10.1093/ecco-jcc/jjy107] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 11.8] [Reference Citation Analysis]
|
| 686 |
Cabriada JL, Ruiz-Zorrilla R, Barrio J, Atienza R, Huerta A, Rodríguez-Lago I, Bernal A, Herrero C. Screening for latent tuberculosis infection in patients with inflammatory bowel disease: Can interferon-gamma release assays replace the tuberculin skin test? Turk J Gastroenterol 2018;29:292-8. [PMID: 29755013 DOI: 10.5152/tjg.2018.17162] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 687 |
Jitsumura M, Cunningham AL, Hitchings MD, Islam S, Davies AP, Row PE, Riddell AD, Kinross J, Wilkinson TS, Jenkins GJ, Williams JG, Harris DA. Protocol for faecal microbiota transplantation in ulcerative colitis (FMTUC): a randomised feasibility study. BMJ Open 2018;8:e021987. [PMID: 30341117 DOI: 10.1136/bmjopen-2018-021987] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 688 |
Urushikubo J, Yanai S, Nakamura S, Kawasaki K, Akasaka R, Sato K, Toya Y, Asakura K, Gonai T, Sugai T, Matsumoto T. Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis. World J Gastroenterol 2018; 24(38): 4384-4392 [PMID: 30344422 DOI: 10.3748/wjg.v24.i38.4384] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 689 |
Tsuda S, Kunisaki R, Kato J, Murakami M, Nishio M, Ogashiwa T, Yoshida T, Kimura H, Kitano M. Patient self-reported symptoms using visual analog scales are useful to estimate endoscopic activity in ulcerative colitis. Intest Res 2018;16:579-87. [PMID: 30301332 DOI: 10.5217/ir.2018.00021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 690 |
Kim DJ, Jeoun YM, Lee DW, Koo JS, Lee SW. Usefulness of fecal immunochemical test and fecal calprotectin for detection of active ulcerative colitis. Intest Res 2018;16:563-70. [PMID: 30301335 DOI: 10.5217/ir.2018.00020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 691 |
Pugliese D, Aratari A, Festa S, Ferraro PM, Monterubbianesi R, Guidi L, Scribano ML, Papi C, Armuzzi A. Sustained Clinical Efficacy and Mucosal Healing of Thiopurine Maintenance Treatment in Ulcerative Colitis: A Real-Life Study. Gastroenterol Res Pract 2018;2018:4195968. [PMID: 30402090 DOI: 10.1155/2018/4195968] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 692 |
Atreya R, Reinisch W, Peyrin-Biroulet L, Scaldaferri F, Admyre C, Knittel T, Kowalski J, Neurath MF, Hawkey C. Clinical efficacy of the Toll-like receptor 9 agonist cobitolimod using patient-reported-outcomes defined clinical endpoints in patients with ulcerative colitis. Dig Liver Dis 2018;50:1019-29. [PMID: 30120066 DOI: 10.1016/j.dld.2018.06.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 693 |
Singh S, Proudfoot J, Xu R, Sandborn WJ. Impact of Obesity on Short- and Intermediate-Term Outcomes in Inflammatory Bowel Diseases: Pooled Analysis of Placebo Arms of Infliximab Clinical Trials. Inflamm Bowel Dis 2018;24:2278-84. [PMID: 29788260 DOI: 10.1093/ibd/izy135] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 694 |
Kedia S, Jain S, Goyal S, Bopanna S, Yadav DP, Sachdev V, Sahni P, Pal S, Dash NR, Makharia G, Travis SPL, Ahuja V. Potential of Fecal Calprotectin as an Objective Marker to Discriminate Hospitalized Patients with Acute Severe Colitis from Outpatients with Less Severe Disease. Dig Dis Sci 2018;63:2747-53. [PMID: 29948556 DOI: 10.1007/s10620-018-5157-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 695 |
Telesco SE, Brodmerkel C, Zhang H, Kim LL, Johanns J, Mazumder A, Li K, Baribaud F, Curran M, Strauss R, Paxson B, Plevy S, Davison T, Knight L, Dibben S, Schreiber S, Sandborn W, Rutgeerts P, Siegel CA, Reinisch W, Greenbaum LE. Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis. Gastroenterology 2018;155:1008-1011.e8. [PMID: 29981298 DOI: 10.1053/j.gastro.2018.06.077] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 8.4] [Reference Citation Analysis]
|
| 696 |
Goertz RS, Klett D, Wildner D, Atreya R, Neurath MF, Strobel D. Quantitative contrast-enhanced ultrasound for monitoring vedolizumab therapy in inflammatory bowel disease patients: a pilot study. Acta Radiol 2018;59:1149-56. [PMID: 29345146 DOI: 10.1177/0284185117752032] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 697 |
Hiraoka S, Inokuchi T, Nakarai A, Takashima S, Takei D, Sugihara Y, Takahara M, Harada K, Okada H, Kato J. Fecal Immunochemical Test and Fecal Calprotectin Results Show Different Profiles in Disease Monitoring for Ulcerative Colitis. Gut Liver 2018;12:142-8. [PMID: 28873508 DOI: 10.5009/gnl17013] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 698 |
Ungaro F, Massimino L, Furfaro F, Rimoldi V, Peyrin-Biroulet L, D'Alessio S, Danese S. Metagenomic analysis of intestinal mucosa revealed a specific eukaryotic gut virome signature in early-diagnosed inflammatory bowel disease. Gut Microbes 2019;10:149-58. [PMID: 30252582 DOI: 10.1080/19490976.2018.1511664] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 699 |
Klepp P, Tollisen A, Røseth A, Cvancarova Småstuen M, Andersen SN, Vatn M, Moum BA, Brackmann S. Real-life chromoendoscopy for dysplasia surveillance in ulcerative colitis. World J Gastroenterol 2018; 24(35): 4069-4076 [PMID: 30254411 DOI: 10.3748/wjg.v24.i35.4069] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 700 |
Khanna R, Zou G, Feagan BG. Evolution of the Randomized Controlled Trial in Inflammatory Bowel Disease: Current Challenges and Future Solutions. Inflamm Bowel Dis 2018;24:2155-64. [PMID: 29788218 DOI: 10.1093/ibd/izy117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 701 |
Figueroa C, Lubascher J, Ibáñez P, Quera R, Kronberg U, Simian D, Flores L. Algoritmos de tratamiento de la colitis ulcerosa desde una experiencia local. Revista Médica Clínica Las Condes 2018;29:570-579. [DOI: 10.1016/j.rmclc.2018.04.013] [Reference Citation Analysis]
|
| 702 |
Oliva S, Thomson M, de Ridder L, Martín-de-Carpi J, Van Biervliet S, Braegger C, Dias JA, Kolacek S, Miele E, Buderus S, Bronsky J, Winter H, Navas-López VM, Assa A, Chong SKF, Afzal NA, Smets F, Shaoul R, Hussey S, Turner D, Cucchiara S. Endoscopy in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto IBD Group of the European Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:414-30. [PMID: 30130311 DOI: 10.1097/MPG.0000000000002092] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 8.6] [Reference Citation Analysis]
|
| 703 |
O'Connell J, Rowan C, Stack R, Harkin G, Parihar V, Chan G, Breslin N, Cullen G, Dunne C, Egan L, Harewood G, Leyden J, MacCarthy F, MacMathuna P, Mahmud N, McKiernan S, McNamara D, Mulcahy H, Murray F, O'Connor A, O'Toole A, Patchett S, Ryan B, Sheridan J, Slattery E, Doherty G, Kevans D. Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis. Eur J Gastroenterol Hepatol 2018;30:1019-26. [PMID: 29878945 DOI: 10.1097/MEG.0000000000001177] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 704 |
Stein J, Walper A, Klemm W, Farrag K, Aksan A, Dignass A. Safety and efficacy of intravenous iron isomaltoside for correction of anaemia in patients with inflammatory bowel disease in everyday clinical practice. Scand J Gastroenterol 2018;53:1059-65. [PMID: 30222479 DOI: 10.1080/00365521.2018.1498914] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 705 |
Guidi L, Pugliese D, Panici Tonucci T, Berrino A, Tolusso B, Basile M, Cantoro L, Balestrieri P, Civitelli F, Bertani L, Marzo M, Felice C, Gremese E, Costa F, Viola F, Cicala M, Kohn A, Gasbarrini A, Rapaccini GL, Ruggeri M, Armuzzi A. Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study. J Crohns Colitis 2018;12:1079-88. [PMID: 29860436 DOI: 10.1093/ecco-jcc/jjy076] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 706 |
Lamb CA, O'Byrne S, Keir ME, Butcher EC. Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease. J Crohns Colitis 2018;12:S653-68. [PMID: 29767705 DOI: 10.1093/ecco-jcc/jjy060] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 707 |
Lee JS, Kim ES, Moon W. Chronological Review of Endoscopic Indices in Inflammatory Bowel Disease. Clin Endosc. 2018;. [PMID: 30130840 DOI: 10.5946/ce.2018.042] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 708 |
Nguyen NH, Fumery M, Dulai PS, Prokop LJ, Sandborn WJ, Murad MH, Singh S. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses. Lancet Gastroenterol Hepatol 2018;3:742-53. [PMID: 30122356 DOI: 10.1016/S2468-1253(18)30231-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 709 |
Liu R, Tang A, Wang X, Shen S. Assessment of Quality of Life in Chinese Patients With Inflammatory Bowel Disease and their Caregivers. Inflamm Bowel Dis 2018;24:2039-47. [PMID: 29788383 DOI: 10.1093/ibd/izy099] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 710 |
Jha AK, Chaudhary M, Dayal VM, Kumar A, Jha SK, Jha P, Purkayastha S, Ranjan R. Optimal cut-off value of fecal calprotectin for the evaluation of ulcerative colitis: An unsolved issue? JGH Open 2018;2:207-13. [PMID: 30483591 DOI: 10.1002/jgh3.12074] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 711 |
Muñoz-Villafranca C, Ortiz de Zarate J, Arreba P, Higuera R, Gómez L, Ibáñez S, Merino O, Muñagorri A, Ogueta M, Rodriguez C, Nantes O, Ramirez de la Piscina P, Rodríguez I, Bernal A, Arévalo J, Cabriada J. Adalimumab treatment of anti-TNF-naïve patients with ulcerative colitis: Deep remission and response factors. Dig Liver Dis 2018;50:812-9. [PMID: 29625907 DOI: 10.1016/j.dld.2018.03.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 712 |
Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, Veres G, Aloi M, Strisciuglio C, Braegger CP, Assa A, Romano C, Hussey S, Stanton M, Pakarinen M, de Ridder L, Katsanos K, Croft N, Navas-López V, Wilson DC, Lawrence S, Russell RK. Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:257-91. [PMID: 30044357 DOI: 10.1097/MPG.0000000000002035] [Cited by in Crossref: 210] [Cited by in F6Publishing: 157] [Article Influence: 42.0] [Reference Citation Analysis]
|
| 713 |
Shimoyama T, Yamamoto T, Umegae S, Matsumoto K. Faecal calprotectin level for assessing endoscopic activity and predicting future clinical course in patients with moderately active ulcerative colitis undergoing granulomonocytapheresis: a prospective cohort study. BMC Gastroenterol 2018;18:120. [PMID: 30068300 DOI: 10.1186/s12876-018-0853-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 714 |
Scaioli E, Sartini A, Bellanova M, Campieri M, Festi D, Bazzoli F, Belluzzi A. Eicosapentaenoic Acid Reduces Fecal Levels of Calprotectin and Prevents Relapse in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol 2018;16:1268-1275.e2. [PMID: 29391271 DOI: 10.1016/j.cgh.2018.01.036] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 715 |
van den Brink G, Stapersma L, Vlug LE, Rizopolous D, Bodelier AG, van Wering H, Hurkmans PCWM, Stuyt RJL, Hendriks DM, van der Burg JAT, Utens EMWJ, Escher JC. Clinical disease activity is associated with anxiety and depressive symptoms in adolescents and young adults with inflammatory bowel disease. Aliment Pharmacol Ther 2018;48:358-69. [PMID: 29897134 DOI: 10.1111/apt.14832] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 716 |
Rodríguez-lago I, Benítez JM, García-sánchez V, Gutiérrez A, Sempere L, Ginard D, Barreiro-de Acosta M, Cabriada JL. Granulocyte and monocyte apheresis in inflammatory bowel disease: The patients’ point of view. Gastroenterología y Hepatología (English Edition) 2018;41:423-431. [DOI: 10.1016/j.gastre.2018.04.020] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 717 |
Rath T, Billmeier U, Ferrazzi F, Vieth M, Ekici A, Neurath MF, Atreya R. Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases. Front Immunol 2018;9:1700. [PMID: 30131801 DOI: 10.3389/fimmu.2018.01700] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 718 |
Garg M, Hendy P, Ding JN, Shaw S, Hold G, Hart A. The Effect of Vitamin D on Intestinal Inflammation and Faecal Microbiota in Patients with Ulcerative Colitis. J Crohns Colitis 2018;12:963-72. [PMID: 29726893 DOI: 10.1093/ecco-jcc/jjy052] [Cited by in Crossref: 63] [Cited by in F6Publishing: 64] [Article Influence: 12.6] [Reference Citation Analysis]
|
| 719 |
Szántó K, Nyári T, Bálint A, Bor R, Milassin Á, Rutka M, Fábián A, Szepes Z, Nagy F, Molnár T, Farkas K. Biological therapy and surgery rates in inflammatory bowel diseases - Data analysis of almost 1000 patients from a Hungarian tertiary IBD center. PLoS One 2018;13:e0200824. [PMID: 30059523 DOI: 10.1371/journal.pone.0200824] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 720 |
Bots S, Nylund K, Löwenberg M, Gecse K, Gilja OH, D'Haens G. Ultrasound for Assessing Disease Activity in IBD Patients: A Systematic Review of Activity Scores. J Crohns Colitis 2018;12:920-9. [PMID: 29684200 DOI: 10.1093/ecco-jcc/jjy048] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 721 |
Toledo-Mauriño JJ, Furuzawa-Carballeda J, Villeda-Ramírez MA, Fonseca-Camarillo G, Meza-Guillen D, Barreto-Zúñiga R, Yamamoto-Furusho JK. The Transient Receptor Potential Vanilloid 1 Is Associated with Active Inflammation in Ulcerative Colitis. Mediators Inflamm 2018;2018:6570371. [PMID: 30150894 DOI: 10.1155/2018/6570371] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 722 |
Hanafy AS, Monir MH, Abdel Malak H, Desoky Aiad M. A Simple Noninvasive Score Predicts Disease Activity and Deep Remission in Ulcerative Colitis. Inflamm Intest Dis 2018;3:16-24. [PMID: 30505838 DOI: 10.1159/000490795] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 723 |
Zittan E, Kelly OB, Gralnek IM, Silverberg MS, Hillary Steinhart A. Fecal calprotectin correlates with active colonic inflammatory bowel disease but not with small intestinal Crohn's disease activity. JGH Open 2018;2:201-6. [PMID: 30483590 DOI: 10.1002/jgh3.12068] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 724 |
Azer SA, Azer S. What can we learn from top-cited articles in inflammatory bowel disease? A bibliometric analysis and assessment of the level of evidence. BMJ Open. 2018;8:e021233. [PMID: 30002009 DOI: 10.1136/bmjopen-2017-021233] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 725 |
Yamamoto-Furusho JK, Fonseca-Camarillo G, Furuzawa-Carballeda J, Sarmiento-Aguilar A, Barreto-Zuñiga R, Martínez-Benitez B, Lara-Velazquez MA. Caspase recruitment domain (CARD) family (CARD9, CARD10, CARD11, CARD14 and CARD15) are increased during active inflammation in patients with inflammatory bowel disease. J Inflamm (Lond) 2018;15:13. [PMID: 30008619 DOI: 10.1186/s12950-018-0189-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 726 |
Yamamoto T, Iida T, Ikeya K, Kato M, Matsuura A, Tamura S, Takano R, Tani S, Osawa S, Sugimoto K, Shimoyama T, Hanai H. A multicenter retrospective study aiming to identify patients who respond well to adsorptive granulomonocytapheresis in moderately to severely active ulcerative colitis. Clin Transl Gastroenterol. 2018;9:170. [PMID: 29977035 DOI: 10.1038/s41424-018-0037-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 727 |
Ricciuto A, Fish J, Carman N, Walters TD, Church PC, Hansen BE, Crowley E, Siddiqui I, Nguyen GC, Kamath BM, Griffiths AM. Symptoms Do Not Correlate With Findings From Colonoscopy in Children With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis. Clin Gastroenterol Hepatol 2018;16:1098-1105.e1. [PMID: 29378308 DOI: 10.1016/j.cgh.2018.01.020] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 728 |
Sofia MA, Ciorba MA, Meckel K, Lim CK, Guillemin GJ, Weber CR, Bissonnette M, Pekow JR. Tryptophan Metabolism through the Kynurenine Pathway is Associated with Endoscopic Inflammation in Ulcerative Colitis. Inflamm Bowel Dis 2018;24:1471-80. [PMID: 29796641 DOI: 10.1093/ibd/izy103] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 11.4] [Reference Citation Analysis]
|
| 729 |
Trivedi PJ, Kiesslich R, Hodson J, Bhala N, Boulton RA, Cooney R, Gui X, Iqbal T, Li KK, Mumtaz S, Pathmakanthan S, Quraishi MN, Sagar VM, Shah A, Sharma N, Siau K, Smith S, Ward S, Widlak MM, Bisschops R, Ghosh S, Iacucci M. The Paddington International Virtual Chromoendoscopy Score in ulcerative colitis exhibits very good inter-rater agreement after computerized module training: a multicenter study across academic and community practice (with video). Gastrointest Endosc 2018;88:95-106.e2. [PMID: 29548940 DOI: 10.1016/j.gie.2018.02.044] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 730 |
Scribano ML. Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence. World J Gastroenterol 2018; 24(23): 2457-2467 [PMID: 29930467 DOI: 10.3748/wjg.v24.i23.2457] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 50] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 731 |
Sabzevary-Ghahfarokhi M, Shohan M, Shirzad H, Rahimian G, Bagheri N, Soltani A, Deris F, Ghatreh-Samani M, Razmara E. The expression analysis of Fra-1 gene and IL-11 protein in Iranian patients with ulcerative colitis. BMC Immunol 2018;19:17. [PMID: 29914371 DOI: 10.1186/s12865-018-0257-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 732 |
Levin A, Yaari S, Stoff R, Caplan O, Wolf DG, Israeli E. Diagnosis of Cytomegalovirus Infection during Exacerbation of Ulcerative Colitis. Digestion 2017;96:142-8. [PMID: 28848127 DOI: 10.1159/000479865] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 733 |
Meijer B, Mulder CJJ, Bouma G, Ponsioen CY, van der Woude CJ, van der Meulen AE, Wintjens DSJ, Dijkstra G, Hoentjen F, Oldenburg B, van Bodegraven AA, de Boer NKH; Dutch Initiative on Crohn and Colitis (ICC) and Parelsnoer Institute. Methotrexate and Thioguanine Rescue Therapy for Conventional Thiopurine Failing Ulcerative Colitis Patients: A Multi-center Database Study on Tolerability and Effectiveness. Inflamm Bowel Dis 2018;24:1558-65. [PMID: 29668998 DOI: 10.1093/ibd/izy047] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 734 |
Aloi M, Bramuzzo M, Arrigo S, Romano C, D'Arcangelo G, Lacorte D, Gatti S, Illiceto MT, Zucconi F, Dilillo D, Zuin G, Knafelz D, Ravelli A, Cucchiara S, Alvisi P; SIGENP IBD Working Group. Efficacy and Safety of Adalimumab in Pediatric Ulcerative Colitis: A Real-life Experience from the SIGENP-IBD Registry. J Pediatr Gastroenterol Nutr 2018;66:920-5. [PMID: 29315163 DOI: 10.1097/MPG.0000000000001883] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 735 |
Ma C, Guizzetti L, Panaccione R, Fedorak RN, Pai RK, Parker CE, Nguyen TM, Khanna R, Vande Casteele N, D'Haens G, Sandborn WJ, Feagan BG, Jairath V. Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. Aliment Pharmacol Ther 2018;47:1578-96. [PMID: 29696670 DOI: 10.1111/apt.14672] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 736 |
Spencer EA, Davis SM, Mack DR, Boyle BM, Griffiths AM, LeLeiko NS, Sauer CG, Keljo DJ, Markowitz JF, Baker SS, Rosh JR, Baldassano RN, Oliva-Hemker M, Pfefferkorn MD, Otley AR, Heyman MB, Noe JD, Patel AS, Rufo PA, Alison Marquis M, Walters TD, Collins MH, Kugathasan S, Denson LA, Hyams JS, Dubinsky MC; PROTECT Study Group. Serologic Reactivity Reflects Clinical Expression of Ulcerative Colitis in Children. Inflamm Bowel Dis 2018;24:1335-43. [PMID: 29718391 DOI: 10.1093/ibd/izy009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 737 |
Singh S, Proudfoot J, Xu R, Sandborn WJ. Obesity and Response to Infliximab in Patients with Inflammatory Bowel Diseases: Pooled Analysis of Individual Participant Data from Clinical Trials. Am J Gastroenterol 2018;113:883-9. [PMID: 29867171 DOI: 10.1038/s41395-018-0104-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 738 |
Soendergaard C, Seidelin JB, Steenholdt C, Nielsen OH. Putative biomarkers of vedolizumab resistance and underlying inflammatory pathways involved in IBD. BMJ Open Gastroenterol 2018;5:e000208. [PMID: 29915667 DOI: 10.1136/bmjgast-2018-000208] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 739 |
Hosomi S, Watanabe K, Nishida Y, Yamagami H, Yukawa T, Otani K, Nagami Y, Tanaka F, Taira K, Kamata N, Tanigawa T, Shiba M, Watanabe T, Nagahara H, Maeda K, Fujiwara Y. Combined Infection of Human Herpes Viruses: A Risk Factor for Subsequent Colectomy in Ulcerative Colitis. Inflamm Bowel Dis 2018;24:1307-15. [PMID: 29668948 DOI: 10.1093/ibd/izy005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 740 |
Gulati S, Emmanuel A, Burt M, Dubois P, Hayee B, Haji A. Outcomes of Endoscopic Resections of Large Laterally Spreading Colorectal Lesions in Inflammatory Bowel Disease: a Single United Kingdom Center Experience. Inflamm Bowel Dis 2018;24:1196-203. [PMID: 29668968 DOI: 10.1093/ibd/izx113] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 741 |
